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Abstract 
The multi-step nature of neoplastic transformation is relatively well accepted, 
although the minimum number of genetic perturbations required for the 
acquisition of a malignant phenotype has not previously been clearly defined. 
Using retroviral gene transfer, cells harbouring mutated Trp53 in conjunction 
with overexpressed MYC have been demonstrated to predispose to B cell 
lymphoma development in mice. We localised retroviral insertion sites in 24 
such lymphomas. Many of these integration sites were similar to those 
identified in other murine models of malignancy. Oncogenes, proto-oncogenes 
and B cell regulators were over-represented within these common integration 
sites. 
cDNAs encoding a selection of genes adjacent to the retroviral insertion sites 
were engineered into separate retroviral expression vectors under the control of 
the retroviral enhancer and promoter region to determine if they facilitated B cell 
transformation . Double transduction of Myb and MYC suggested that the 
overexpression of Myb and MYC in Trp53 mutated cells is sufficient for 
autonomous B cell growth in vitro. 
This novel finding improves understanding of the genetic basis of B cell 
transformation , and further research based on these findings may provide 
insights into the pathogenesis and cellular pathways implicated in the 
development of B cell lymphoma. The recognition that Myb and MYC were the 
most notable oncogenes implicated in the induction of B-cell lymphoma 
increases the need and perhaps opportunity to consider experimental strategies 
that inhibit Myb and/or MYC function and thus may offer new therapeutic 
approaches to treating such malignancies . 
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1. Introduction 
1. 1 Preamble 
B cell lymphoproliferative disorders are the most common haematological 
malignancy. Despite much research a common unifying pathogenesis has not 
been elucidated, limiting targeted drug development. 
In more general terms, basic principles such as the number of oncogenic 'hits' 
that a B cell requires to become neoplastic is still contentious, and the specific 
pathways that need to be dysregulated in B cells to induce lymphoma remains 
uncertain. One approach to this problem is to work backwards from malignant 
lymphomas, identifying the accumulated mutations within them and testing 
whether these are required for the malignant state by attempting to restore them 
to normal. This thesis explores the problem from the opposite direction, by 
starting with cohorts of normal B lymphocytes, introducing defined oncogenic 
mutations singly and in combination, and tracing their consequences for B cell 
growth and survival. 
1.2 Malignant transformation in general 
Dysregulation of the normal homeostatic pathways is required for malignant 
transformation. The seminal paper published in 2000 by Hanahan and 
Weinberg [1] (and subsequently updated in 2010 [2]) describes six attributes 
that a cell must attain before it has a fully malignant phenotype: 
1. Self-sufficiency in grovvth signals 
2. Insensitivity to growth-inhibitory (antigrowth) signals 
3. Evasion of programmed cell death (apoptosis) 
4. Limitless replicative potential 
5. Sustained angiogenesis, and 
6. Tissue invasion and metastasis. 
It is not known how mariy different genetic mutations are required to confer 
these attributes, nor how many different combinations might exist to achieve 
18 
Chapter 1: Introduction 
malignant transformation of a given cell lineage. Recent exome and genome 
sequencing of human mature B cell lymphomas have revealed that these 
typically have accumulated 30 or more somatic mutations that alter protein 
sequence [3-6], but it remains unresolved how many of these are "driver" 
mutations(conferring a selective growth advantage) as opposed to "passenger" 
mutations (concepts reviewed by Vogelstein et al [7]). 
1.3 Murine models of human lymphoma 
B cell neoplasms can be divided broadly into those that express surface 
immunoglobulin, the mature B cell lymphomas and leukaemias that arise from a 
diverse number of normal mature B cell counterparts (Table 1 ), surface 
immunoglobulin-negative leukaemias that derive from pre-B cells and pro-B 
cells, and myelomas and plasmacytomas derived from terminally differentiated 
plasma cells. Many similarities are seen in human and murine mature B cell 
lymphoma [8,9]. Concordance, however, is not complete, with the differences 
likely to reflect species-specific idiosyncrasies together with differences in the 
way the tumours are classified. In both species, classification currently focuses 
on histopathological parameters. Ideally, mature lymphoma subtypes would be 
classified by the constellation of oncogenic driver mutations, but as most of 
these mutations are only just being elucidated this is currently limited to 
mutations in MYC or BCL2 that were discovered cytogenetically several 
decades ago. 
While spontaneous murine mature B cell lymphoproliferative disorders do occur, 
the lymphoid malignancies in mice that have been extensively studied in a 
laboratory setting are usually induced by genetic engineering and somatic 
mutagenesis with retroviruses or other agents. While this hastens 
lymphomagenesis and improves consistency, the relevance of such a 
manipulated system to the very pleomorphic collection of human B cell 
lymphoma needs to be considered. Mouse models of lymphoma can be used 
to advance understanding of human disease, but recognition of species-specific 
differences is important in order not to overstate the significance of findings in 
murine research. 
19 
Better understanding of the molecular drivers of human and mouse B cell 
malignancy will improve the alignment between experimental animal models 
and the clinical entitities. This is elegantly illustrated by the evolution of MYC-
transgenic mouse models for Burkitt lymphoma. The first such animal model 
was the Eµ-Myc transgenic mouse [1 0], which recapitulates one of the most 
frequent oncogenic mutations in Burkitt lymphoma [11-13]. However, these 
animals primarily develop pre-B cell leukaemias and lymphomas, and not the 
germinal centre-origin malignancies corresponding to Burkitt lymphoma. To 
better emulate Burkitt lymphomagenesis, Rajewsky and colleagues [14] recently 
engineered transgenic mice that conditionally expressed a deregulated Myc 
gene only in germinal centre (GC) B cells. When they combined that with a 
second transgene that conditionally expressed an overactive Pl3-kinase in the 
GC B cells, malignant mature B cell lymphomas arose that shared gene 
expression profile with Burkitt lymphoma but also acquired somatic mutations in 
the same Cyclin-O3 gene that has recently been identified by whole 
transcriptome sequencing of Burkitt lymphoma [5].The latter studies revealed 
exaggerated Pl3K-signalling as a recurring feature of Burkitt lymphoma, 
reinforcing the congruence between the human disease and the animal model. 
The goal of this thesis is to define other components that cooperate with MYC 
to drive neoplastic proliferation of mature B cells. 
20 
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Table 1.1 Common human mature B cell neoplasms 
Human mature B cell 
neoplasm 
WHO classification [15] 
Follicular lymphoma 
Burkitt-like lymphoma 
Chronic lymphocytic 
leukaemia/ Small 
lymphocytic lymphoma 
Hairy cell leukaemia 
None known 
Normal B cell Corresponding spontaneous 
correlate murine neoplasm in inbred 
Germinal 
centre B cell 
Germinal 
centre or post 
germinal 
centre B cell 
Post germinal 
centre or 
naive B cell 
Post germinal 
centre B cell 
Unknown 
strains(s) or genetically 
manipulated murine 
models(m) 
Follicular B cell lymphoma (s) 
(m) 
Burkitt-like lymphoma (s) 
Small B-cell lymphoma (s) 
None known 
B natural killer cell lymphoma 
(s) 
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1 .4 Mature B cell physiology 
An appreciation of the pathways that facilitate normal mature B cell survival and 
growth and the different stages of B cell differentiation is required before 
dissection of the abnormalities that precipitate the development of lymphoma 
can be undertaken. 
1.4.1 Survival or Apoptosis 
BCR (B cell receptor) and BAFF (B cell-activating factor) pathways: The 
main pathways that are required for mature B cell survival are those that involve 
signalling through the B cell receptor and the BAFF pathway [16]. Inducible 
deletion of the B cell receptor on mature B cells leads to a significant depletion 
of their numbers [17], which has been demonstrated to be due to a loss of 
downstream signalling [18]. This cannot be due to loss of antigen specific 
signalling as all B cells are lost, not just those specific for a certain antigen. The 
B cell receptor appears to be able to transmit low level signals without receptor 
cross linking [19], which may be the survival signals required for maintenance of 
the mature B cell pool. The downstream pathways activated by the B cell 
receptor are complicated, including many signalling proteins whose mutation 
result in B cell immunodeficiency disorders, such as Bruton's tyrosine kinase 
responsible for X-linked agammaglobulinaemia, demonstrating the importance 
of these pathways in B cell development, survival and function (reviewed by 
Conley et al) [20]. An important target of these pathways is activation of the 
phosphoinositide 3-kinases (Pl3K), (reviewed in Okkenhaug et al) [21] which 
result in activation of the serine/threonine kinase AKT/PKB and play an 
important role in regulating cellular metabolism and growth by activating the 
mammalian target of rapamycin (mTOR). Rajewsky and colleagues 
demonstrated that expression of a constitutively activate form of Pl3K could 
prevent loss of B cells when their surface BCR was ablated, whereas activating 
mutations in other BCR-activated signalling pathways such as NF-KB could not 
[22]. 
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Genetic deficiency of the tumour necrosis factor-related cytokine, BAFF [23], or 
one of its receptors, BAFFR [24], causes profound defects in mature B cell 
survival. BAFF administration promotes survival of mature B cells in vitro [24] 
and transgenic mice overexpressing BAFF demonstrate increased numbers of 
mature B cells [25]. The downstream signalling pathways from the BAFF 
receptor mediating. this effect are still not well defined, but are thought to include 
protein kinase C delta (PKCo) [26], BCL2 family proteins [27] and both the 
classical and alternate NF-KB pathways. Mutations in the beta subunit of 
lkappaB kinase (IKKb) that result in constitutively active NF-kB signalling are 
sufficient to substitute for BAFFR and promote survival of mature B cells in vivo 
or in vitro [28]. While this causes larger numbers of mature B cells to 
accumulate in vivo, the cells remain non-cycling GO cells. AKT is also activated 
through BAFF receptor binding [29], although the mechanism of this activation 
remains to be elucidated. 
As with all mammalian cells, the final stages of apoptosis in mature B cells is 
co-ordinated by two pathways, an intrinsic or mitochondrial pathway regulated 
by BCL2 and related proteins, and an extrinsic pathway involving members of 
the tumour necrosis factor family. 
BCL2 family: The mitochondrial or intrinsic pathway of apoptosis is triggered by 
the translocation onto the mitochondrial membrane of pro-apoptotic BCL2 
family members, BAX and BAK, causing cytochrome c release into the cytosol 
and sequentially cell death through a caspase cascade (reviewed by Marsden 
and Strasser [30]). The BCL2 family of proteins have homologous regions and 
have either pro apoptotic (eg BAX, BIM, NOXA, PUMA) or anti apoptotic (eg 
BCL2, BCLXL, MCL 1) functions. Deficiency of Bcl2 causes a profound 
deficiency of mature B cells [31,32] while enforced expression of Bc/2 promotes 
accumulation of large numbers of resting mature B cells [33] [34]. 
Fas: The extrinsic apoptosis pathway is stimulated by tumour necrosis family 
members such as Fas ligand binding to Fas (CD95) or other 'death receptors' 
on the cell surface [35]. This precipitates downstream signalling which results 
in activation of caspase-8 which then activates other downstream caspases, 
resulting in death of the cell. 
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Apoptotic pathways are inextricably linked to the B cell activation pathways in 
order to maintain homeostasis. BAFF stimulation has been demonstrated to 
reduce B cell apoptosis in vitro and in vivo [36]. Anti-apoptotic members of the 
BCL2 family, notably Mc/1, have been demonstrated to be induced by BAFF 
stimulation of B cells, while Bc/2 itself is induced by signals through the 
canonical NF-KB pathway [37]. BIM is pro-apoptotic, and it has been shown 
[27] that its expression is upregulated by BCR binding, and that this is blocked 
by BAFF binding, thus inhibiting apoptosis. Some of these interactions between 
the survival and apoptotic pathways may be mediated by AKT/PKB. 
1.4.2 Growth signals for B cell proliferation 
Important steps required for mature B cell proliferation can be subdivided into: 
-Mitogen binding to B cell surface 
-Signal transduction: surface to nuclear cell cycle control mechanisms 
-Cell cycle progression 
Mitogen binding to B cell surface 
Cross linking of the B cell receptor by antigen precipitates recruitment and 
activation of SYK (spleen tyrosine kinase), a tyrosine kinase, which drives 
multiple complex signalling pathways! including elevation of intracellular calcium 
and activation of the ERK MAP kinase pathway and the canonical NF-KB 
pathway [38]. Replication of mature B cells is classically stimulated by cross 
linking of the B cell receptor by antigen in association with a co-stimulatory 
signal such as CD40-CD40 ligand binding provided by T cells. Like BAFF 1 
CD40 binding can activate both the classical and alternate NF-KB pathways 1 
although CD40 ligand signalling! or agonistic antibodies to CD40, are potent 
mitogens for B cells whereas BAFF alone is not mitogenic although it augments 
the B cell proliferation stimulated by anti-lgM [39] or CD40 ligand [36]. 
Thymus independent antigens are a group of antigens that include viral nucleic 
acids and bacterial lipids and polysaccharides able to stimulate B cells in the 
absence of helper T cells. This response is mediated by Toll-like receptors 
(TLR) which are found on most cells! including B cells 1 with different TLR being 
stimulated by different microorganism antigens. Toll-like receptors have some 
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downstream signalling pathways in common such as the NF-KB pathway and 
mitogen activated protein kinase (MAPK) pathway [40], many of which are 
similar to the pathways activated by BCR binding, but each receptor subtype 
also has its own unique features and thus differing patterns of gene expression 
are seen with activation of different TLR subtypes. 
Signal transduction: surface to nuclear cell cycle control mechanisms 
NF-KB pathway: Multiple pathways help to transduce the B cell surface binding 
signal to the nucleus to promote proliferation. One such pathway is the Nuclear 
factor kappa B (NF-KB) pathway, which is essential for B cell survival and for 
BCR, CD40 or TLR-induced proliferation, as demonstrated by knock out models 
[41 ], and reviewed by Gerondakis et al [42]. The NF-KB family has five 
homologous members, all of which are transcription factors. They are RELA 
(also called p65), c-REL, RELB, p105/p50 (also called NF-KB1) and p1 00/p52 
(also called NF-KB2). These factors are only active in the nucleus, where they 
can regulate gene transcription, but are usually in the cytoplasm bound to 
inhibitory proteins. 
In the classical NF-kB activation pathway signalling through -cell surface 
receptors enables phosphorylation of these inhibitory proteins by the IKB kinase 
complex, leading to their ubiquitination and degradation and allowing nuclear 
translocation of NF-KB family members and activation of gene transcription . 
This pathway can be stimulated in B cells by the BCR, CD40, and TLR4 or 
TLR9. Genes that have been shown to be transcribed in B cells in response to 
canonical NF-kB signalling encode key cell cycle proteins (eg Myc [43], Cyclin 
D1 [44], IRF4 [45]) and anti-apoptotic members of the Bcl2 family (eg BclXL, 
A1/Bfl1) [46]. 
The alternative NF-kB activation pathway is activated by ligand binding to 
members of the TNF receptor superfamily such as the BAFF receptor or CD40. 
Activation of this pathway results in activation of IKKa which phosphorylates 
p1 00/p52, allowing its partial proteolysis, facilitating its translocation into the 
nucleus. Activation of the alternative pathway in B cells induces the anti-
apoptotic Bcl2 family of genes in addition to Pim-2 kinase [46]. 
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B cell cycle progression 
This process is promoted by various cyclin dependent kinases at specific stages 
of the cell cycle, the activity of which are modulated by cyclins and cyclin 
dependent kinase inhibitors [4 7]. In B cells, multiple factors influence the 
activity of these components: 
CCND1, CCND2, CCND3: Cyclin 01 is normally only expressed at the G1 
phase of the cell cycle and in conjunction with multiple other cyclins and cyclin 
dependent kinases facilitates the G1/S phase transition by phosphorylating and 
inactivating the Retinoblastoma tumour suppressor protein. In some cases of 
Chronic lymphocytic leukemia, CCN01 is dysregulated by a chromosomal 
translocation fusing it with the IGH locus [48]. Cyclin 02 is rapidly induced by 
BCR signalling [49], and high expression of CCN02 is highly predictive of 
shorter overall survival in human OLBCL [50]. Cyclin 03 is required for 
proliferation of germinal centre B cells [51 ], and recurrent somatic mutations 
that stabilize the protein are observed in Burkitt lymphoma [5] and its animal 
model [14]. 
MYC is a transcriptional amplifier that is essential for B cells to enlarge and 
enter cell cycle [52]. A detailed discussion of MYC is provided below. 
mTOR and P13-kinase. mTOR encodes a protein kinase that is the target of 
the immunosuppressive drug rapamycin, and is an important regulator of cell 
growth , survival , metabolism and proliferation and modulates protein translation 
(reviewed by Laplante and Sabatini [53]). mTOR is stimulated by diverse 
upstream pathways , notably the Pl3K/AKT pathway [21]. The precise 
mechanism of interaction between mTOR and Myc is unclear, but it has been 
suggested that activation of Myc suppresses TSC2, a suppressor of mTOR [54]. 
TGF/3: Transforming growth factor beta is an anti-proliferative factor for B 
lymphocytes that blocks cell progression at the G1 -S phase transition check 
point [55]. TGF~ targets include some cyclin dependent kinases, the 
retinoblastoma protein and Myc, the latter possibly through the NF-KB pathway 
[56]. 
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DNA damage response pathway: This pathway is activated in response to 
DNA damage, predominantly to double strand breaks. The upstream regulators 
of this pathway include kinases encoded by ATM (Ataxia telangiectasia 
mutated) and ATR (ATM-Rad3-related). They phosphorylate various proteins to 
facilitate modifications in cell cycle activity and protein repair, including 
phosphorylation of MDM2 which results in stabilisation of p53 [57]. TP53 
(Trp53 in mice) encodes the transcription factor p53 which induces inhibitors of 
cell cycle and promoters of apoptosis, and is discussed in detail in Section 1.6. 
1.4.3 Differentiation 
Tightly co-ordinated differential gene expression is required at each stage of B 
cell development to facilitate the development of mature B cells from multipotent 
stem cells. In brief, the earliest stage of mature (defined as having surface 
immunoglobulin) B cell development is the na"fve B cell. These cells are often 
CDS positive and circulate in the blood in addition to being found in primary 
lymphoid follicles and mantle zones. A small proportion of these cells are 
subsequently exposed to specific antigen inducing T cell-dependent 
-
proliferation and migrate into the centre of a primary follicle where they form a 
germinal centre. Germinal centre cells express CD10 and BCL6 and commonly 
undergo somatic hypermutation and class switch recombination. These cells 
subsequently become plasma cells or post germinal centre memory B cells 
which are found in blood and lymph nodes and the follicular marginal zones of 
lymph nodes, spleen and mucosa associated lymphoid tissue. Some of the 
important genes in this maturation process include: 
PAX5 is a member of the PAX family of transcription factor genes. This gene is 
only expressed within the B cell lineage in the haemopoietic system. Pro-B 
cells require PAX5 expression to differentiate into more mature B cells [58]. 
PAX5 is also required to maintain the identity of the mature B cell [59]. PAX5 is 
not expressed in plasma cells, and it has been demonstrated [60] that Blimp1-
induced suppression of PAX5 is required for plasma cell differentiation. 
BCL6 (B cell lymphoma 6) encodes a protein of the same name which is a 
repressor of transcription. Its expression is required for the formation of 
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germinal centres [61 ], and its expression needs to be suppressed for the 
differentiation of germinal centre B cells into non-dividing memory cells or 
plasma cells. Its precise role in this process is still being clarified, but it has 
been shown that it suppresses the DNA damage-sensing machinery, allowing 
somatic hypermutation and class switch recombination [62]. 
JRF4 (Interferon regulatory factor 4) (also called MUM1) encodes a transcription 
factor that is critical throughout much of B cell development. IRF4 is induced by 
the NF-KB pathway, and it in turn suppresses Bc/6 [63]. Teng et al [64] 
demonstrated that its expression reduces the cell cycle progression of germinal 
centre B cell-derived Burkitt lymphoma cells. The same group also confirmed 
that IRF4 represses Bc/6 expression and induces BLIMP-1 expression, 
facilitating plasmacytic differentiation. IRF4's role modifying the expression of 
r 
genes critical for B cell differentiation suggests that its induction at the later 
stages of the germinal centre formation helps co-ordinate the termination of this 
stage of maturation and further B cell differentiation to the plasma cell stage. 
BLIMP-1 (B lymphocyte induced maturation protein-1, encoded by the Prdm1 
gene) is a transcriptional repressor, the expression of which induces 
plasmacytic differentiation through modulation of expression of a large number 
of genes controlling mature B cell homeostasis and immunoglobulin production 
including Pax5, Myc, and Bc/6 (reviewed in Johnson et al [65]). The expression 
of Prdm 1 is suppressed by Bcl6 [66]. 
1.5 
1.5.1 
Basis for mature B cell 
lymphoproliferative disorders 
Broad Aetiology 
Much research has been undertaken into the genetic perturbations that 
predispose, precipitate and perpetuate B cell lymphomas; usually focussing on 
genetic factors within the B cell ('cell autonomous'). It must be remembered, 
however, that non-autonomous genetic factors , such as those influencing the 
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tumour microenvironment, are likely to also be influential. In addition, although 
this thesis refers specifically to genetic defects, non genetic defects are clearly 
important in B cell lymphoma. Such factors include the immune response to the 
tumour, changes in the cytokine milieu, growth factors, and hormonal changes 
such as steroid levels. In addition, mesenchymal stem cells are also thought 
that play an important role (reviewed in [67]). B cell extrinsic factors causing B 
cell activation also need to be considered. Bacterial infections such as 
Helicobacter pylori and Chlamydia trachomatis and viruses such as Hepatitis C 
and HIV have been clearly associated with an increased incidence of lymphoma 
[68]. Toll-like receptors may be significant in this regard, with repeated 
stimulation of cell cycling by recurrent viral or bacterial infections facilitating the 
outgrowth of a malignant clone. Support for this comes particularly from the 
recent finding that activating mutations in MYDBB, encoding a critical 
intracellular mediator of TLR signalling, are found in nearly 100% of 
Waldenstrom macroglobulinaemia [69] and more than 30%> of DLBCL [70]. 
The increased incidence of B cell lymphoma in patients with autoimmune 
diseases re-emphasises the importance of immune dysregulation in the 
aetiology and propagation of B cell lymphoma [71]. Defects in immune 
surveillance also contribute to the development of malignancy [72], including 
lymphoma. An example is perforin deficient mice, which have a high incidence 
of B cell lymphoma (among other lymphoma types), with cell transfer 
experiments demonstrating that these lymphomas are rapidly destroyed in mice 
with the same genetic background but with intact perforin genes [73]. Perforin 
is critical for the cytotoxicity of NK cells and CDS positive T cells, and is not 
made by B cells, consistent with a role for NK and T cell surveillance against B 
cell lymphoma. 
Mouse plasmacytoma can be caused by persistent peritoneal irritation in 
BALB/c mice by intraperitoneal injection of pristine. Most of these tumours 
overexpress Myc, with greater than 80°/o harbouring a mutation that leads to the 
juxtaposition of the murine immunoglobulin heavy chain gene on chromosome 
12 with the murine Myc gene on chromosome 15 [74]. The incidence of 
plasmacytoma can be further modified by altering gut bacterial flora, or 
exposure to cholera toxin, and other strains of mice are relatively resistant to 
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the development of a plasmacytoma in identical conditions [75], all of which 
suggests that host and environmental factors interact and strongly influence B 
cell transformation. 
In summary, B cell lymphoma is thus likely to be a multifactorial process, and 
while the following discussion focuses on genetic factors within the B cell, these 
alone are unlikely to fully explain the pathogenesis of this diverse malignancy. 
1.5.2 MicroRNAs 
MicroRNAs (miRNAs) were first identified in 1993 [76] although their role in 
modulation of gene expression was not defined until 2000 [77]. Since then 
extensive research has helped clarify their role in normal and aberrant human 
cellular processes. They are short nucleotide sequences which are encoded by 
the genome and act by reducing translation and altering stability and 
polyadenylation of target messenger RNA. In the recently released miRBase 
19, 2019 unique mature human miRNA sequences are described [78], and it is 
well known that a single microRNA can modulate the translation of hundreds of 
mRNAs, and thus their sphere of influence is enormous and they add an 
important layer to the complex web of gene expression regulation. 
MicroRNAs are variably expressed at various stages of B cell development, 
suggesting a role in differentiation [79]. Zhang et al [80] showed that B cell 
stage-specific miRNAs are often conserved between 8-cell malignancies and 
the corresponding normal B cell developmental stage from which they are 
presumed to arise. However, some miRNA expression profiles are perturbed in 
neoplasia , with the microRNA profile of mature B cell lymphoproliferative 
disorders varying with the lymphoma subtype (reviewed in [81]), although 
whether this is a primary or secondary event has not been well defined. Calin 
et al [82] identified that miRNA genes are frequently located at cancer-
associated frag ile sites or common breakpoint regions , suggesting that their 
dysregulation may modulate the initiation of neoplastic transformation. 
Deletion of chromosome 13q 14 is the most commonly identified genetic 
mutation in CLL, found in approximately 50% of cases, and associated with 
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longer time to first treatment. The relevance of this mutation was unclear until it 
was revealed that this region encoded the miR-16-1/miR-15a cluster [83] which 
was subsequently demonstrated to negatively regulate BCL2 [84]. miR-155 is 
very highly expressed in Hodgkin Lymphoma, Primary Mediastinal B cell 
Lymphoma and Diffuse Large B cell Lymphoma of the Activated B cell subtype . 
Overexpression of this cluster in the murine B cell compartment (Eµ-mmu-
miR 155 construct) initially results in a pre-leukaemic pre-B cell proliferation 
which progresses to a B cell malignancy [85] suggesting that defects in this 
cluster may be a primary event in lymphomagenesis. Paradoxically, Burkitt 
lymphoma demonstrates a markedly reduced expression of miR-155 [86]. 
To date microRNA expression has been shown to have diagnostic and 
prognostic significance in some B cell lymphoproliferative disorders (reviewed in 
[81 ]), with ongoing research into their therapeutic utility. This is a rapidly 
developing field, and further research is likely to significantly contribute to our 
understanding of the pathogenesis of B cell lymphoma. 
1.5.3 Epigenetic changes 
Epigenetic modifications also need to be considered, although there is less 
definitive literature dissecting their implication in lymphoma. It has been 
proposed that methylation, particularly of CpG islands associated with gene 
promoters (the CpG components of which are often methylated in 
transcriptionally inactive genes), may inhibit gene expression . DNA Methylation 
patterns are often different in malignant cells compared to their normal 
counterparts. Pike et al [87] analysed cases of Diffuse Large B cell Lymphoma 
demonstrating significant CpG island methylation, a frequent association 
between CpG island methylation and reduced expression of the downstream 
gene, and differential methylation patterns between subtypes. Mestre-
Escorihuela et al [88] demonstrated methylation of putative tumour suppressor 
genes and corresponding reduced expression levels in many types of 
lymphoma. In all these studies, however, it remained unclear whether these 
abnormalities were primary or secondary events in lymphomagenesis. 
Epigenetic changes also include histone modifications. Morin et al [4] and 
Pasqualucci et al [89] showed that histone-modifying gene·s, notably MLL2 and 
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EZH2, were frequently mutated in both DLBCL and Follicular Lymphoma 
suggesting that epigenetic changes have a primary role in tumour initiation or 
progression. 
1.5.4 Causes of somatic mutation in B cell lymphoma 
The mutating effect of ionising radiation and chemicals on DNA is well 
recognised. In addition, spontaneous DNA mutations occur constantly due to 
defects in DNA synthesis, repair or recombination. Furthermore, recurrent 
translocations are found in many types of B cell lymphoma such as the t(8;14) 
in Burkitt lymphoma, t(11 ;14) in Mantle Cell Lymphoma and t(14;18) in Follicular 
Lymphoma. These translocations allow juxtaposition of a proto-oncogene with 
the immunoglobulin heavy chain locus causing overexpression of the former. 
The recurrent nature of these mutations and their unique occurrence in B cells 
suggests that the aetiology of these mutations may be relatively B cell specific. 
V(D)J recombination occurs as B cells mature, facilitated by recombinase 
activating genes (RAG). IGH:BCL2 translocations appear to arise as errors in 
this process. Somatic hypermutation and class switch recombination are 
initiated by activation-induced cytidine deaminase (AID) upon antigen and CD40 
stimulation of mature B cells. /GH:MYC translocations typically arise as errors 
of class switch recombination. AID deaminates cytosines on the DNA of 
immunoglobulin genes thereby generating a lesion that results in DNA mutation 
or breakage. Aberrant somatic hypermutation is thought to contribute to B cell 
lymphomagenesis. AID has been demonstrated to facilitate initial genetic 
mutations that predispose a B cell to malignant transformation and subsequent 
mutations that facilitate tumour evolution (reviewed in Okazaki et al [90]). 
Aberrant somatic hypermutation and class switch recombination in 
lymphomagenesis may explain why most B cell lymphomas are derived from 
germinal centre B cells or their descendants. This may also explain the 
importance of an intact B cell receptor for lymphomagenesis, as it is cross-
linking of the B cell receptor that stimulates the germinal centre reaction. 
lnsertional mutagenesis by retroviruses strongly promotes lymphomagenesis in 
mice. This is best illustrated by the acceleration of B cell lymphomas in Eµ-Myc 
32 
Chapter 1: Introduction 
transgenic mice upon infection with Moloney murine leukaemia virus [91,92]. 
Repeated cycles of MuLV virus production, infection and provirus integration in 
activated B cells results in copies of the proviral enhancer and promoter being 
inserted into different cellular genes, where it frequently leads to dysregulated 
expression of the cellular gene (reviewed by Uren et al [93]). A large database 
of retroviral insertion sites in lymphoma has been assembled [94], with recurrent 
integration sites implicated as potential oncogenes. 
1.5.5 Mutations in survival/apoptotic pathways and 
evasion of programmed cell death 
BCR: Signalling through the B cell receptor has been demonstrated to be 
important in the persistence of B cell lymphoma [95], with Refaeli et al 
demonstrating tumour regression on disruption of B cell receptor signalling. 
The contribution that B cell receptor signalling is likely to play in 
lymphomagenesis is further emphasised by the observation that translocations 
which involve immunoglobulin loci are non-random, being almost always found 
on the non-productively rearranged locus, leaving the other locus to contribute 
to the formation of the B cell receptor [96]. The association between infections 
such as hepatitis C and Helicobacter pylori and lymphoma, and the disease 
regression that may be seen with treatment of the infection again strengthens 
the case for the importance of the B cell receptor for lymphomagenesis [97]. 
CARD11 encodes an intracellular protein essential for BCR-signalling to the 
canonical NF-kB pathway and induction of B cell proliferation, but not for CD40 
or Toll like receptor-mediated signalling of these events. Recently, activating 
mutations in CARD11 have been found in approximately 10% of human Diffuse 
Large B cell Lymphomas [98,99]. Lenz et al [98] also demonstrated that 
experimental reproduction of such mutations in lymphoma cell lines produced 
constitutive NF-KB activation. Likewise, shRNA knock-down of CARD11 inhibits 
the growth and survival of human Diffuse Large B cell Lymphoma cell lines 
[100]. These activated Card11 alleles were sufficient on their own to promote 
enormous but ultimately self-limiting B cell proliferation when introduced by 
retroviral gene transfer into antigen-activated normal mature B cells [101 ]. 
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These observations further suggest that dysregulated BCR signalling to NF-kB 
is an important element of lymphomagenesis. 
BAFF and its family have been demonstrated to be critical for the survival of 
some B cell lymphoma lines [102]. Human B cell lymphomas express BAFF 
receptor, and high serum levels of BAFF was found to be an independent 
prognostic factor for overall survival in treated Diffuse Large B cell Lymphoma 
[103], although whether this elevation is primary or secondary to transformation 
remains to be determined. 
ATM: Mutations in both copies of the A TM gene cause Ataxia telangiectasia, a 
syndrome which includes neuronal degeneration and a susceptibility to cancer. 
The malignancies are predominantly lymphoid, being of either B or T cell origin 
[104]. A TM has also been demonstrated to potentiate the induction of 
lymphoma in the setting of Myc overexpression through an impaired apoptotic 
response [105]. 
BCL2 family: Apoptotic pathways are commonly disrupted in low growth 
fraction lymphomas. The t(14; 18) typically seen in Follicular Lymphoma in 
humans, and involves a translocation between BCL2 and the immunoglobulin 
heavy chain enhancer. Dysregulation of BCL2 expression alone is insufficient 
for a malignant phenotype, as demonstrated by the detection of small numbers 
of cells in normal individuals with the characteristic t(14; 18) [106] , and by mouse 
models showing that Bc/2 overexpression under the influence of the VavP 
promoter induces polyclonal B cell expansion initially , followed by follicular 
lymphoma at greater than 10 months of age [34], the latter presumably requiring 
further genetic defects. Likewise, Bc/2 overexpression under the control of the 
immunoglobulin heavy chain enhancer and promoter does not cause 
lymphoma, but promotes extensive accumulation of small resting follicular B 
cells [33]. 
Fas: Patients with germline FAS mutations demonstrate an increased incidence 
of both B cell and T cell lymphoma (the former including both non-Hodgkin 
lymphoma and Hodgkin lymphoma) [107]. While the simple explanation for this 
is that defective apoptosis in B cells facilitates the accumulati.on of genetic 
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defects in B cells, altered immune surveillance has also been proposed to be 
contributory, with the T cell defect produced by FAS mutation facilitating the 
development of the malignancy [107,108]. 
1.5.6 Mutations in proliferative pathways and self-
sufficiency for growth factors 
Surface binding factors 
BCR: Refaeli et al [95] demonstrated that stimulation of the B cell receptor in 
Myc-overexpressing mice accelerated lymphomagenesis and that the 
phenotype of the resulting B cell lymphoma was dependent on the activational 
status of the BCR. 
Signal transduction pathways 
The NF-KB pathway has been demonstrated to be highly significant in many 
types of B cell lymphoma (reviewed in [109]), consistent with its pivotal role in 
normal B cell homeostasis and proliferation. The founding member of this 
transcription factor family, Rel, was discovered because a mytated viral 
derivative, v-Rel, is the B cell leukaemia-transforming oncogene carried by the 
avian reticuloendotheliosis retrovirus [11 O]. 
Inhibition of this pathway has been shown to cause regression of cell lines 
modelling the activated B cell-like subtype of Diffuse Large B cell Lymphoma 
[100,111]. This subtype of lymphoma has also been demonstrated to 
commonly harbour mutations in genes that regulate the NF-KB pathway [99], 
suggesting that dysregulation of this pathway can be a primary pathogenetic 
event. A20, a negative regulator of the pathway, was the most commonly 
mutated gene in Diffuse Large B cell Lymphoma in the studies performed by 
Compagna et al [99], and when Kato et al [112] re-expressed this gene in a 
lymphoma cell line with no functional A20 alleles, down regulation of the NF-KB 
pathway resulted in a consequential reduction in cell growth and increased 
apoptosis. 
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Other subtypes of B cell lymphoma also commonly harbour mutations in the 
genes influencing the NF-KB pathway [112,113]. Mucosa-associated lymphoid 
tissue (MALT) lymphoma is associated with chronic antigenic stimulation, but 
also demonstrates a number of common genetic mutations. Three of the most 
common chromosomal translocations seen in MALT lymphoma result in 
dysregulation of the NF-KB pathway through their interactions with upstream 
genes including BCL-10, MALT1 and CARD11 (reviewed in Nakagawa et al 
[114]). 
SYK: Blocking of signalling through Syk, which acts downstream of the B cell 
receptor as above, has also been shown [115] to precipitate apoptosis is both 
cell lines and tumour suspensions of Diffuse Large B cell Lymphoma, the 
responsive cells being demonstrated to have intact BCR signalling prior to the 
introduction of the inhibitor. In addition, Syk kinase has been found to be 
constitutively phosphorylated in CLL cells [116], with many cells demonstrating 
increased apoptosis when exposed to a Syk inhibitor. 
Cell cycle factors 
MYC is discussed in detail in Section 1.7. 
mTOR: m TOR has been demonstrated to be overexpressed in several 
lymphoproliferative disorders (reviewed in [117]). Research has focussed on 
Mantle cell Lymphoma where the mTOR pathway has been demonstrated in 
cell lines and patient samples to be activated, with experimental reduction in 
activation of mTOR inducing cell cycle arrest and apoptosis in Mantle Cell 
Lymphoma cell lines [118]. Clinical trials have confirmed the efficacy of an 
mTOR inhibitor [119] in Mantle cell Lymphoma. 
The links between Myc and the mTOR pathway were discussed briefly earlier. 
Early work [120] reported that everolimus , an mTOR inhibitor, reduced 
lymphomagenesis in Eµ-myc mice by up to 90%, despite no effect on the level 
of Myc expression suggesting that much of Myc's activity is mediated through 
the mTOR pathway. 
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TGF-J3: The role of TGF-~ in B cell lymphoma still remains to be clearly defined 
although it is known to enhance angiogenesis, tumour spread and potentially 
reducing immune surveillance in solid tumours (reviewed by Elliott et al [121]). 
Both B cells and T cells produce TGF-~, and this increases with activation [122]. 
Some B cell malignancies have been shown to have an altered response to 
TGF-~ [123]. These factors may influence the development and progression of 
B cell lymphoma, but this remains to be clarified. 
CCND1 encodes Cyclin D1, dysregulation of which is seen in Mantle Cell 
Lymphoma in humans, with the classic t(11 ;14) juxtaposing the immunoglobulin 
heavy chain enhancer with CCND1. A French group also demonstrated that 
21 % of myeloma patients have translocation t(11 ;14) using fluorescence in situ 
hybridisation (FISH) [124], resulting in up regulation of CCND1. 
1.5.7 Mutations affecting differentiation and its 
inhibitory effect on growth 
Bcl6: Intuitively Bcl6's role in faciliting somatic hypermutation_ and class switch 
recombination through suppression of the DNA damage-sensing process may 
also be permissive for the survival of defective B cells that would otherwise be 
forced to undergo apoptosis, potentially allowing the development of a 
malignant clone. Mouse models overexpressing Bc/6 demonstrate an initial 
polyclonal proliferation of mature B cells, followed by the outgrowth of a B cell 
lymphoma resembling human Diffuse Large B cell Lymphoma [125]. Bc/6 is 
commonly mutated in human B cell lymphoma, with its overexpression being 
characteristic of the germinal centre type of Diffuse Large B cell Lymphoma 
[126]. 
PAX5 somatic mutations were identified in 32% of paediatric ALL in one study 
[127]. t(9; 14)(p13;q32) was initially reported in approximately 50% of 
lymphoplasmacytoid lymphomas, and suggested [128] to cause juxtaposition of 
the PAX5 gene with lgH regulatory elements, although more recent publications 
[129,130] have failed to confirm this association. 
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IRF4: /RF4 is expressed in a significant proportion of B cell lymphomas [131], 
although its role, if any, in the pathogenesis is still being defined. Alteration in 
the IRF4 binding domain of BCL6 has been noted in a significant proportion of 
Diffuse Large B cell Lymphoma and Burkitt Lymphoma cell lines [63]. This 
would result in failure of down regulation of BCL6, and may thus facilitate 
lymphomagenesis. It has also been suggested that IRF4 plays a key role in the 
transformation of B cells by EBV in vivo and in vitro [132]. 
BLIMP-1 (the human equivalent being called positive regulatory domain-I 
binding factor-1 (PRO/BF1)) has potential relevance in lymphomagenesis in 
view of its critical role in B cell maturation. It has been demonstrated that 
overexpression of BLIMP-1 hastened apoptosis of a lymphoma cell line [133], 
but BLIMP-1 's role in lymphomagenesis remains to be clarified. 
1.6 p53 
1.6.1 p53's role as a tumour suppressor gene 
TP53 (Trp53 in mice) is one of the most intensively studied tumour suppressor 
genes , encoding the protein p53. It is the most frequently mutated gene in 
human cancers. The first reports of the importance of p53 in cancer were 
published in 1979 when it was identified in simian virus 40 transformed cell lines 
and tumours by multiple groups [134-137]. It was initially believed to be an 
oncogene , and it vvas almost a decade before it was appreciated [138] that the 
p53 cDNA clones that had been identified as promoting cellular transformation 
actually encoded mutant p53 , explaining their oncogenic properties. p53 
defective mice [139] and humans [140,141] clearly have a cancer-prone 
phenotype. 
The molecular basis for its tumour suppressor function is complex, as p53 is a 
DNA-binding nuclear protein that activates or represses transcription of 
numerous target genes. Ablation of individual p53 target genes has been 
unsuccessful in replicating the tumour-prone p53 knockout phenotype [142] 
suggesting that its tumour suppressor role may not be due to dysregulation of a 
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single pathway. PUMA and NOXA are proapoptotic members of the BH3-only 
Bcl2 family that are strongly induced by p53, and they play key roles in p53 
mediated apoptosis [143,144], but neither Puma null mice nor Noxa null mice 
are predisposed to cancer, although reduced Puma expression cooperates with 
other oncogenic mutations [145,146]. The potential redundancy between Puma 
and Noxa illustrates why mutations in Trp53 itself are so potent compared to 
mutations in individual target genes. Liu et al [147] developed a p53 mutant 
mouse which had lost it apoptosis-promoting function but retained much of its 
cell cycle arrest capability, and demonstrated that these mice were much less 
tumour-prone than p53 knockout mice. Brady et al [148] showed that specific 
mutations of p53 were able to abrogate its role in cell cycle arrest and apoptosis 
as a response to DNA damage but enabled it to maintain it tumour suppressor 
and senescence functions, although complete abolition of transcriptional 
activation function enhanced tumour growth. 
1.6.2 p53's role in lymphomagenesis 
While p53 mutations are not uncommon in haematological malignancies, the 
incidence is lower than seen in solid tumours [149]. Within the International 
Agency for Research on Cancer (IARC) TP53 database (November 2010 
release) 19.3% of lymphoid malignancies harboured a mutation in the TP53 
coding sequence [150] with mutations being seen in most exons, most of which 
were point mutations. TP53 dysfunction can also occur at an epigenetic, mRNA 
or protein level (reviewed by Xu-Monette et al [151 ]). Dysregulation of the p53 
pathway, either upstream or downstream from the p53 protein is probably even 
more common than gene mutation. Overexpression of MDM2, a ubiquitin ligase 
that degrades p53, is frequent in B cell lymphoma [152], and inactivating 
mutations at the INK4a/ARF locus (encoding p14(ARF) a inhibitor of MDM2 and 
hence an activator of p53) have also been identified in some B cell lymphomas 
[153]. Mutations in the ATM (ataxia telangiectasia mutated) gene (which 
encodes a p53 activating kinase) have also been reported [154] in CLL and 
associated with p53 dysfunction. Burkitt lymphoma has a particularly high rate 
of mutations in TP53, MDM2 and INK4A [5,155]. 
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p53 mutations in lymphoproliferative disorders confer a poorer prognosis. TP53 
mutations are more common in high rather than low growth fraction lymphoma 
[156] and it has thus been suggested that mutated p53 facilitates the 
progression of low grade lymphomas to high grade variants, or a more 
aggressive clinical course. Two small studies [157 ,158] have shown that 
patients with transformed Follicular Lymphoma commonly acquired p53 
mutations in the process of transformation. Malcikova et al [159] showed that 
some p53 defects in patients with CLL occurred post therapy, but in contrast, 
Pekova et al [160] were unable to confirm an increased incidence of TP53 
mutations in patients with CLL post chemotherapy. 
1.6.3 p53's physiological role 
p53 is a transcription factor that transactivates or transrepresses hundreds of 
target genes including large numbers of microRNAs (reviewed in [151 ]). More 
recently it has also been demonstrated to have a cytosolic transcription-
independent functions [161 ]. Its diverse functions include regulation of cell-
cycle arrest, DNA repair, apoptosis , senescence, and autophagy in response to 
various forms of cellular stress , including oncogene activation, DNA damage, 
and hypoxia. The p53 protein is usually found in low levels in murine cells 
bound to Mdm2 which facilitates its degradation. Its cellular level and activity is 
modulated in diverse ways including post-translational modification [162] and 
altered binding to Mdm2. The function of p53 in the context of cellular stress 
depends on a multiplicity of factors including the cell type, cell-cycle stage , the 
nature of the insult and other oncogenic mutations within the cell. While the 
diverse functio-ns of p53 do not operate in isolation the best defined roles are 
summarised separately below for clarity. 
Apoptosis: p53 facilitates apoptosis in several ways , the best defined being 
through the intrinsic apoptotic pathway mediated by BCL2 family proteins. 
Within the nucleus p53 induces expression of pro apoptotic BAX and PUMA 
[145]. Within the cytoplasm p53 binds to BCL-XL with subsequent PUMA 
binding releasing p53 to directly activate BAX and induce mitochondrial outer 
membrane permeabilisation [163] activating a downstream caspase cascade 
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precipitating apoptosis. p53 can also modulate apoptosis in other ways 
including via the extrinsic apoptotic pathway (reviewed in [164]). 
Cell cycle arrest: p53 causes a reversible cell cycle arrest at the G1 
checkpoint predominantly through downstream activation of p21 which 
subsequently inhibits cyclin-dependent kinases [165,166]. There have also 
been suggestions that p53 acts at other cell cycle control checkpoints [167,168]. 
DNA repair: In the setting of genotoxic stress p53 mediates DNA repair 
mechanisms. p53 has been shown to modulate nucleotide-excision repair, 
base-excision repair mismatch repair, non-homologous end-joining and 
homologous recombination [169] in both a transactivation dependent and 
independent fashion. 
Senescence: Senescence is defined as a cell losing its capacity to divide. 
Oncogene activation or genotoxic stress (such as DNA damage or reduction in 
telomere length) may precipitate a senescent state. p53 plays a role in 
senescence which is probably at least partially mediated by p21 [170,171]. 
Autophagy: This is predominantly a homeostatic process where damaged 
proteins and organelles are recycled for nutrients, although is enhanced in the 
context of cellular stress. Recently p53 has been shown to modulate autophagy 
[172]. In general, nuclear p53 promotes autophagy with downstream pathways 
including modulation of the damage-regulated autophagy modulator (DRAM) 
gene expression [173] and negative regulation of the mTOR pathway [17 4]. 
This process probably promotes cell survival under stressors such as nutrient 
deprivation or hypoxia. In contrast, cytoplasmic p53 inhibits autophagy [175], 
the mechanisms of which remain poorly defined, but the consequences of which 
appear to enhance cell death. 
1.7 Myc 
MYC overexpression is very common in a diverse range of cancers. Its 
significance in neoplasia was identified when the oncogenic retrovirus avian 
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myelocytomatosis virus was found to have a cellular homologue [176]. 
Subsequent work rapidly confirmed that this gene was activated in many animal 
and human tumours (reviewed by Nesbit et al [177]). Myc dysregulation may 
occur in many ways including copy number amplifications [178], modulation of 
transcription or translation and post translational modification. Extensive 
research has failed to isolate specific Myc-mediated dysregulated cellular 
pathways in oncogenesis but recent publications [179,180] show that rather 
than targeting specific genes , Myc exponentially amplifies the output of existing 
transcriptionally active genes. 
1.7.1 Myc's role in lymphoma 
Early studies identified the Myc locus as a common integration site in avian 
leucocytosis virus induced lymphoma [181]. Later murine experiments [182] 
subsequently confirmed that sites adjacent to the Myc gene were common 
integration sites in murine leukemia virus-induced lymphoma. Outside of 
retrovirus-induced cancer, one of the first examples of spontaneous mutation of 
a cellular proto-oncogene into an oncogene was the recurrent /gH translocation 
first discovered to activate Myc expression in mouse plasmacytomas [183] and 
subsequently confirmed in human Burkitt lymphoma [184,185]. Increased Myc 
expression by translocation of Myc adjacent to the immunoglobulin locus was 
shown experimentally in Eµ-myc transgenic mice [1 O] and by retroviral 
transduction [186] to expedite lymphoma development, and such models have 
been very valuable in enhancing understanding of lymphocyte biology and 
lymphomagenesis. 
Myc overexpressing mouse models have demonstrated that Myc dysregulation 
alone is insufficient for cellular transformation, evidenced by the time lag before 
tumours develop and the clonal nature of the resulting neoplasms [10,187]. Eµ-
myc transgenic mice almost always develop B cell lymphoma with age, prior to 
which they have a significant expansion of their B cell compartment , with a 
predominance of large polyclonal pre-B cells [188]. A frequent somatic 
mutation in the clonal lymphomas that develop in these mice is inactivation of 
the Trp53 pathway, which plays a critical role in preventing Myc-induced 
transformation [189,190] . These experiments and others in fibroblasts [191-
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194] emphasize the potent cooperation between oncogenically activated Myc, 
which promotes growth but also activates p53-mediated cell cycle arrest and 
apoptosis, and oncogenic inactivation of p53. Myc has also been shown 
[187,195] to contribute to lymphoma viability with some lymphoma regression 
demonstrated with the withdrawal of Myc overexpression. 
Pairing of MYC and TP53 mutations is a cardinal feature of human Burkitt 
Lymphoma. Burkitt Lymphoma was first described in 1958 [196] by Dennis 
Burkitt as a sarcoma, but subsequently found to be lymphoid in origin and 
named in his honour. This highly aggressive B cell lymphoma is characterised 
by MYC overexpression. Three subtypes have been identified [15]. Endemic 
Burkitt lymphoma is the subtype originally described by Burkitt and 
characteristically occurs in equatorial developing countries such as Africa and 
Papua New Guinea. This classically affects extranodal sites such as the jaw 
and facial bones, and is the most common malignancy in children in these 
regions. Sporadic Burkitt Lymphoma is seen worldwide, characteristically in 
younger patients, although remains an uncommon lymphoma (1-2% of 
lymphomas in developed countries). Immunodeficiency-associated Burkitt 
lymphoma is mainly seen in the context of HIV infection. 
Endemic Burkitt Lymphoma is strongly associated with EBV infection, with the 
majority of tumour cells containing the EBV genome [197]. Sporadic and 
Immunodeficiency-associated Burkitt Lymphoma is less strongly associated 
with EBV infection, with approximately 30% and 25-40% respectively of cases 
having detectable virus. The role of EBV in lymphomagenesis remains unclear 
and is discussed in more detail in Section 1.9. More recently the role of 
Plasmodium [198] has been investigated as the distribution of endemic Burkitt 
Lymphoma mirrors the distribution of endemic malaria. It has been proposed 
that the role of such infections is stimulation of polyclonal B cell proliferation, 
potentially enhancing survival of cells acquiring chromosomal translocations 
(such as those resulting in MYC overexpression) and modulating immune 
responses. The association between HIV infection and Burkitt lymphoma is 
also likely to be due to more than virus-associated immunosuppression as 
these lymphomas tend to develop prior to the onset of marked 
immunosuppression. 
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Other lymphoma subtypes have been shown to have MYC overexpression, 
albeit in a smaller percentage of cases. Diffuse large B cell lymphoma is 
associated with MYC overexpression in ten percent of cases, conferring a poor 
prognosis [199]. In plasma cell myeloma MYC translocations are seen in 15% 
of patients [200] (using fluorescence in situ hybridisation) and in this setting the 
gene is commonly dysregulated by complex chromosomal rearrangements 
[201 ]. 
1.7.2 Myc's physiological role 
MYC encodes a transcription factor which influences a broad range of cellular 
functions. Like p53, its targets are numerous and complex. A screen for MYC 
binding sites in human cells demonstrated that MYC target sites are found in 
promoters of approximately 11 % of genes [202] with vast numbers of target 
genes also identified in a B cell model [203]. Myc mediates most of its 
transcription regulation by dimerisation with Max and subsequent direct binding 
to the promoter sequence of target genes. Intracellular levels of Myc are tightly 
regulated at multiple levels. Its transcription is modulated by numerous 
transcription factors in additioil to diverse other regulatory factors which are 
dependent on DNA configuration (reviewed in [204]). MicroRNAs also modulate 
the stability and translation of Myc mRNA. The Myc protein is short lived and is 
subject to post translational modification (reviewed by Thomas et al [205]). 
Myc-mediated gene repression appears to occur via several different 
mechanisms including functional interference with transcription activators such 
as Miz-1 and recruitment of co-repressor proteins [206]. Some of Myc's 
downstream effects are modulated by microRNAs. The best defined is the miR-
17-92 cluster which post translationally represses many target mRNAs including 
E2F1 activity and several components of the TGF-~ signalling pathway [207], 
thereby promoting proliferation and cell survival [208]. More recently a non 
transcription-dependent role has also been demonstrated [209]. 
Myc promotes cell cycle progression through selective activation and repression 
of cyclins and cyclin dependent kinases [210,211]. B cells with a targeted 
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deletion of the Myc gene are unable to be stimulated to enlarge and proliferate 
in response to B cell receptor or other mitogenic stimuli [52]. Although counter 
intuitive, Myc also accelerates apoptosis [191 ], particularly in the setting of a 
growth factor deficiency, and in a dose-dependent fashion [192]. This is 
predominantly mediated by p53 [193,194] although in p53 null pre-B cells Myc-
mediated apoptosis is reduced but not entirely abolished [189]. The Bcl2 family 
of proteins are downstream effectors of Myc-mediated p53 dependent and 
independent apoptosis [212,213] with Bcl2 being able to rescue cells from Myc-
mediated apoptosis [214]. 
Myc's role in carbohydrate [215] and DNA metabolism and amino acid transport 
[211] has more recently been recognised. 
1.8 Myb 
The work subsequently detailed in this thesis identified c-Myb as a potent co-
operator with oncogenically activated Myc and inactivated Trp53 for inducing 
growth-factor independent proliferation of mature B cells, and -thus its function 
and role in neoplasia are reviewed here. 
Myb was initially discovered as the cellular precursor of the v-Myb oncogene 
(reviewed in [216]). v-Myb was identified as a novel sequence homologous to 
vertebrate mRNAs that had been acquired in two replication defective 
retroviruses, Avian Myeloblastosis Virus (AMV) and E26 virus, both of which 
induce myeloid leukaemia in chickens [217-220]. The AMV proviral genome 
had acquired a spliced cDNA encoding an N- and C-terminally truncated Myb 
sequence, while E26 had acquired a combination of spliced cDNA sequences 
from two cellular genes, Ets-1 and Myb, with the Myb coding sequence 
truncated at its N- and C-terminus and being oncogenic [221-227]. 
Myb also emerged as an oncogene in retrovirus-induced mouse myeloid 
leukaemias and plasmacytoid lymphosarcomas, where recurrent integrations of 
Mul V resulted in dysregulated expression of Myb mRNA and caused aberrant 
splicing truncating either the N- or C-terminus, in a manner _resembling the 
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dysregulation and truncation characteristic of v-Myb in the chicken transforming 
vi ruses [228-231]. 
1.8.1 Myb's role in oncogenesis 
Abnormalities in the MYB locus or in MYB gene expression have been 
observed in several solid tumours including colon carcinomas [232,233], 
melanomas [234] and breast cancers [235] (reviewed by Gonda et al [236]), 
many demonstrating amplification rather than mutation of the gene. MYB has 
also been shown [237] to form one component of a fusion oncogene in adenoid 
cystic carcinomas of the breast and head and neck in which it is truncated at the 
C-terminus. MYB dysregulation has been identified in cases of T-ALL in infants 
[238], the mechanism of MYB overexpression being through either a 
juxtaposition of the MYB locus with the T-cell receptor locus, or gene 
duplication. Knock down of MYB expression in several MYB-overexpressing T-
ALL lines precipitates cell differentiation [239], suggesting that the MYB defect 
may be integral to the leukaemia initiation or proliferation , rather than a 
secondary effect. 
1.8.2 Myb's physiological role 
MYB encodes a highly conserved 75 kilodalton nuclear protein whose role as a 
transcription factor has been most intensively studied [216] . It has a DNA 
binding domain at its amino terminus that binds to targets which have a DNA 
consensus sequence known as the Myb binding site. It also has a 
transactivating domain and a negative regulatory domain, the latter at the 
carboxyl terminus. Myb (also called c-myb) belongs to a transcription factor 
family in humans and mice that also includes A-Myb (Myb/1), which is highly 
expressed in germinal centre B cells , and the ubiquitously expressed 8-Myb 
(Myb/2). These three transcription factors have a significant similarity at the 
protein sequence level with the highest homology in their DNA binding domains 
[240]. 
Myb is required for early haemopoiesis [241,242] with the loss of the Myb gene 
being embryonically lethal at day 14.5 due to anaemia as a consequence of a 
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failure of haemopoietic development. Both early and late myeloid differentiation 
is dependent on Myb expression [243] but in mice with hypomorphic alleles 
lymphoid maturation is more suppressed than myeloid maturation (reviewed by 
Greig et al [244]). Early studies in cell lines showed Myb overexpression 
impairs maturation of normal and malignant myeloid cells [245-247]. Myb 
expression is required for maintenance of selected myeloid leukaemia stem 
cells [248] and overexpression enhances proliferation and inhibits differentiation 
of haemopoietic (myeloid) stem cells [249-251]. Overall, dysregulated Myb 
modulates both haemopoietic cell growth and differentiation, but the precise 
mechanism of these actions remains elusive. 
Ess et al [252] demonstrated high Myb expression during murine development 
in non-haemopoietic organs such as tooth buds, thyroid, proximal airway 
epithelium, hair follicles and gastrointestinal crypt epithelium. Interestingly, th is 
group also demonstrated that the last three sites had high Myb levels into 
adulthood and that loss of Myb was associated with initiation of terminal 
differentiation, rather than loss of mitotic activity. A recurring pattern is that Myb 
is particularly active at early stages of cellular differentiation, its level being 
suppressed with, or its suppression causing, terminal differentiation [216]. 
1.8.3 Regulation and downstream targets 
One of the difficulties in clarifying the role of Myb in normal and mal ignant cells 
is that mutations in the gene can substantially change its activity. Lui et al [253] 
showed that mutations such as N or C-terminal deletions or DNA binding 
domain mutations conferred a unique set of target genes and activities. v-Myb 
is truncated at both the N-terminus and C-terminus in addition to harbouring 
point mutations, and is strongly oncogenic. In contrast, full length c-Myb has a 
much weaker growth-promoting effect when overexpressed [250,254]. The 
precise role of the N-terminus remains to be clarified, but the C-terminus is 
thought to play an important negative regulatory role with C-terminal truncations 
increasing transforming capacity in haemopoietic cells [255] in addition to 
reducing Myb protein degradation [256]. 
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Regulation of Myb expression is complex, changing according to the context 
and cell type. The Myb promoter has been characterised (with Myb itself 
binding to this region and enhancing its own expression) [257], but other 
mechanisms of transcriptional regulation are potentially more important. A 
variable block in transcriptional elongation at the level of the first intron was 
identified in 1988 [258]. Factors regulating this block remain to be well-defined 
but to date the oestrogen receptor [259] and NF-KB pathway [260] have been 
shown to have a modulatory activity. Alternative mRNA splicing also occurs to 
produce a naturally C-terminal truncated protein [261 ], with the alternative 
proteins having different transcriptional activities [262]. MicroRNAs control the 
level of Myb mRNA and translation and are discussed in more detail below. 
Post translational modifications such as phosphorylation [263] and 
ubiquitination [264] also occur, altering protein activity. MYS also co-operates 
(via specific MYS domains) with many transcriptional co-activators and co-
repressors (reviewed by Oh et al [240]) including Ets family members, 
p300/Creb binding protein, CCAAT binding protein (c/EBP) family members and 
the alpha subunit of core binding factor (CBF) in transactivation of target 
promoters. Mutations in Myb which alter these interactions modify Myb's ability 
to regulate myeloid differentiation and proliferation [265]. 
MYB's downstream target genes are numerous [216]. Several publications 
[253,266] have demonstrated that the genes dysregulated by Myb 
overexpression were different in different cell lines. Most research has been 
performed in myeloid cells. A study by Zhao et al [267] analysed a myeloid 
stem cell model with inducible Myb expression by ChlP-sequencing and gene 
expression profiling to identify genes whose expression was directly modulated 
by Myb . This study unexpectedly demonstrated that Myb directly repressed a 
large number of genes. Myb was seen to activate gene sets associated with 
myeloid proliferation and self-renewal while repressing genes relating to 
myeloid differentiation. Genes directly modulated by Myb included those 
mediating cellular functions such as apoptosis, growth and proliferation, cell 
cycle and cell signalling . In addition Myb directly modulated the expression of 
many transcription factors including upregulating Myc. Quintana et al [268] 
looked at Myb binding targets in breast cancer cell lines using ChlP-on-chip 
assays and found over 10 000 binding sites, although the number of genes that 
48 
Chapter 1: Introduction 
have been confirmed to be dysregulated by Myb in the same cell lines is much 
lower [253,269]. 
1.8.4 Myb's role in B cells 
Pro-B cells and pre-B cells express significantly higher levels of Myb than more 
mature B cells [270]. Mutations that decrease Myb activity in B cell progenitors 
reduce or abolish B cell development, with the most pronounced block in the 
transition from the pro-B cell stage to the pre-B cell stage [271,272]. The use of 
tetracycline-regulated Myb expression in a Myb knockout embryonic stem cell 
line suggested that the expression of Myb needed to be strictly regulated to 
ensure proper maturation of B lymphocytes [273]. It remains unclear why B cell 
maturation is so dependent on Myb. Greig and colleagues [274] used 
hypomorphic alleles to show that Myb was required for cytokine (particularly IL-
7) dependent B cell development, but that IL-7 receptor activation alone was 
unable to replace the role of Myb in B lymphopoiesis. As mentioned above, 
knockdown of Myb expression in T-ALL cell lines promoted differentiation 
suggesting that it may have a pathogenic role at least in a subset of T-ALL 
-
patients. Less is known about the role of Myb in B-cell leukaemia and 
lymphoma. Waldron et al [275] used a p1908CR/ABL_dependent pre-B-cell 
leukaemia model to show that Myb hemizygous B-cells are less leukaemogenic 
and clonogenic than their normal counterparts. This study did not examine 
whether the reduction in Myb also promoted B cell differentiation, as the T cell 
work may suggest. 
Myb expression is low in mature B cells, although it increases with B cell 
activation [276] in association with the G1 to S phase transition. Thomas et al 
[271] suggested that conditional ablation of Myb in mature B cells did not impair 
proliferation of splenic B cells but instead prevented them from remaining in a 
quiescent GO state and enhanced their apoptosis. There is, however, a paucity 
of publications exploring the role of Myb in mature B cells, particularly the 
consequences of Myb overexpression. 
The regulation of Myb expression in B cells is likely to be complex. Bender et al 
[277] demonstrated that a block in transcription elongation was underlying the 
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markedly lower Myb mRNA levels in mature versus immature murine B cells. 
The same group [278] subsequently demonstrated that members of the NF-KB 
family were likely to modulate this process. Myb mRNA also is negatively 
regulated by miRNA-150 [267,279], the former group confirming that ectopic 
expression of this micro RNA inhibits the pro B to pre B cell maturation step, as 
is seen with Myb inactivation. 
1.8.5 Myb's role in lymphomagenesis 
The importance of Myb in B cell lymphomas is implied through retroviral studies, 
including work by Kanter et al [280] which demonstrated that B cell lymphomas 
induced by a modified form of the Avian Leukosis Virus all had retroviral 
integrations in or near the Myb locus. The Retroviral Tagged Cancer Gene 
Database demonstrates many murine models of B cell lymphoma with insertion 
sites near the Myb locus. The mechanism by which Myb enhances 
lymphomagenesis, however, remains unclear. 
Myb is known to regulate and be regulated by several microRNAs as discussed 
below. Better definition of these interactions and other genes dysregulated 
simultaneously may be the key to understanding Myb's role in lymphoma. The 
clear role of miRNA-150 in suppressing Myb expression has been mentioned 
above, but the relationship between this microRNA and B cell lymphoma is not 
well defined. Zhao [267] demonstrated that micro RNA 15a was able to reduced 
Myb expression, and that Myb is able to bind to the MiR-1 Sa promoter, creating 
an autoregulatory feedback loop. This is of particular interest because the 
region on 13q where MiR-15a is located is commonly deleted in CLL [83,281], 
suggesting that its dysregulation may be involved in the disease pathogenesis. 
Vargova et al [282] reported that Myb is able to up regulate miR-155 which has 
been shown to be overexpressed in many B cell lymphoproliferative disorders 
[283 ,284] although, interestingly, it is usually downregulated in Burkitt 
lymphoma [86]. Overall , knowledge regarding the interactions between Myb 
and microRNAs is fragmented and thus their significance in lymphoma remains 
to be fully defined. 
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1.9 EBV and B cell transformation 
The development of Burkitt Lymphoma, characterised by the t(8; 14) 
translocation that increases expression of the MYC proto-oncogene, appears to 
be facilitated by Epstein Barr Virus (EBV) infection. Almost all forms of endemic 
Burkitt Lymphoma contain detectable EBV genome, while a significant 
proportion (15-85%) of non-endemic (sporadic) Burkitt Lymphoma also has 
detectable EBV sequences (although the inability to detect the viral components 
in most lymphomas does not preclude EBV from having a role in their 
pathogenesis). EBV induces infected cells to express multiple proteins, many 
of which affect B cell growth. Latent membrane protein 1 (LMP1) has been 
demonstrated to be important for the transformation of B cells [285] by 
mimicking CD40 ligand/CD40 signalling [286]. Transgenic mice overexpressing 
LMP1 have an increased incidence of B cell lymphoma [287], however this is 
mainly at an advanced age, and the lymphomas are clonal, confirming that 
LMP1 alone is insufficient to induce autonomous B cell proliferation. 
The way in which EBV facilitates B cell transformation in the ~presence of t(8; 14) 
remains contentious, but research [288,289] has suggested that EBV-encoded 
proteins are able to reduce cell apoptosis, allowing unlinking of the cell cycle-
promoting capacity of MYC from its apoptosis-promoting effect. The former 
group suggested that this uncoupling was mediated by Epstein-Barr nuclear 
antigen 1 (EBNA-1 ). The latter group demonstrated that latent membrane 
protein 2A (LMP2A) was able to protect cells overexpressing it in conjunction 
with Myc from apoptosis, and that these mice also developed accelerated 
lymphoma compared to Myc overexpressing mice, which was associated with 
increased expression of Bc/-X(L). The EBV genome also encodes microRNAs, 
some of which have been demonstrated to modulate PUMA, a member of the 
anti-apoptotic BCL2 family [290] and a transcriptional target of p53. Similarly, 
EBV encoded microRNAs have been demonstrated to influence the protein 
expression of LMP1 and its regulation of the NF-kB pathway [291]. This further 
broadens the possible mechanisms through which EBV immortalizes B cells. 
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Alternately, it may be that EBV infection enhances B cell activation and 
proliferation, allowing cells with mutations (such as t(8;14)) to survive where 
they otherwise would have undergone apoptosis. It has been suggested that 
the reduced apoptosis seen in EBV-infected cells is mediated through 
decreased expression of the proapoptotic Bcl2 family member, Bim [292]. p53 
is another clear candidate, and it has been demonstrated that the p14ARF-
MDM2-p53 pathway is mutated in various ways in most Burkitt Lymphoma-
derived cell lines [155]. EBV EBER RNAs are small non coding RNAs that are 
produced in abundance in EBV infected cells and show evolutionary 
conservation [293]. They are also postulated to have a role in apoptosis and 
cellular transformation (reviewed in [293]) but the mechanisms are still unclear. 
1.10 Retroviral insertional mutagenesis 
1.10.1 Background 
Identification of critical proto-oncogenes and tumour suppressor genes involved 
in tumourigenesis can be undertaken in multiple different ways. Retroviral 
insertional mutagenesis has been developed to assist in identification of such 
genes. 
Retroviruses are RNA viruses that are reverse transcribed through a DNA 
intermediate as part of their life cycle. Wild type retroviruses have three critical 
genes: pol (encoding the enzymes reverse transcriptase and integrase), gag 
(encoding structural proteins), and env (encoding envelope glycoprotein). The 
virus binds to cellular surface proteins and is subsequently able to enter the cell 
to integrate its reverse transcribed DNA provirus into host DNA during mitosis. 
It then utilises host enzymatic machinery for transcription and translation of its 
own genes. 
By virtue of the fact that retroviruses insert into DNA, they cause genetic 
mutations in the host (reviewed in Uren et al [93]). The most frequent 
insertional mutagenic event is a gain-of-function resulting from dysregulated 
transcription of genes near the provirus insertion site. Strong promoter and 
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enhancer elements are located in the Long Terminal Repeats (L TRs) at either 
end of the integrated provirus, and these act both locally and at a distance to 
increase transcription of neighbouring genes. Occasionally, integration in 
protein coding exons may result in absence or truncation of the normally 
transcribed host protein, or create a fusion host/virus protein. Mutations in non-
coding regions can induce a plethora of alterations such as modifications of 
protein stability [294] or transcriptional regulation. Loss-of-function mutations 
are uncommon [93], however, due to the heterozygous nature of provirus 
integrations and the need to integrate in much smaller target sites. 
Retroviral mutagenesis has been harnessed for research in several ways. 
Changes in cell characteristics such as alterations in cell proliferation, apoptosis 
or differentiation may be seen as a consequence of retroviral infection. The 
retroviral integration site can be identified in such cells, identifying neighbouring 
genes, the altered expression of which may be contributing to the observed 
phenotype. Similarly, overexpression of specific genes encoded within the 
retroviral construct may further impact upon the phenotype observed, and thus 
genes contributing to dysregulated cell growth may be identified. 
The likelihood of retroviral mutagenesis increases with the number of separate 
proviral integrations. Thus, replication competent retroviruses such as MuLV 
are potent accelerators of lymphomagenesis in genetically predisposed mice 
(reviewed in Mikkers et al [295]). Retroviruses have been engineered to 
improve their utility and safety. Ecotropic retroviruses are unable to infect 
human cells. Replication defective retroviruses lack the structural genes 
required for replication and require packaging cells that supply these viral 
particle components in trans such as Phoenix cells developed by the Nolan 
laboratory at Stanford University. Components within the L TR can be 
manipulated to alter their activity in particular cell types (for example Mouse 
Stem Cell Virus L TR resists methylation and inactivation in haemopoietic stem 
cells), or deletions in the 3' L TR can be introduced to self-inactivate the L TR 
enhancer/promoter in the integrated provirus (so-called self-inactivating 
vectors). Specific DNA sequences can be inserted into retroviruses , allowing 
ectopic expression of genes in the transduced cells, further altering the 
retroviral oncogenicity. In fact, many important oncogenes including Src, Myc 
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and Myb were first recognized because mutant versions are encoded and 
expressed by naturally arising retroviruses. 
The genomic site within which a retrovirus inserts is not sequence-dependent, 
but neither is it entirely random, with various host and retroviral factors having 
an impact. This has been sadly but elegantly demonstrated in two retroviral 
gene delivery trials for X-linked Severe Combined Immunodeficiency. Transfer 
of the deficient y chain into autologous CD34 cells utilising a replication-
defective retroviral Moloney murine leukemia viral vector resulted in improved T 
cell counts in most patients, but in 2003 it was reported [296] that 2 of the 
patients had subsequently developed T cell leukaemia, both having a retroviral 
integration site in the vicinity of the LM02 gene in the leukaemic clone 
permitting dysregulated expression of this gene. The most recent reports 
describe 5 patients having developed T cell leukaemia , 4 of whom have 
demonstrable retroviral insertions within or near the LM02 gene [297]. 
Many studies have reviewed the propensity of retroviruses to insert into 
preferred sites within the genome (for example the review by Bushman [298]). 
This is critical because if retroviral mutagenesis is being used to identify 
oncogenes and their insertion sites are non-random, the pattern of integration 
may better reflect the predilection of the virus integration machinery for a certain 
site in the genome, rather than selection for integrations near proto-oncogenes 
or tumour suppressor genes. It has been demonstrated that variations in the 
L TR produce different insertion patterns [299 ,300]. Local structural features 
such as methylation pattern [301] rather than actual DNA sequence have also 
been shown to influence the integration pattern of specific retroviruses. 
Transcriptional activity has been shown to be important for integration site 
selection by Moloney murine leukemia virus [302]. A large study by Wu et al 
[303] compared the integration sites of the murine leukemia virus (ML V) with the 
human immunodeficiency virus-1 (HIV-1) in HeLa cells. They confirmed that 
MLV selectively integrated near the transcription start site of the more actively 
transcribed genes, particularly in the region of gene promoters , while HIV-1 
preferentially integrated anywhere in the transcribed region but not upstream of 
the transcriptional start site. These and other studies demonstrate that different 
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virus/host combinations cause a different spectrum of insertion sites within the 
mouse genome. 
Retroviral insertional mutagenesis contrasts with the more recently developed 
DNA transposon systems. Commonly used systems include the 'Sleeping 
Beauty' system, based on the Tc1 /mariner superfamily of transposons 
reconstructed from fossil sequences in 1997 [304] and the moth-derived 
'PiggyBac' system. Transposons are synthetic segments of DNA which can 
stably integrate into DNA within a single cell, although are not able to cross cell 
membranes, so are not intrinsically infectious. They can be modified to 
incorporate a gene of interest (although transposition efficiency is inversely 
correlated with gene length [305] within the Sleeping Beauty system) and can 
thus be used for genetic transformation and insertional mutagenesis in many 
vertebrate cells including murine and human. 
Several distinct advantages over the retroviral systems are a more random 
integration site distribution [306,307] , low immunogenicity and reduced cost of 
mass production, making this system particularly appealing for gene therapy. 
There are, however, several drawbacks currently limiting their use in research 
and gene therapy. Transposons require a delivery system such as a plasmid to 
reach the cell nucleus which is often less efficient than retroviral transduction. 
Safety issues are always a paramount consideration for gene therapy 
particularly, and while transposons theoretically have a better safety profile 
than retroviral vectors due to their more random integration into the genome, 
their clinical development is at a much earlier phase and thus their safety profile 
remains to be fully elucidated. There is also less experience in the scientific 
community with this method of insertional mutagenesis and thus retroviral 
methods are still currently widely utilised. 
1.10.2 Retrovirus insertional mutagenesis screens 
lnsertional mutagenesis by infecting mice with replication competent 
retroviruses has proved to be a powerful tool to identify potential tumour 
associated genes [93]. Such screens commonly identify proto-oncogenes, 
whose activity is enhanced by the retroviral insertion. Tumour suppressor 
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genes are less commonly isolated, the retroviral insertion reducing gene 
expression, but both alleles of a tumour suppressor gene must generally be lost 
for a significant phenotype, so these are most commonly identified if one copy 
of the gene is already mutated. However, occasionally haploinsufficiency, with 
the loss of a single allele of a gene, will be associated with a specific 
phenotype. 
Often these screens are performed by infecting strains of mice that are already 
predisposed to cancer, as first described in Eµ-myc transgenic mice [91,92], 
facilitating identification of somatically mutated genes that co-operate with the 
inherited oncogene in the formation of cancer. The lack of expected common 
sites of integration in such models can help identify genes that work within a 
common pathway, mutation of both not having a co-operative effect in 
tumourigenesis. 
1.10.3 Methods of integration site identification 
Retroviral insertion sites can be identified by amplifying the genomic sequences 
flanking the retroviral insertion site. Traditionally integration site analysis was 
performed by Southern blot analysis and genomic library screening. More 
recent sequencing of the mouse genome and publication in a readily accessible 
online format has greatly facilitated the identification of the genomic location of 
each integration site and the surrounding genes. 
PCR-based techniques have been developed to amplify a short segment of 
DNA flanking the integrated provirus. They include Inverse PCR, and the linker-
based Vectorette-PCR and Splinkerette PCR, the latter of which is utilised in 
this thesis. This employs a splinkerette - an adaptor molecule containing a 
hairpin loop - to ensure that there is no non-specific DNA binding. The principle 
is illustrated below (Figure 1.1) and the method detailed in the Materials and 
Methods section . 
Newer techniques are constantly being developed including linear amplification-
mediated (LAM) PCR [308] in which PCR is initially performed with vector-
specific primers , target DNA is isolated, followed by further PCR and 
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sequencing of amplicons. Nonrestrictive LAM-PCR [309] is a more recent 
development based on the former but which avoids the use of restriction 
enzymes and incorporates high throughput sequencing. Clearly the aim of 
newer methods is to enhance speed and efficiency of integration site analysis, 
facilitating rapid identification of larger numbers of insertion sites, allowing 
increased scale and throughput of retrovirus insertional mutagenesis screens . 
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Figure 1.1 Schematic representation of the splinkerette PCR technique 
Sequential steps are illustrated in red . 
a) 
b) 
c) 
d) 
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a) DNA is digested with a restriction enzyme (eg Sau3AI) which results in some 
fragments containing the retroviral - genomic (bold) DNA junction . 
b) An adapter (containing a hairpin loop, to ensure that there is no non-specific 
DNA binding) binds to the ends of the restriction enzyme-digested DNA. 
c) One primer complementary to the retroviral long terminal repeat and another 
primer containing the same sequence as the non-hairpin strand of the adapter 
are added . The first round of PCR can thus only amplify the complementary 
strand to the retroviral L TR. 
d) The second primer can now anneal to this product, allowing exponential 
amplification of the retroviral-genomic DNA junction (and an internal retroviral 
segment) using primers in both directions. 
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1.10.4 Methods of integration site data analysis 
Retroviral insertion, through the retroviral enhancer elements, can modify the 
activity of genes up to 270kb [31 0] away. Identifying the important gene whose 
activity has been modified by the integration and thus altered the cell phenotype 
is thus difficult when the provirus has integrated in a gene-rich region. By 
looking at the pattern of integration sites in a large number of retrovirus-induced 
cancers, clusters of "common insertion sites" (CIS) around a particular gene can 
help to indicate which gene is likely to be the insertionally activated oncogene. 
The definition of a common insertion site, however, is difficult as the number 
that can be found in a particular experiment depends on the size of the 
"window" defining a common site. If the window is too large, even random 
patterns of integration will appear to create common integration sites just by 
chance. If the window is too small, common sites of integration around proto-
oncogenes may be missed because of long-range effects of the proviral L TRs. 
Defining the correct size is further complicated by the propensity for retroviruses 
to integrate near or in transcriptionally active genes, and the fact that gene 
density can vary by more than 10-fold across the genome. As common 
insertion sites give a probability that a gene is significant, this ··must be followed 
up by functional experiments to test that overexpression or knock down of the 
candidate gene does indeed cause the expected phenotype. Corroboration 
with independent evidence for oncogenic activity in human studies or other 
animals also helps to redress the statistical uncertainty of interpreting common 
integration site data. 
1.10.5 Retrovirus tagged cancer gene database 
A database was developed in Nancy Jenkins and Neal Copeland's laboratory 
[94] to collate data about retroviral integration sites in mouse models of 
malignancy in order to facilitate identification of common insertion sites in 
different tumour models and enable online searching. This is freely available on 
the internet (http://RTCGD.ncifcrf.gov). As a proof of principle, within the most 
common 10 insertion sites in this database are the genes Myc, Myb, Notch 1 
and Pim 1, all of which are well established proto-oncogenes in humans and 
rodents and known to be frequently mutated in lymphomas by a variety of 
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means. The beauty of this type of gene discovery is that the data is derived 
from a whole genome approach, so the results are not skewed due to 
preconceived ideas about particular genes or pathways. 
1.10.6 Retroviral mutagenesis in Myc transgenic mice 
In order to enhance understanding of the genes that co-operate with Myc 
overexpression in lymphomagenesis, van Lohuizen et al [92] infected Eµ-myc 
mice with Moloney Murine Leukaemia Virus. This process enhanced 
lymphomagenesis and identified four common insertion sites, Pim-1, Bmi-1, 
Pa/-1 and Bla-1. Haupt et al [91] published a similar study in the same journal 
issue, identifying common insertion sites at the Pim-1, Pim-2, Bmi-1 and Emi-1 
loci. 
Bmi-1 is a member of the Polycomb group of proteins, which are transcriptional 
repressors. The action of Bmi-1 in enhancing lymphomagenesis was 
subsequently shown to be mediated through suppression of lnk4a expression 
[311]. lnk4a encodes the tumour suppressors p19ARF and p16, the former 
stabilising p53, and the latter blocking phosphorylation (inactivation) of the 
retinoblastoma protein. Thus, one of the actions of the common insertion site 
locus Bmi-1 in Eµ-myc mice is transcriptional repression of the p53 pathway. 
1.10.7 Retroviral mutagenesis in Trp53 defective mice 
Two large studies have performed retroviral mutagenesis in mice that 
harboured a primary or secondary p53 defect. The first [312] utilised Cdkn2a 
(encoding p19ARF)-defective mice which have increased binding of p53 to 
Mdm2, and thus reduced p53 activity. These mice also have disruption of the 
retinoblastoma pathway as this gene also encodes p16INK4a. In total 565 
integration sites were isolated, identifying 45 common insertion sites. The most 
common insertion site in their population of lymphomas and histiocytic 
sarcomas was in Myc. The second paper [313] performed mutagenesis in 
p19(ARF)-/- mice, p53-/- mice and wild type mice, transducing them with 
Moloney Murine Leukaemia Virus. The group analysed 51 0 tumours , 
predominantly B cell lymphomas and T cell lymphomas, and · over 1 0 000 
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independent insertion sites and 346 common insertion sites were isolated. Myc 
was the second most common insertion site, with Myc-insertion-containing 
tumours having an over representation of Nfkbi/1/Lta, CCnd3, mmu-mir-106a-
363 and Rasgrp 1 mutations. 
1 .11 Number of required steps for 
malignant transformation 
The minimum number of oncogenic 'hits' required for a neoplasm to develop 
remains contentious. The question is somewhat artificial, however, as cellular 
pathways are not active in isolation, and dysregulation of one is likely to have 
an impact on multiple other pathways. Clearly, the nature of the mutations, in 
addition to the number, needs to be addressed. In addition this issue has 
become more complicated recently with the discovery of non-protein-coding 
genes (microRNAs), the importance of the microenvironment, epigenetic 
factors, significant inter-individual variation in gene expression, among other 
factors, which are likely to have a significant impact on lymphomagenesis. 
1.11.1 Human studies 
Human studies suggest that more than one oncogenic mutation is required for 
the development of solid tumours. The multistep nature of malignant 
transformation was demonstrated in colon carcinoma and its precursor lesions 
by Vogelstein et al [314], suggesting that two lesions are likely to be insufficient 
for a malignant phenotype. Similarly, the timing and diversity of tumours [140] 
in patients with germline TP53 gene mutation (Li-Fraumeni Syndrome) is 
consistent with further oncogenic events being required for the development of 
a malignant phenotype. This multi hit hypothesis concurs with the broad 
spectrum of capabilities that a cell must acquire before becoming fully 
neoplastic [1 ], with a single or even two oncogenic mutations being unlikely to 
provide all these requirements. 
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Resequencing studies have found that, on average, there are 80 amino acid-
changing somatic mutations in human colon or breast cancers, with "mountains" 
of frequently mutated genes and "hills" of less frequently mutated genes [315]. 
In view of these and similar studies, some groups have proposed mathematical 
models of cancer in which tumourigenesis is driven by mutations in many 
genes, each of which provides only a small growth advantage [316]. A 
subsequent publication analysing pancreatic cancer [317] reported an average 
of 67 genetic alterations in a set of 24 pancreatic cancers, the majority of which 
were point mutations. A recent study [318] sequencing four cases of Chronic 
lymphocytic leukaemia identified 46 somatic mutations that could potentially 
affect gene function. These studies, however, cannot determine which genetic 
mutations are instrumental in tumourigenesis. 
Haemopoietic tumours may require fewer mutations than solid tumours. In 
particular, normal mature B cells are endowed with three of the six malignant 
cell attributes considered by Hanahan and Weinberg: the capacity to migrate 
and invade normal tissues; indefinite replication in the process of maintaining 
life-long immunity; and the ability to promote (lymph)angiogenesis [319]. In 
addition, as a consequence of RAG and AID gene-mediated mutations [320], 
mature B cells may more readily acquire genetic lesions which confer a 
proliferative advantage. 
The BCR-ABL translocation in Chronic Myeloid Leukaemia (CML) appears to be 
sufficient alone to cause the disease, confirmed by the efficacy of human 
tyrosine kinase inhibitors targeting this molecular mechanism. Mouse models 
appear to concur, with Daley et al [321] demonstrating the retrovirus-induced 
expression of P210bcrlabt could induce a myeloproliferative disorder resembling 
CML, and Honda et al [322] showed that progeny of transgenic mice with 
21 Ober/ab! d d h p expresse un er t e control of a tee promoter also developed a 
disease resembling CML. However, small numbers of B cells with the BCR-
ABL translocation have been isolated in a significant proportion of normal 
individuals [323 ,324] suggesting that this translocation may only be sufficient in 
myeloid precursors or stem cells. 
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Human studies are enlightening with regards to lymphoid malignancy. Limpens 
et al [106] demonstrated that over half of a small number of healthy blood 
donors had t(14; 18)(q32;q21) (which juxtaposes the BCL2 gene with the /GH 
gene) detected by sensitive PCR methods in their peripheral blood 
lymphocytes, although at an estimated frequency of 1 in 105 or less circulating 
B cells. This is the translocation seen in 80% of human Follicular Lymphoma, 
resulting in overexpression of BCL2 and a consequential block in apoptosis. 
Many of the normal individuals in this study had greater than one t(l4; 18)-
carrying 8-cell clone, and all breakpoints had a structure similar to that seen in 
Follicular Lymphoma. As the proportion of people identified harbouring this 
mutation far exceeds the proportion likely to develop Follicular Lymphoma, even 
over a lifetime, these results suggest that further genetic defects are required 
for the development of lymphoma. Similarly, Summers et al [325] confirmed 
that low levels of the t(14; 18) are found in a substantial proportion of the normal 
population. 
An interesting publication by Cong et al [326] identified aberrant BCL2 
expression in germinal centre cells in 23 lymph node biopsies, with micro 
.. 
dissection and PCR performed on a smaller number of these cases suggesting 
that the cells had clonally rearranged immunoglobulin heavy chain genes, 
labelling this as 'in situ localisation of Follicular Lymphoma. Five of twenty three 
patients had Follicular Lymphoma at another site, and 3/23 subsequently 
developed Follicular Lymphoma at relatively short follow up. A small study by 
Muller [327] demonstrated persistence of clones with t(8;14) Uuxtaposition of 
MYC with /gH) in 4 HIV positive patients which persisted from 1 to 9 years, with 
the development of only one t(8;14) negative lymphoma in the follow up period. 
Similar studies have not been published analysing the incidence of t(8; 14) in 
non-HIV infected normal populations. 
In general a single defect selects against further defects in that pathway. This 
is demonstrated by a review of the Retroviral Tagged Cancer Gene Database 
[94] which shows that while insertion sites near Myc are commonly seen in 
retrovirus induced B cell lymphomas, if the mouse genotype already results in 
overexpression of Myc, then insertion sites near Myc are much less common. 
Similarly, inactivation of p53 is commonly seen in Burkitt Lymphoma. Lindstrom 
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et al [155] demonstrated that in Burkitt cell lines with intact p53, other mutations 
in the p53 pathway are more commonly identified that in those with mutated 
p53. This concept has been recently disputed. Chanudet et al [328] have 
demonstrated that some MALT lymphomas have two distinct defects in the NF-
KB pathway, one of which involved a tumour suppressor gene. These findings 
suggest that perhaps there is a threshold of pathway activation beyond which 
the dysregulation of that pathway facilitates lymphomagenesis. If a single 
defect is insufficient to cross this threshold then further defects in the same 
pathway may be complementary. 
Viruses such as EBV and HHV8 are thought to be oncogenic in their own right, 
infecting and transforming cells, as opposed to viruses such as hepatitis C 
which are associated with an increased risk of lymphoma, but are not directly 
oncogenic. EBV [289] and HHV8 [329] all produce multiple viral products which 
affect diverse cellular pathways, so such an infection cannot be truly regarded 
as a single defect precipitating lymphoma. 
1.11.2 Murine research 
Some caution is required when extrapolating from murine studies, as murine 
cells are more readily immortalised than human cells by chemicals or 
transfection of oncogenes [330], the reason for which is unclear but possibilities 
include suboptimal DNA repair mechanisms, or variations in telomerase activity 
[331 ]. The number and nature of genetic hits required for the development of 
solid tumours has been addressed to some extent in mouse models . Early 
seminal studies in rodent fibroblasts indicated that pairs of mutations , such as 
Ras and Myc [332] or Myc and Trp53 [194,333] were sufficient to transform 
them to growth factor-independent proliferation. 
With regards to haemopoietic malignancy, overexpression of a single proto-
oncogene such as Bc/2 [33] or Myc [334] is insufficient alone to induce 
lymphoma. Mice constitutively expressing Myc and Bc/2 under the influence of 
the immunoglobulin heavy chain pron1oter have increased numbers of pre-B 
cells and B cells, but these are not initially clonal and do not grow rapidly in cell 
culture , although these mice subsequently rapidly develop a clonal aggressive 
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lymphoma [335], suggesting that at least one more oncogenic hit is required for 
tumour outgrowth. Murine research has, as with human research, 
demonstrated small populations of apparently benign lymphocytes with 
characteristic chromosomal translocations. Raschke et al [336] demonstrated 
small numbers of cells with a translocation between Myc and lgA, with the 
numbers of these cells increasing post immunisation with cholera toxin. 
Similarly, Ramiro et al [337] have showed that small number of stimulated non 
malignant B cells in vitro harbour a Myc-lgH translocation, numbers of which 
increased in the setting of Atm deficiency or p53 deficiency 
1.12 Nature of pathway dysregulation 
> 
precipitating B cell malignancy 
It has long been postulated that dysregulation of complementary pathways 
within a single cell is required for the acquisition of a malignant phenotype, such 
as a proliferative advantage potentiating the effect of an apoptotic defect. 
Mouse models with a single genetic defect that alone is insufficient to 
precipitate uncontrolled cell proliferation have been very useful in clarifying the 
nature of complementary genetic events that enhance the development of 
malignancy as co-operative spontaneous mutations, or those facilitated by 
retroviral or chemical mutagenesis, can often be detected in the final tumour. 
The genes and pathways commonly dysregulated in human mature B cell 
lymphoma are discussed below. Specific subtypes of human B cell non 
Hodgkin lymphoma will be reviewed separately in conjunction with the most 
relevant mouse models. 
Burkitt Lymphoma: This is characterised by MYC overexpression and has a 
unique combination of dysregulated genes [5]. Burkitt Lymphoma cells are 
BCL6 positive and commonly CD10 positive, their maturation and activation 
state being similar to that of an actively proliferating germinal centre cell. 
Schmitz et al identified that mutations in TCF3 and its negative regulator /03 
were found in 70% of cases of sporadic Burkitt Lymphoma analysed. TCF3 
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regulates B cell specific gene transcription during B cell development, but 
interestingly its knock down was toxic to Burkitt cell lines but not DLBCL cell 
lines. The group suggested that the dependence on TCF3 signalling related to 
its role in up regulation of immunoglobulin heavy and light chains which are two 
components of the B-cell receptor, the mutation disrupting tonic B cell receptor 
signalling. The B cell receptor is critical for the survival of mature B cells [17, 18] 
with tonic signalling though the Pl3K pathway being important in both normal B 
cells [22] and Burkitt Lymphoma cells [338]. Refaeli et al [95] demonstrated that 
a mouse model overexpressing Myc only developed a Burkitt-like phenotype if 
the B cell receptor was activated and Sander et al [14] showed that constitutive 
Myc expression and Pl3K activity in murine germinal centre B cells produced 
lymphomas with many features in common with Burkitt Lymphoma. The mir-17-
92 cluster of microRNAs promotes Myc-induced lymphoma [339], and 
antagonises PTEN, a negative regulator of Pl3K signalling [340,341]. Genomic 
amplification resulting in high expression of the miR-17-92 cluster is not 
uncommon in Burkitt Lymphoma [342,343] and may be an alternative 
mechanism by which selected cases of Burkitt lymphoma have enhanced Pl3K 
signalling. 
Interestingly, the NF-KB pathway does not seem to be particularly active in 
Burkitt Lymphoma, with NF-KB target genes being expressed at a lower level 
than seen in DLBCL [344]. Klapproth et al [345] have shown that NF-KB 
pathway activity appears to promote apoptosis in Myc-induced lymphoma. 
Suppression of the p53 pathway is also very commonly seen in Burkitt 
Lymphoma. Mutations in the gene expressing p53 have been identified in 
approximately 30% of Burkitt Lymphoma biopsies and 60-70% of Burkitt 
Lymphoma cell lines [155]. Mutations in ARF, a tumour suppressor gene that 
binds to and inhibits MDM2, the p53 suppressor, are common in Eµ-myc 
lymphoma [189] and Burkitt cell lines [155]. Wilda et al [346] identified 
disruption of the ARF-MDM2-p53 apoptotic pathway in 55%, of their cases of 
paediatric sporadic Burkitt Lymphoma. Defects in apoptotic pathways in Burkitt 
Lymphoma and Myc overexpressing murine models are discussed in more 
detail in Section 1.13.2 below. 
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Mantle cell lymphoma provides an example of complementary pathway 
dysregulation in B cell lymphoma. Mantle cell lymphoma is thought to 
correspond to the na·,ve B cell but has a characteristic t(11; 14) which results in 
overexpression of CCN01 encoding cyclin D1 (which promotes cell cycle 
progression). Studies of human Mantle cell lymphomas frequently demonstrate 
a wide spectrum of additional genetic mutations, the genes encoded in these 
regions commonly being involved in cell cycle regulation or the DNA damage 
response pathway [347]. Interestingly, transgenic mice with a recapitulation of 
this translocation (Eµ cyclin D1) have a relatively normal B cell compartment, 
but when crossed with Eµ N-myc mice (which themselves have a low lymphoma 
incidence and long latency period) the progeny rapidly develop B cell lymphoma 
[348]. 
Follicular Lymphoma: The maturation and activation state of Follicular 
Lymphoma cells best corresponds to normal germinal centre B cells. Up to 
85% of cases are characterised by the t(14;18)(q32;q21) or a variant 
translocation which relocates the anti-apoptotic BCL2 oncogene into an 
immunoglobulin (/G) gene locus, leading to deregulated expression of the BCL2 
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protein [349]. A subpopulation of the remaining cases demonstrate BCL2 
overexpression, but some morphologically classical cases do not appear to 
have dysregulated BCL2 [349]. As discussed in Section 1.11 this classic 
translocation alone is insufficient in humans to cause lymphoma. Murine 
models where the Bc/2 gene is under the control of the immunoglobulin heavy 
chain locus exhibit prolonged cell survival and an expanded lymphoid 
compartment [33,350] but do not readily develop lymphoma. In contrast, 
models where the Bc/2 gene is placed under the control of the Vav gene 
regulatory sequences (which results in overexpression of Bc/2 in multiple 
haemopoietic lineages rather than just B cells) show delayed development of 
Follicular Lymphoma [34]. This group confirmed that help from the expanded T 
cell population was required for lymphomagenesis. 
Diffuse large B cell lymphoma (DLBCL): Diffuse large B cell lymphoma cells 
also have mutated immunoglobulin variable region genes consistent with cells 
that have been exposed to the germinal centre. Two important subtypes of 
DLBCL have been identified, Activated B cell-like (ABC) and Germinal centre-
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like (GCB), each having a different prognosis, gene expression profile and likely 
cell of origin. Lenz et al [351] showed that in GCB DLBCL amplification of the 
mir-17-92 microRNA cluster (often associated with MYC overexpression), REL 
amplification and deletion of the tumor suppressor PTEN were common, but 
these events did not commonly occur in ABC DLBCL. Iqbal et al [352] 
demonstrated that 34% of the GCB subtypes had t(14;18) but no demonstrable 
change in prognosis compared to the negative GCB subtypes. The genes 
differentially expressed between the two groups were heterogeneous including 
genes involved in apoptosis, adhesion/migration, cell cycle progression and 
regulation and a number of transcription factors. The ABC subtype of DLBCL 
has been shown by many groups [99,100,112] to be dependent on constitutive 
activity of the NF-KB pathway which may be driven by CARD11 mutations [98], 
MYDBB mutations [70] or other mutations that facilitate chronic active B cell 
receptor signalling [353] . In addition , Lenz et al [351] demonstrated that FOXP1 
and SP/8 (an ETS family transcription factor) were commonly overexpressed 
and the INK4a/ARF tumor suppressor locus was commonly deleted in ABC 
DLBCL but not GCB DLBCL. Reduced BLIMP1 expression, often due to 
biallelic inactivation [354], has also been shown to be specific for the ABC 
rather than GCB subtypes of DLBCL. 
Hairy cell leukaemia is an uncommon mature B cell lymphoproliferative 
disorder which does not clearly correspond to a specific stage of B cell 
development. It is of particular interest because recently the BRAF E600V 
mutation was identified in almost all cases [355 ,356]. BRAF is a component of 
the RAS-RAF-MAPK signalling pathway, the V600E mutation resulting in the 
constitutive activation of BRAF kinase. This pathway relays extracellular 
signals to the nucleus and is critical for regulation of cellular proliferation , 
differentiation and survival. This pathway had not been previously 
demonstrated to be consistently dysregulated in human mature B cell 
lymphoma . With regards to murine models , Alexander et al [357] 
demonstrated that transduction of v-H-ras or v-raf expressing retroviruses into 
Eµ-myc mouse bone marrow resulted in increased numbers of pre-B cell 
colonies in soft agar within several days which was not seen with either of these 
genetic mutations alone. These colonies were oligoclonal and grew as tumours 
in nude mice. In concordance with these findings , Schwartz- et al [358] 
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demonstrated that murine pre-B cells doubly transduced with a Myc-encoding 
retrovirus and a v-Ha-ras-encoding retrovirus could grow autonomously in vitro 
and were tumourigenic in syngeneic mice. The way in which the RAS-RAF-
MAPK signalling pathway co-operates with Myc remains unclear. Similarly, co-
operating mutations in human Hairy cell leukaemia have not yet been well 
defined, although the initial publication [355] identifying this genetic defect 
through whole exome sequencing did not clearly identify any other potentially 
co-operating genes. 
Marginal zone lymphoma: This is postulated to be derived from a post 
germinal centre memory B cell with three main types depending on the site of 
origin: splenic, nodal and mucosa associated lymphoid tissue (MALT). MALT 
lymphoma is thought to commonly be initiated by chronic antigenic stimulation 
(infective agents or autoantigens). Subsequent genetic events commonly result 
in dysregulation of the NF-KB pathway (reviewed in [359]). 
In conclusion, the various mature B cell lymphoma subtypes correspond to 
different normal stages of B cell differentiation and thus their constitutively 
active pathways will vary. The dysregulated pathways and genes that have to 
date been identified in mature B cell lymphoma vary from subtype to subtype. 
This is consistent with the nature of the complementary genetic perturbations 
which facilitate the cell's acquisition of the full complement of capabilities 
described by Hanahan and Weinburg [1,2] varying according to the B cell's 
innately active pathways. 
1.13 Dysregulation of Trp53 and Myc 
1.13.1 Background 
Dual Trp53 and Myc dysregulation is commonly seen in both human and murine 
lymphoproliferative disorders. Eµ-myc mutant mice are predisposed to B cell 
lymphoma, but the dysregulation of Myc alone is insufficient to cause lymphoma 
(reviewed in Section 1.7.1). Analyses of lymphomas developing in such mice 
demonstrate a high likelihood of mutations in the ARF-Mdm2-p53 pathway 
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[189]. The same group also demonstrated that Eµ-myc mice had a more rapid 
onset of tumour development in the setting of Ari (an activator of p53) 
deficiency [189] . Similarly, in addition to the classic translocations resulting in 
overexpression of MYC in human Burkitt lymphoma, mutation analysis 
commonly demonstrates inactivation of the ARF-MDM2-p53 pathway as 
discussed in Section 1.12 above . In addition , Martins et al [360] showed that 
restoration of p53 function in Eµ-myc lymphomas in vivo resulted in tumour 
apoptosis and prolonged mouse survival , consistent with the p53 defect being 
important for tumour maintenance rather than just its initiation. 
It has been contentious whether combined dysregulation of both p53 and Myc 
are alone sufficient to allow neoplastic B cell proliferation . Zindy et al [333] 
suggested that mouse embryo fibroblasts can be immortalised by a combination 
of Myc overexpression and a p53 pathway defect. Schmitt et al [361] showed 
that Eµ- myc mice rapidly developed lymphomas in the setting of a Trp53 gene 
defect, with almost all resulting lymphomas demonstrating deletion of the 
remaining p53 allele . Similarly, Jacobs et al [362] demonstrated an oligoclonal 
or clonal aggressive B cell leukaemia developing rapidly in Eµ-myc mice with 
heterozygosity at the lnk4a-Ari locus ( encoding the two tumour suppressors 
p16 and p19Arf, the latter preventing the degradation and inactivation of p53) 
with 15/15 of their tumours demonstrating loss of their remaining lnk4a-Ari 
locus. These studies have suggested that, in the setting of Myc 
overexpression , homozygous inactivation of Trp53 was the remaining 'hit' 
required for a B cel l to acquire a neoplastic phenotype . In contrast, it has also 
been shown that lymphomas that arise in ARF null Myc overexpressing 
transgenic mice are clonal [212] consistent with at least three oncogenic hits 
being required for this subpopulation of cells to grow out. Yu et al [363] refute 
this . They transduced p53-null bone marrow cells with a Myc expressing 
retrovi rus , injecting the resulting cells subcutaneously into syngeneic mice. 
Analysis of the resulti ng tumours showed that they were polyclonal , the group 
concluding that a Trp53 defect and Myc overexpression are sufficient alone to 
cause tumours. The deficits in th is argument are that an additional mutagenic 
hit is provided in each cell by the very event of retroviral integration , and the 
lack of confirmation that the resulting cel lular outgrowths were neoplastic, with 
no mention of spread of the tumour beyond the skin. 
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The frequency with which gain-of-function mutations in TCF3 and loss of 
function mutations in its negative regulator /03 were identified in the recent 
publication by Schmitz et al [5] indicate that this mutation occurs in conjunction 
with MYC overexpression and a p53 pathway defect in many Burkitt 
lymphomas. Sander et al [14] demonstrated cooperation between Pl3 kinase 
pathway activation and MYC overexpression for germinal centre lymphomas in 
mice. Tonic B cell receptor signalling to Pl3K, exaggerated by unrestrained 
TCF3, may thus cooperate with Myc overexpression and a p53 pathway 
mutation in Burkitt lymphoma to drive the highly proliferative phenotype that 
characterizes this lymphoma subtype. 
Evidence that MYC activation and Trp53 inactivation are alone insufficient for B 
cell transformation has come from research performed by a previous PhD 
student in the Goodnow Laboratory, Dr Lixin Rui. Dr Lixin isolated mature 
splenic B cells from mice, activated them in vitro, and transduced them with a 
replication-defective retroviral vector encoding human MYC and either green 
fluorescent protein (GFP) or tail-less human CD4 (huC04). Expression of GFP 
-
or huC04 was from an internal ribosome entry sequence within the same 
mRNA as MYC, and thus identified MYC-transduced and expressing B cells in 
flow cytometric analysis. Upon re-injection of approximately 1 million of these 
cells into syngeneic mice or lymphopenic Rag1-null mice, the GFP positive B 
cells rapidly disappeared if they co-expressed MYC, similar to control cells 
transduced with empty vector encoding only GFP. Even when the splenic B 
cells were obtained from mice carrying a homozygous inactivating mutation in 
Trp53, the combination of enforced MYC and defective p53 was insufficient to 
promote spontaneous proliferation upon re-introduction into syngeneic mice or 
lymphopenic Rag1-null mice (Figure 1.2). 
However, if recipient mice of MYC transduced Trp53 mutant B cells were 
tracked for several months, a small percentage of syngeneic recipients and 
most Rag1-null recipients developed an aggressive surface lgM+ GFP+ B cell 
lymphoma that invaded spleen, lymph nodes, and extra lymphoid sites such as 
kidney and liver (Table 1.2 and Figure 1.3). No lymphoma developed in 
recipients of transduced B cells that had a normal Trp53 gene. Control 
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experiments were not performed in which non-transduced Trp53 mutant cells, 
or mutant cells transduced with an empty GFP expressing vector, were injected 
into Rag1-null recipients . Since all of the lymphomas were GFP positive this 
implied that MYC, expressed from the same bicistronic vector, was contributing 
to lymphomagenesis , being consistent with the published evidence for 
cooperation between MYC and Trp53. It remains possible that the specific DNA 
mutation conferred through retroviral transduction was actually the event 
cooperating with the p53 defect in a small number of cells , facilitating outgrowth , 
with Myc/GFP expression merely confirming successful retroviral integration. 
Since approximately 1 million MYC positive Trp53 mutant B cells were injected 
into each recipient mouse, and the majority did not proliferate over the course of 
5-10 days as measured by dilution of a cell-division tracking dye , these data 
indicate that transformation to growth factor self-sufficiency by the MYC plus 
Trp53 combination was inefficient and occurred in as few as one cell in a 
million . 
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Figure 1.2 MYC activation and Trp53 inactivation are insufficient for B cell 
transformation 
Unpublished data from Dr Lixin Rui. 
The left panels show flow cytometric analysis of spleen B cells with (A) Trp53 wildtype 
or (B)homozygous mutant Trp53 after in vitro transduction with a bicistronic retroviral 
vector encoding MYC and huCD4+. The x-axis measures relative fluorescence with 
the dye CFSE, which has been incorporated into the cells to measure its dilution 
during any subsequent cell divisions. Middle and right panels show flow cytometric 
analysis of spleen cells from Rag1 null mice 10 days after intravenous injection with 
the input donor cells on the left. The donor B cells (within gate) were identified by 
staining with antibodies to the B cell marker B220, and an lgM allotypic marker, lgM 8 , 
that is unique to the donor B cells. The right panels are gated on the donor B cells, 
showing the huCD4/MYC-expressing subset and CFSE fluorescence. Only a small 
percentage of the donor B cells have divided and diluted out CFSE during the 10 day 
period, ie shown a left shift and this percentage is not increased in the MYC/huCD4+ 
fraction. 
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Table 1.2 Tumour incidence in recipients of MYC-transduced antigen-specific 
B cells 
Unpublished data from Dr Lixin Rui. 
Summary of the occurrence of lymphomas in recipients of MYCIGFP transduced 
(MYC) spleen B cells from C57BL/6 mice carrying either normal Trp53 (p53wt) or 
homozygous mutant Trp53 (p53Bbl) genes. In the final two experiments, the B cells 
were co-transduced with two retroviral vectors, one encoding MYC/GFP and the other 
encoding the cytokine BAFF/huCD4 or an empty huCD4 vector (EV) 
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Donor cells 
(m ii I ion/recipient) 
p53wt MYC (4) 
P53Bbl MYC (4) 
p53wt MYC (6) 
p53Bbl MYC (6) 
p53wt MYC (5) 
p53Bbl MYC (5) 
p53Bbl MYC (4) 
p53Bbl MYC (2.5) 
p53Bbl MYC (2.5) 
p53Bbl MYC+EV (4) 
p53Bbl MYC +BAFF(4) 
p53Bbl MYC+EV (4) 
p53Bbl MYC +BAFF(4) 
Recipient 
C57BL/6 
C57BL/6 
C57BL/6 
C57BL/6 
C57BU6 
C57BL/6 
Rag KO 
C57BL/6 
Rag KO+ T cells 
C57BL/6 
C57BL/6 
C57BL/6 
C57BL/6 
Days post Lymphoma 
transfer 
30 days 
30 days 
35 days 
35 days 
45 days 
45 days 
55 days 
78 days 
78 days 
84 days 
84 days 
65 days 
65 days 
Incidence 
0/4 
1/4 
0/6 
1/6 
0/10 
3/10 
17/18 
2/8 
8/8 
1/5 
5/5 
1/4 
4/4 
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Figure 1.3 Tumour phenotype in recipients of MYC-transduced antigen specific 
B cells 
Unpublished data from Dr Lixin Rui 
A) The photograph shows spleens from syngeneic or Rag1null mice that received 
MYC/GFP-transduced Trp53 homozygous mutant spleen B cells 78 days earlier. A 
spleen from a control mouse that did not receive transferred cells is shown for 
reference. 
B) Representative flow cytometric analysis of enlarged spleens. The top panels show 
the frequency of lgM+ GFP+ donor B cells (green gate) or lgM+ GFP- donor B cells 
(red gate). The lower panels show forward scatter of these gated cells (as a measure 
of relative cell size) and DNA content (Rag1 null recipient). This reveals a greatly 
increased population of MYC/GFP+ donor cells that are markedly enlarged and contain 
a large fraction of cells in S, G2 or M phase of the cell cycle . 
A) 
B) 
C57BL/6 
recipients 
Rag KO 
recipients 
CS 7 BL/6 ( splenomega ly) Rag KO 
10' .-------.;=======., 10' .-------.;====-, 
9.76° 
ro 
2 
cn 10 ' 
_50 
10 1 
10 ° ;.;-lf-............ ...--~~.....i 10 ° 
10 ° 10 1 10 2 10 3 10 4 100 10 1 102 103 104 
8 
c6 
:::J 
0 (.) 4 
2 
Myc-GFP 
0 0 
10 
8 
6 
...... 
C 
i5 4 
(.) 
2 
0 200 400 600 800 1000 0 200 400 600 800 1000 0 
Forward scatter 
C57BL/6 
control 
0 200 400 600 800 1000 
DNA content 
75 
1.13.2 Mechanism of Myc-Trp53 mutation co-operation 
Two distinct mechanisms of p53 activation by Myc have been relatively well 
defined , although other mechanisms undoubtedly exist. The first is via 
transcriptional induction of the ARF tumour suppressor gene. Bouchard et al 
[364] demonstrated that Myc overexpression induced increased expression of 
FoxO transcription factors , which were able to bind to and activate the lnk4a/Arf_ 
locus , thus enhancing p53 expression through Mdm2 suppression. The other 
mechanism is via the DNA damage response pathway and the activation of 
ATM [365]. MicroRNAs have been demonstrated to mediate large networks of 
gene interactions , and thus are likely to be implicated in Myc-p53 interactions. 
Sotilo et al showed that in Myc overexpressing B cells miR-34a inhibited p53-
dependent apoptosis [366], and Chang et al [367] reported that miR-34a is 
induced by p53 following DNA damage, promoting apoptosis , which suggests a 
negative feedback mechanism to modulate apoptosis, but this remains to be 
confirmed . 
The simple hypothesis to explain the interaction between dysregulated p53 and 
Myc in promoting lymphomagenesis is that loss of p53 abrogates the apoptotic 
limb of Myc's actions, allowing its proliferative capacity to act unchecked. Two 
groups [145 ,146] demonstrated that inhibition of Puma , a BCL2 family member 
that mediates the apoptotic functions of p53, greatly accelerated B cell 
lymphomagenesis in Eµ-myc mice, with the incidence being similar to that seen 
with p53 inhibition . This suggests that it is a defect in the apoptotic function of 
p53 rather than its role in cell cycle regulation that is critical in 
lymphomagenesis, as p53 cell cycle check points did not seems to be 
compromised . This correlates well with human studies [146] that demonstrated 
that 12 of 17 Burkitt lymphoma specimens analysed had reduced PUMA 
expression . 
However, not all Myc-mediated apoptosis appears to be channelled thorough 
p53 [212]. Bim , a pro-apoptotic member of the BCL2 family, is induced by Myc 
and can mediate Myc-induced apoptosis , its loss promoting malignancy in Eµ-
Myc mice [368] . The same group also demonstrated that loss of Sim removes 
the strong selection pressure for functional inactivation of the p53 apoptotic 
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pathway that is normally seen during Myc-induced lymphomagenesis. This 
alone suggests that the loss of Bim either facilitates apoptosis in a p53-
independent manner, or that Bim is downstream of p53. Two point mutations 
(P57S and T58A) in the MYC gene found commonly Burkitt Lymphoma [369] 
have been demonstrated to enhance the gene's transforming ability [370] with 
this mutant MYC being confirmed to have reduced up regulation of BIM, without 
any change in its effect on p53. 
The Myc-mutant Trp53 cooperation could potentially extend beyond an 
apoptosis-specific effect. A Trp53 mutation would impair cell cycle arrest in the 
setting of a DNA-toxic insult, and inhibit repair of such a defect. This would 
facilitate accumulation of genetic mutations, some of which are likely to 
cooperate with Myc and promote transformation. The relatively new concept of 
senescence may help explain how mutant Trp53 facilitates Myc-induced 
lymphomagenesis in some instances. p53 has been shown to mediate 
senescence in lymphomas induced by Myc overexpression and three different 
groups [371-373] have demonstrated that promotion of senescence in such 
lymphomas delays development of overt disease. Overall, it appears that there 
·-
are multiple mechanisms of Myc - Trp53 mutation cooperation in B cell 
transformation. 
1.14 The current study 
The study [313] of retroviral mutagenesis in p53-deficient and Eµ-myc mice 
described above emphasise the potent collaboration between increased Myc 
and inactivation of the p53 pathway in lymphomagenesis. Since the 
lymphomas had many other integration sites in addition to retrovirally expressed 
MYC, this poses the question of whether these represent collaborating third, 
fourth, or fifth oncogenic mutations or simply 'passenger integrations'. If they 
they are collaborating mutations, it is also unknown whether these are 
specifically necessary for growth factor self-sufficiency, evasion of apoptosis, 
limitless replication potential, escape from immune surveillance, or other 
attributes of malignant lymphomas. 
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Better clarification of the molecular basis of the co-operation between p53 loss 
and MYC overexpression may facilitate comprehension of the precise role of 
these genes in lymphomagenesis, but would also be directly relevant to the 
pathogenesis of Burkitt Lymphoma. This B cell lymphoma subtype is 
characterised by MYC overexpression, commonly accompanied by a defect in 
the p53 pathway, but also carrying many other recurrent mutations such as 
unrestrained TCF3 and CCN03. A more precise understanding of how Myc, 
p53 and other mutations co-operate to drive spontaneous proliferation of 
mature, antigen-activated B cells may facilitate development of targeted 
therapies for this highly aggressive malignancy. 
This thesis addresses these questions by a different approach to retroviral 
mutagenesis in p53 deficient B cells. The earlier studies cited above employed 
a replicating retrovirus acting iteratively over many months in an unknown 
number of precursor cells to create many proviral integration sites per 
lymphoma. This made it difficult to trace the mechanism of action or efficiency 
of any individual retroviral insertion. In the approach employed here, a single 
round of retroviral transduction was performed with a replication-defective 
retrovirus in a limited number of mature, antigen plus CD40-activated B cells. 
This finite cohort of B cells with a small number of proviral integrations was then 
traced for their proliferative self-sufficiency in the absence of antigen or CD40 
stimuli in vivo or in vitro. This allowed Myc-p53 cooperating oncogenic 
mutations to be identified that efficiently promote B cell proliferation in the 
absence of normal mitogenic stimuli. 
In particular, I hypothesised that mature B cells that had previously been 
activated by antigen and CD40, acquired a constitutively expressed MYC/GFP 
retroviral vector, and carried homozygous inactive Trp53, nevertheless still 
required at least one additional mutation before they could continue proliferating 
when antigen and CD40 stimuli were withdrawn in vitro or in vivo. 
I hypothesised that the clonal B lymphomas that arose from this procedure had 
acquired a "third oncogenic hit" created by insertional mutagenesis during 
integration of the MYCIGFP proviral vector. 
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I thus aimed to: 
(1) identify the MYC/GFP vector insertion sites in a series of these clonal B 
lymphomas; 
(2) identify candidate co-operating oncogenes in the vicinity of these 
integrations; and 
(3) experimentally test whether or not retroviral overexpression of the candidate 
genes completed a triad with MYC and p53 mutations and became sufficient for 
B cells to continue proliferating for long periods after antigen and CD40 stimuli 
were withdrawn. 
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2. Materials and 
Methods 
2.1 Mice 
C57BL/6 mice were bred and housed in the Australian Phenomics Facility at the 
Australian National University (ANU). All mouse breeding and experiments 
were performed according to protocols approved by the Australian National 
University Animal Ethics and Experimentation Committee. 
Trp538b1ast mice were identified through ENU mutagenesis [374]. The early 
onset of tumours in these mice suggested a Trp53 defect and sequencing of 
this gene demonstrated a point mutation in the DNA binding domain. The strain 
is listed as Trp538b1 on the MGI (Mouse Genome Informatics) database with the 
ID MGl:3611496. 
lgHEL mice produce large numbers of B cells with rearranged immunoglobulin 
heavy and light chains to have high affinity for Hen Egg Lysozyme (HEL) [375] 
and thus are able to activated simultaneously by exposure to HEL. The 
transgenic mouse has an ID MGl:2384162 in the MGI database. 
Trp53Bb!aSf mice were bred with lgHEL mice to generate lgHEL Trp53BblaSt/ BblaSf 
mice, lgHEL Trp53BblaSt/Wt mice lgHEL Trp53wtlwt mice. 
Rag1KO C57BL/6 recipient mice were used. 
Mouse genotyping was performed in the Australian Phenomics Facility, ANU. 
2.2 Common recipes 
2.2.1 Ammonium- Chloride-Potassium (ACK) lysis 
solution 
The following were combined in MilliQ water: 
-0.1 SM NH4CI (FW 53.49) - 8.29 g in 1 litre 
-1 0mM KHCO3 (FW 100.12)- 1 g in 1 litre 
-0.1 mM Na2EDTA (FW 372.24)-0.03729 in 1 litre 
The pH was adjusted to 7.2-7.4 with 1 N HCI and the solution filtered. 
2.2.2 Fluorescence activated cell sorting (FACS) wash 
solution 
Forty ml of heat inactivated Fetal Calf Serum (final concentration 2%) and 20 ml 
of 10% sodium azide (final concentration 0.1 %) were added to 2 litres of 
Phosphate buffered saline (PBS) (Media/Wash JCSMR) and stored at 4°C. 
2.2.3 Roswell Park Memorial Institute Medium (RPMI) 
complete medium 
RPMl-1640(Gibco®) was supplemented with Penicillin (100 U/ml), Streptomycin 
(0.1 mg/ml) , L-Glutamine (2 mM) (Gibco®), 1 0mM HEP ES (pH 7.0) (Gibco®), 
50 µM 2-Mercaptoethanol (2-ME) solution (Gibco®) and 10% heat inactivated 
Fetal Calf Serum. 
2.2.4 Super Optimal Broth (SOB) 
Twenty g Bacto Tryptone, 5 g Bacto Yeast Extract, 2 ml SM NaCl and 1.25 ml 
2M KCI were added to Milli-Q H2O and the volume made up to 990 ml and 
autoclaved. Ten ml Milli-Q H2O containing1 M MgSO4.7H2O and 1 M 
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MgCb.6H2O was also autoclaved. The two solutions were mixed and stored at 
4°c. 
2.2.5 Transformation buffer (TB) 
PIPES (10 mM) 3.0 g, CaCl2.2H2O (15 mM) 2.2 g and KCI (250 mM) 18.6 g 
were added to 950 ml Milli-Q H2O. The pH was adjusted to 6.7 with KOH. To 
that solution 10.9 g of 55mM MnCb.4H2O was added. The solution was 
sterilised by filtration and stored at 4°C. 
2.2.6 Lysogeny broth (LB) agar plates 
Six g of Bacto Agar was added to 400 ml of L-Broth (John Curtin School of 
Medical Research (JCSMR) stores) and autoclaved. Once the mixture had 
cooled below 50°C, 500 µI of 100 mg/ml ampicillin was added (final 
concentration 100 µg/ml). Eighteen ml of the warm mixture was added to agar 
plates in a laminar flow hood, and allowed to dry. Plates were then stored at 
4°C away from light. 
2.3 Retroviral constructs 
2.3.1 Background 
Murine stem cell virus (MSCV) [376] is an ecotropic retrovirus which is able to 
infect haemopoietic cells, including stem cells. pMXs is based on the Moloney 
murine leukaemia virus (MMLV) retroviral vector [377], and is able to infect most 
murine cell lines. A bicistronic vector is one that encodes two different genes 
separated by an internal ribosome entry site (IRES), allowing co expression of 
both genes. The MSCV-human MYCIGFP vector was produced by Lixin Rui, 
using a gift of MSCV-GFP backbone from the Nolan laboratory. A subset of the 
lymphomas used a modification of the above vector containing an amino acid 
substitution in MYC at Thr58 which abolishes Bim induction. The pMXs-Red 
empty vector was produced by Keisuke Horikawa using the pMXs-lG backbone 
from the Kitamura [377] laboratory, replacing the GFP sequence with the 
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DsRed Express 1 sequence (Clontech). These viruses are replication 
defective, and so while a single cell can be infected by more than one virus, one 
virus can only infect one cell and cannot produce further copies to infect other 
cells or the same cell. This means that the number of retroviral infections in 
each cell, and thus the number of insertion sites cannot change once the viral 
supernatant is removed from the cell surface. The pBluescript II SK cloning 
vector (Stratagene) was used for initial cloning. Figure 2.1 demonstrates the 
three vector maps with relevant restriction enzyme sites. 
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Figure 2.1 Vector maps 
a) pMXs-DsRed 
b) MSCV-MYC-GFP 
c) pBluescript II SK 
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2.3.2 cDNA inserts 
The cDNA sequence inserted into the empty vector was obtained by using a 50 
µI polymerase chain reaction (PCR) containing 0.5 µI Platinum Pfx (lnvitrogen), 
5 µI Pfx reaction buffer (1 OX), 1 µI normal mouse spleen cDNA, 1.5 µI 
deoxyribonucleotide triphosphates (dNTPs) (1 0mM), 1 µI MgSO4, 0.75 µI 
forward primer, 0.75 µI reverse primer, 39.5 µI MilliQ H2O. 
Principles of forward primer design: 2-4 Ts (so that sufficient overhang for 
enzyme to cut), followed by the restriction enzyme digest site, followed by first 6 
bases of the Kozak sequence (GCCACC) followed by the first 24 bases of 
transcribed sequence from the National Center for Biotechnology Information 
(NCBI) website (http://www.ncbi.nlm.nih.gov/genbank/). 
Principles of reverse primer design: reverse complement of the combination of 
the last 24 bases of the sequence followed by restriction enzyme cleavage site 
followed by 2-4Ts. The primer sequences are detailed below with the restriction 
enzyme sites underlined and the portion of the Kozak sequence prior to the 
initiation codon in bold. 
Myb: (restriction enzymes BamHI (New England Biolabs (NEB)) and Xhol 
(NEB)) 
forward:5' TTG GAT CCG CCA CCA TGG CCC GGA GAC CCC GAC ACA GC 3' 
reverse:5' AAA ACT CGA GTC ACA TGA CCA GAG TTC GAG CTG A 3' 
lkbkb: (restriction enzymes EcoRI (NEB) and Xhol) 
forward:5' TGA ATT CGC CAC CAT GAG CTG GTC ACC GTC CCT CCC A 3' 
reverse:5' AAA ACT CGA GTC AGG CGG TTA CCG TGA AGC TTC T 3' 
Laptm5: (restriction enzymes BamHI (NEB) and Xhol) 
forward :5' TTT TGG ATC CGC CAC CAT GGC CTC CCG TGC AGC GCC GGT C 3' 
reverse:5 ' AAA ACT CGA GTC ACA CTT CTG AGT ATG GGG GTG G 3' 
Lmo2: (restriction enzymes EcoRI and Xhol) 
forward:5' TTT TGA ATT CGC CAC CAT GTC CTC GGC CAT CGA AAG GAA G 3' 
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reverse:5' AAA ACT CGA GCT AGA TGA TCC CAT TGA TCT TGG T 3' 
The PCR cycling conditions were 94°C for 2 minutes, 35 cycles of 94°C for 15 
sec, 55°C for 30 sec, 68°C for 1 minute per 1000 bp product, and final extension 
at 68°C for 10 min. Product was confirmed by running 5 µI of the 50 µI reaction 
on a 50 µI minigel at 100 volts. The product was then purified using the Qiagen 
PCR purification kit and eluted with Milli-Q water. 
2.3.3 Digest of insert and empty vector 
The PCR products were digested in a 30 µI reaction containing 3 µI NEB buffer 
(1 OX), 3 µI 1 0xBSA, 20 µI, 1.5 µI Restriction enzyme1, 1.5 µI Restriction 
enzyme2. The empty vector was digested in a 50 µI reaction containing 5 µI 
NEB buffer (1 OX), 5 µI Bovine serum albumin (BSA) (1 OX), 3 µI DNA, 33 µI Milli-
Q H2O, 2 µI Restriction enzyme1, 2 µI Restriction enzyme2. Reactions were 
incubated at 37°C for 2 hours. One µI of alkaline phosphatase (Takara) was 
added to each of the vector digests after 1.5 hours to prevent vector self-
ligation. 
2.3.4 Purification and ligation 
Digests were run on a 1 % Tris-acetate-EDT A (TAE) agarose gel, stained with 
Ethidium Bromide and subsequently visualised with ultraviolet light. Bands 
were cut from the gel, purified and eluted in approximately 40 µI elution buffer 
for vector (Qiagen gel extraction protocol) and in 7-12 µI elution buffer (using 
the QIAEX II protocol from Qiagen) for the insert. One µI of each specimen was 
run on a gel to ensure a pure product had been obtained. 
Inserts and pBluescript II SK cloning vector were ligated to form the desired 
ligated plasmid in a 5 µI reaction containing 0.5 µI cloning vector, 1.5 µI insert, 
0.5 µI T4DNA Ligase (LigaFast™ Rapid DNA Ligation System, Promega) and 
2.5 µI ligation buffer. The reaction mix was incubated at room temperature for 
15 minutes. 
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2.3.5 Transformation 
Fifty µI of freshly thawed competent E. coli (DH5a) cells were added to 5 µI 
ligated plasmid, incubated at 4°C on ice for 10 minutes, heat shocked for 30 
seconds at 37°C and returned to ice. LB medium (250 µI) was added to each 
tube and incubated at 37°C with agitation for 30 minutes. Two hundred µI was 
then plated over entire surface of ampicillin-containing agar plate and incubated 
for 14 hours at 37°C. Six clones were selected and grown in a 15 ml round 
bottom tube for greater than 8 hours in 2 ml LB/Ampicillin (100 µg/ml) at 37°C 
with agitation. Plasmid DNA was extracted from each clone with Wizard® Plus 
SV Minipreps DNA Purification Systems (Promega), as per protocol, digesting 
5% with appropriate restriction enzymes and running it on a gel to confirm the 
correct band size for the vector and insert combination. Another portion of the 
Miniprep DNA from the clones with the correct band pattern was sequenced to 
ensure that the insert sequence is not mutated using primers in both directions 
(pBluescript II SK primers for either side of the multicloning sites T3 
(ATTAACCCTCACTAAAGGGA) and T7 (TAATACGACTCACTATAGGG)). A 
20 µI sequencing reaction was prepared as per Section 2.9.5 below. The 
sequence was confirmed using Sequencher™ version 4.2 (Gene Codes 
Corporation). 
Plasmids were subsequently digested with restriction enzymes and inserts 
purified and ligated with the pMXs Dsred vector, as per purification and ligation 
protocols above. Transformation was performed as above but cultures were 
grown in 2 litre flasks and the plasmid DNA extracted using Gerard Biotech 
Hurricane Maxi Prep Protocol, based on the alkaline lysis method. The purity 
and concentration of the resulting DNA was analysed using the spectrometer 
and band size was confirmed by gel electrophoresis of the products of 
restriction enzyme digests. 
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2.4 Transfection - Calcium Phosphate 
method 
Day O: Phoenix cells (a gift from the Nolan laboratory, Stanford) were 
replated in T75 (BO Biosciences) flask aiming for 60% confluence at 
transfection. 
Day 1: Chloroquine (25 µM) was added to cells 5-15 min prior to addition of 
DNA solution. Thirty µg DNA, (1317 µI minus DNA volume) µI MilliQ H20, 183 
µI 2M CaCb, and the solution were vortexed. Fifteen hundred µI 2xHEPES 
(Sigma) Buffered Saline pH optimised around 7.0 was added and the mixtures 
were subsequently 'bubbled' for 15 sec. After a 1 minute incubation at room 
temperature the suspension was quickly and evenly distributed into the medium 
above the cell monolayer and the plate rocked to evenly distribute particles. 
This was incubated at 37°C and observed under microscope after 1-2 hours 
looking for small dark calcium granules. The supernatant wa? carefully 
replaced with Dulbecco's Modified Eagle Medium (DMEM) medium (Gibco®) 
and incubated overnight. 
Day 2: The medium was changed to RPM I-CM. 
Day 3: The supernatant was pipetted into 15 ml tubes, centrifuged at 1500 
rpm for 7 min to pellet cellular debris and frozen at -80°C. 
Day 4: Supernatant was removed as per Day 3. The remaining Phoenix 
cells were then trypsinised and analysed using FACS for GFP or DsRed 
expression to confirm vector expression. 
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2.5 Production of competent cells 
Competent cells were made based on Inoue et al's published protocol [378], 
based on the Hanahan protocol [379]. DH5a cells were thawed, plated on an 
ampicillin-free LB agar plate and cultured at 37°C overnight. The following 
morning 10-12 colonies were inoculated into 250 ml SOB medium in a sterile 2 
litre flask and grown at room temperature with vigorous shaking until the optical 
density was between 0.4 and 0.5. The flask was then placed on ice for 10 
minutes, spun down and the pellet resuspended in 80 ml ice cold transformation 
buffer (TB) and incubated on ice for 10 minutes. The pellet was then spun 
down again and resuspended in 20 ml ice cold TB. Slowly 1.2 ml Dimethyl 
Sulfoxide (DMSO) was added to the resulting suspension and it was frozen at 
minus 80°C in 1 ml aliquots . 
2.6 Production of anti CD40 
1C10 cells were thawed from liquid nitrogen storage and grown in RPM I-CM. 
At approximately 1 litre of culture fresh media was no longer added as the 
culture grew with consequential cell lysis. The supernatant was then run on a 
selective liquid chromatography column and the resulting concentrate of anti 
CD40 antibody dialysed in sterile PBS. The antibody concentrate was titrated 
against previous batches by stimulating B cells and assessing CD69 expression 
at 48 hours. 
2.7 Transduction 
Day 0: One /gHEL Trp538blasUBblast mouse and one control /gHEL Trp53wtlwt mouse · 
was injected with 4-6 mg HEL (Sigma®) intraperitoneally. Mice were culled 6-8 
hours later by cervical dislocation and the spleen was transported in RPMI 
complete medium. A single cell suspension was made in a sterile Petri dish 
using a sterile cell filter and 3 ml syringe barrel , and returned to the same tube. 
This was centrifuged at 1200 rpm for 7 minutes at room temperature and the 
supernatant removed. Red cells were lysed with 5 ml ACK lysis buffer for 2 
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minutes at room temperature, replenished with 10ml RPM I-CM to cease lysis, 
and centrifuged again at 1200 rpm for 7 minutes at room temperature and the 
supernatant removed. After RPMI complete media was replenished cells were 
counted and viability assessed using a haemocytometer and trypan blue, 
diluted to 2 x 106 cells/ml and cultured at 37°C with 5% CO2 for 24-36 hours with 
10 µg/ml of anti-CD40. 
Day 1: The viral supernatants were thawed and kept on ice away from light. 
Cells were suspended at 108 cells/ml in RPMI complete medium. The viral 
supernatant(s) was transferred into 6-well plates (approx 2 ml/plate). DOTAP 
Liposomal Transfection Reagent (Roche Cat No. 11811177001) ( 10 µg/ml final 
concentration) was added to optimise transfection [380]. Three to six million 
(30-60 µI) cells were then added to each well and this was spin-inoculated at 
2500-2800 rpm for 90 minutes at room temperature. Half of the supernatant 
was removed and replaced with RPMI complete medium and 10 µg/ml of anti-
CD40 and cells were cultured for at least 24 hours at 37°C 
Day 3: Cells were counted, viability assessed and 106 cells from the /gHEL 
Trp538 b1ast1 Bbtast mouse spleen and control splenocytes we·re Llsed for FACS 
analysis. The remaining cells were washed and either cultured in vitro or 
divided between 4-5 recipient Rag1 KO mice, injecting approximately 2 million 
cells/mouse at 10-20 million cells/ml through the lateral tail vein. For in vitro 
culture, cells were plated in 6 well plates at 2 x 106 cells per ml, each well 
containing 2 ml of RPMI complete media, and incubated at 37°C with 5% CO2 . 
Several wells were plated out for each gene combination allowing a whole well 
of cells to be analysed at each time point without disturbing the other wells. At 
the predetermined timepoints the contents of each well was harvested by 
pipetting, resuspended and the concentration of viable cells was counted using 
a haemocytometer. For flow cytometric analysis of in vitro cultured cells, the 
cells were washed and transferred to a 96 well plate for staining using the 
FACS protocol described below. Integration of haemocytometric results 
(concentration of viable cells) with flow cytometric results (percentage of viable 
cells expressing specific fluorochromes) enabled calculation of the numbers of 
cells expressing specific fluorochromes. 
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2.8 Spleen FAGS Protocol 
Cells were placed in a round-bottomed 96-well plate (at approx 106 cells/ 25 
µI/well). Ice-cold FACS buffer (100-150 µI) was added and this was centrifuged 
at 1340 rpm for 4 minutes at 4°C, the supernatant removed and vortexed. The 
above two steps were repeated. The resulting cells were incubated with a 
CD16/CD32 monoclonal antibody (to block complexed lgG receptors and thus 
reduce background staining) and incubated at 4°C for 20 minutes. The specific 
antibody (at optimal concentrations determined by titration) was then added 
after a wash step, incubating at 4°C for 30 minutes in the dark. Cells were 
washed twice with FACS buffer as above, resuspended in 50-100 µI FACS 
buffer and transferred into cluster tubes. FACS antibodies used are tabulated in 
Table 2.1. 
Data acquisition was on the four channel BO FACS Calibur and analysis was 
performed with the FlowJo (Tree Star Inc) software. When required for 
calibration the Immune-Brite TM Standards Kit (Beckman Coulter 66034 73) was 
used. Graphs were drawn with the GraphPad Prisms software. 
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Table 2.1 Antibodies used for immunophenotyping 
Antigen Conjugate Source 
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2.9 Splinkerette PCR 
2.9.1 DNA 
Genomic DNA was extracted from lymphoma samples using QIAamp DNA mini 
kit (Qiagen) according to the manufacturer's 'Blood and body fluid' protocol. 
Genomic DNA (1.5 µg) was digested in a 20 µI total reaction volume containing 
2 µI Sau3AI (4000U/ml) , 2 µI Sau3A 1 buffer (1 OX) , 2 µI BSA (1 OX) and H2O. 
The reaction was incubated at 37°C for 3 hours , followed by a heat inactivation 
step at 65°C for 20 min. 
2.9.2 Primers 
HMSpAa: 5' CGA AGA GTA ACC GTT GCT AGG AGA GAC CGT GGC TGA ATG 
AGA CTG GTG TCG ACA CTA GTG G 3' 
HMSpBb-Sau3A 1: 5' GAT CCC ACT AGT GTC GAC ACC AGT CTC T AA TTT TTT 
TTT TCA AAA AAA 3' 
AB949NEW : 5' GCT AGC TTG CCA AAC CTA CAG GTG G 3' 
HM5p1: 5' CGA AGA GTA ACC GTT GCT AGG AGA GAC C 3' 
HM001: 5' GCC AAA CCT ACA GGT GGG GTC TTT 3' 
HM5p2: 5' GTG GCT GAA TGA GAC TGG TGT CGA C 3' 
2.9.3 Annealing and ligation 
The splinkerette primers were annealed in a 20 µI reaction volume containing 
7.5 µI of HMSpAa (20 µM), 7.5 µI of HMSpBb-Sau3A1 (20 µM) , 2 µI NEB Buffer 
2 (1 OX) and H2O. Annealing was performed at 95°C for 5 min and followed by a 
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slow cool down process to room temperature. The ligation reaction was 
performed overnight at 16°C in a 20 µI total reaction volume containing 7 µI 
Sau3AI digested genomic DNA, 1 µI annealed splinkerette oligonucleotides, 
0.5-1.0 µI T4 DNA ligase (10 U/µI), 2 µI ligation buffer (1 OX) and H2O. The 
ligation reaction was subsequently inactivated at 65°C for 20 min. The ligated 
samples were purified using QIAquick PCR purification kit (Qiagen) and eluted 
in 30 µI according to the manufacturer's protocol. 
2.9.4 PCR 
Ten µI of the purified samples was amplified in a 50 µI PCR reaction volume 
containing 1 µI long terminal repeat (L TR) specific primer AB949NEW (20 µM), 
1 µI splinkerette specific primer HMSp1 (20 µM), 2.5µ1 dNTPs (10 mM), 3.0 µI 
MgCl2 (50 mM), 0.5µ1 Platinum Taq (5 U/µl)(lnvitrogen) and 5 µI Platinum Taq 
buffer (1 Ox). PCR cycling condition were 94°C for 2 min, 94°C for 1 min, 68°C 
for 30 sec, 72°C for 90 sec, 30 cycles of 94 °C for 30 sec, 65°C for 30 sec, 72°C 
for 2 min, and followed by final extension at 72°C for 10 min . The primary PCR 
products were diluted 200 fold and 5 µI of the diluted products were used as the 
template for the secondary PCR reaction. This was performed in a 50 µI 
reaction volume containing 5 µI diluted primary PCR product, 0.5 µI nested 
primer HM001 (20 µM), 0.5 µI of nested primer HMSp2 (20 µM), 2.5 µI dNTPs 
(10 mM), 2.5 µI Mg Cb (50 mM), 0.5 µI Platinum Taq (5 u/µI) and 5 µI of 
Platinum Taq buffer (10X). The secondary PCR cycling condition were 94°C for 
90 sec, 30 cycles of 94°C for 30 sec, 60°C for 30 sec, 72°C for 90 sec, and final 
extension at 72°C for 7 min. The nested PCR products were resolved by 
electrophoresis using 2% sodium borate agarose gel. Individual bands were 
excised from the gel and DNA extracted using the QIAquick Gel Extraction Kit 
(Qiagen) according to the manufacturer's protocol. 
2.9.5 Sequencing reaction 
A 20 µI reaction mix was made containing 1 µI Big Dye 3.1, 3.5 µI 5x CSA 
Buffer (Applied Biosystems), 0.175 µI (3.2 pmol) primer (20 µM), template -
less than 50 ng and H2O. The PCR program was 94°C for 5 min, (96°C for 1 0 
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sec j 50°C for 5 sec, 60°C for 4 min) x 30 and finishing with 10°C for 10 minutes. 
Each sample was run separately with the HM001 primer and HMSp2 primer and 
results were compared for quality control. The PCR reaction was spun and 50 
µI 100% EtOH (final concentration of 70%), 2 µI 3M NaOAc (pH 4.6) and 2 µI 
EDTA (0.125M) were added to the 20 µI reaction. Tubes were inverted 4 times, 
incubated at room temperature for 15 min and then centrifuged for 30 min at full 
speed at room temperature and then centrifuged upside-down on tissue for one 
min at 180g. Seventy µI 70% EtOH was added to wash, and the specimen was 
centrifuged 1 O min at full speed at room temperature, centrifuged upside-down 
on tissue for 1 min at 180 g, air dried in the dark for 10 min at room 
temperature, and submitted for sequencing at -20°C in the dark. Sequencing 
was performed by the Australian Cancer Research Foundation Biomolecular 
Resource Facility (ACRF BRF) at the John Curtin School of Medical Research, 
utilising Big Dye Terminator v3.1 Cycle Sequencing Kit according to the 
manufacturer's protocol. 
2.10 RNA isolation and cDNA production 
Cells (5-10 x 106) were pelleted, lysed in 1 ml Trizol® Reagent (lnvitrogen) by 
repetitive pipetting and incubated for 5-10 min at room temperature. The 
insoluble material was pelleted by centrifugation at 12,000 g for 1 O minutes at 2 
to 8°C, and the RNA-containing supernatant transferred to a fresh tube. 0.2 ml 
of chloroform (Sigma) was added and the tubes shaken vigorously for 15 
seconds and then incubated at 15 to 30°C for 2 to 3 minutes. The samples 
were then centrifuged at 12,000 g for 15 minutes at 2 to 8°C, separating the 
mixture into a lower red , phenol-chloroform phase, an interphase, and a 
colourless upper aqueous phase containing RNA. The aqueous phase was 
transferred to a fresh tube containing 0.5 ml of isopropanol and inverted several -
times to ensure mixing. The samples were incubated at 15 to 30°C for 10 
minutes and centrifuged at 12,000 g for 1 O minutes at 2 to 8°C. The 
supernatant was removed and the RNA pellet washed once with 1 ml 75% 
ethanol. The sample was vortexed until pellet floated and centrifuged at 7,500 
g for 5 minutes at 2 to 8°C. The ethanol was removed, and the specimen 
respun briefly and excess ethanol removed with a pipette. The RNA pellet was 
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air dried for 1-2 minutes, and dissolved in 20 (for cells) - 50 (spleen) µI RNase-
free water and incubated for 10 minutes at 55 to 60°C. RNA was stored in 
aliquots at -70°C after spectrophotometric concentration and integrity analysis 
(A260:A280 ratio) (NanaDrop, Thermo Scientific). cDNA was produced utilising 
the lnvitrogen Superscript™ Ill First-Strand Synthesis System for RT-PCR 
(Catalogue no 18080-051 ). The initial reaction mix contained 1 µI 50 µM 
oligo(dT)2o primers, 5 µg RNA, 1 µ11 0mM dNTP mix and was made up to 10 µI 
with RNase free water. This was incubated for 5 minutes at 65°C and then 
placed on ice for 1 minute. The cDNA synthesis mix was added to this, which 
contained 2 µI 1 0xRT buffer, 4 µI 25mM Mg Cb, 2 µI 0.1 M OTT, 1 µI RNaseOUT 
(40 U/µI) and 1 µI Superscript Ill (200 U/µI). After mixing the reaction was 
incubated at 50°C for 50 minutes and then 85°C for 5 minutes, and then placed 
on ice. Finally 1 µI of RNase H was added to each tube it was incubated for 20 
minutes at 37°C and stored at -20°C. 
2.11 Real time PCR 
All primers were purchased from GeneWorks Pty Ltd. Primer~ were designed 
with the assistance of the Primer Bank 
(http://pga.mgh.harvard.edu/primerbank/) [381]. Primers were designed to span 
exon-exon boundaries in order to avoid amplification of any contaminating DNA, 
with annealing temperatures of 58-60°C, G+C content of 40-60%, target length 
of 20 nucleotides and the amplified PCR product was approximately 80-250 
base pairs in length. 
Primer sequences: 
Myb: forward: 5' AGACCCCGACACAGCATCTA 3' 
reverse: 5' CAGCAGCCCATCGTAGTCAT 3' 
Beta Actin: forward: 5' TGTTACCAACTGGGACGACA 3' 
reverse: 5' AAGGAAGGCTGGAAAAGAGC 3' 
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The Real time PCR reaction master mix contained 2 µI cDNA diluted 1/10, 1 µI 
forward primer (5 µM), 1 µI reverse primer (5 µM), 5 µI SYBR® Green PCR 
Master Mix (Applied Biosystems) and 1 µI MillQ water. Amplifications were 
performed in 384-well optical reaction plates (Applied Biosystems) using the 
7900HT Fast Real-Time PCR System (at the ACRF BRF, JCSMR, ANU). The 
reaction conditions were 50°C for 2 min, 95°C for 10 min, 40 cycles each of: 
95°C for 15 sec, 60°C for 1 min. To confirm that a single product was 
generated (ie no primer dimers) PCR amplicons were analysed by dissociation 
curves (95°C for 15 sec, 60°C for 1 min, 95°C for 15 sec). Raw data was 
analysed using SOS 2.2.2 software (Applied Biosystems) with the default fixed 
fluorescent threshold set at a value of 0.2 and baseline set from cycles 3-15, 
manually ensuring that these values were appropriate. 
The comparative Cr method for relative quantitation of gene expression was 
used. The CT is the cycle number at which the replicating amplicon associated 
fluorescence crosses a threshold. To ensure approximately equal target and 
reference amplification efficiency, standard curves were generated for each 
primer pair to determine primer efficiencies using serial 4-fold dilutions of cDNA. 
The slope of the curve generated by the relative amounts of cDNA (log 10 input; 
x-axis) versus cycle threshold (Ct) value (y-axis) was used to determine primer 
efficiency. They were found to be between 0.95 and 1.05 using the formula E = 
1 o-1isiope_1 as demonstrated in Figure 2.2. The normalised expression of a gene 
relative to a selected baseline could thus be estimated, assuming equivalent 
priming efficiencies for the target and reference genes, using the formula [382]: 
Comparative expression level = 2 -llllct 
where LiCT=CT(target)-CT(normaliser) and MCT=sampleb.CT -referenceb.CT 
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Figure 2.2 Amplification efficiency of primer pairs 
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2.12 Microarray 
Microarray analyses of oligo-dT primed RNA were performed using the 
Affymetrix GeneChip®Gene 1.0 ST Array System for Mouse. RNA was isolated 
(as per Section 2.10) from the following: 1. "Activated cells", p53 wild type 
splenocytes 24 hours after harvest from antigen stimulated mice and culture 
with anti-CD40 antibody; 2. "MYC transduced cells", Trp53 mutant anti-CD40 
activated B cells flow cytometrically sorted for GFP+ cells 2 days after 
spinoculation with GFPIMYC retrovirus with CD40 still in culture; 3 and 4, 
"Outgrowth one and two" , two independent outgrowths of Myb+MYC dual 
transduced B cell lines stably growing in culture for several weeks, each 
containing approximately 33% viable GFP positive cells. Approximately 5 µg of 
RNA was used per sample, the concentration ranging from 300-1000 ng/µI. 
The cell sorting was performed by the Microscopy & Cytometry Resource 
Facility at JCSMR. Poly-A+ mRNA in each of the RNA samples was converted 
to cDNA using oligo-dT priming , and then to biotinylated cRNA that was 
hybridized to Affymetrix GeneChip® 1.0 ST Arrays for mouse and scanned as 
per the manufacturer's protocol , these steps being performed by staff of the 
Australian Cancer Research Foundation (ACRF) Biomolecular Resource 
Facility (BRF) at the John Curtin School of Medical Research using a 
GeneChip® Fluidics Station 450 and GeneChip® Scanner. Analysis of raw 
data was also performed at the ACRF BRF using Partek® software to obtain 
log2(signal intensity) for each gene for each of the four samples and fold 
changes between samples. 
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Chapter 3: Establishing an efficient model for malignant transformation of a finite cohort of mature B cells 
3.1 Introduction 
All published experimental models of B lymphoid malignancy involve an 
undefined but extremely large or limitless number of B cells that comprise the 
target for somatic mutations that eventually lead to a clonal malignancy. For 
example, the bone marrow produces approximately three million pre-B cells per 
day [383] so by the age of 12 weeks when a pre-B cell malignancy has evolved 
in an Eµ-Myc-transgenic mouse, several hundred million pre-B cells will have 
been subject to dysregulated Myc plus an unknown number of other mutations. 
Similarly, when Myc-transgenic mice are infected with the replication-competent 
retrovirus, Moloney Murine Leukaemia Virus, an unknown number of pre-B and 
B cells will have been infected and frequently there will have been many rounds 
of super infection, with current technology capable of identifying an average of 
approximately 20 [313 ,384]) integration sites in the malignant clone that finally 
evolves. While these approaches provide a powerful way to demonstrate 
cooperation between mutations to produce a malignancy, they do not allow 
analysis of how many additional mutations were needed for malignant 
transformation of B cells as it is well established that the majority of retroviral 
integrations in MMLV-induced tumours are "passenger mutations" and only a 
few are thought to be "d river mutations". Likewise, a large but unknown number 
of passenger mutations are likely to have accumulated in spontaneous 
lymphomas in Eµ-Myc transgenic mice. 
This chapter sought to establish in my hands a new experimental strategy to 
solve this problem, by limiting MYC dysregulation to a finite cohort of mature B 
cells and limiting retroviral insertional mutagenesis to a single round of 
integration with a replication defective retrovirus. To link these two processes, 
mature B cells bearing a Trp53 loss-of-function mutation were transduced in 
culture with a replication-defective retrovirus expressing MYC and GFP, and 
then a small number of these cells were injected into immunodeficient Rag1-KO 
mice to determine if this single round of mutagenesis was sufficient for_ 
malignant transformation of mature B cells. The results in this chapter establish 
the incidence and characteristics of the resulting lymphomas. 
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3.2 Incidence of lymphomas 
As discussed in Section 1.13, lymphomatous outgrowths were seen in a small 
percentage of C57BL/6 recipient mice injected with MYC transduced lgHEL 
Trp53Bbtast18b1ast splenocytes, but such outgrowths were evident in most Rag1 KO 
recipients (Lixin, unpublished data). lgHEL mice produce large numbers of B 
cells with rearranged immunoglobulin heavy and light chains with a high affinity 
for Hen Egg Lysozyme (HEL) [375]. This allows simultaneous physiological 
activation of B cells by antigen, instead of anti-lgM as a surrogate, and 
minimizes cell-to-cell variability caused by different antibody specificities and 
affinities of expressed BC Rs. The expression of this uniform, HEL-binding lgM 
BCR also serves as a unique marker to track mature B cells from the donor, 
both by allowing staining to detect B cells that bind HEL antigen and because 
the lgM constant region carries an amino acid polymorphism (a-allotype) that 
can be detected with anti-lgMa monoclonal antibody and differs from the lgMb 
allotype expressed by C57BL/6 mice. 
Twelve intravenous injections of MYC transduced /gHEL Trp53~btaSll Bbtast 
splenocytes into Rag 1 KO mice (see Materials and Methods for details) were 
performed over three separate experiments (Table 3.1 ). Despite giving a finite 
cohort of MYC transduced B cells, and noting that the MYC retrovirus is not 
replication competent, in all three experiments an initial cohort of recipient mice 
was euthanised between day 36 and 38 of cell transfer because the mice were 
cachectic with prominent abdominal distension. Dissection demonstrated 
hepatosplenomegaly, often with ascites and lymphadenopathy. The remaining 
3 mice in experiment 1 and 4 mice in experiment 2 were not so unwell at the 
time of euthanasia, with more subtle clinical manifestations such as ruffled fur, 
mild abdominal distension and lethargy. 
As discussed in Section 1.13.1 control experiments in which Trp53 mutant cells 
transduced with an empty vector (without MYC overexpression) were injected 
into recipients were not performed, raising the question of whether or not the 
transduced MYC provirus was necessary for malignant outgrowths. Since only 
a small percentage of the injected cells were transduced and expressed GFP, 
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yet each malignancy was uniformly GFP positive, this indicates that MYC/GFP 
transduced cells were greatly favoured for malignant transformation, however 
this bias for GFP expressing cells could result from the activity of MYC, the 
mutagenic effect of proviral integration, or the combination of the two. To 
resolve this point, it would be valuable in future studies to confirm 
experimentally the rate at which B cell malignancies evolve in recipients of 
Trp53 mutant B cells transduced with empty vector-GFP. If there was an 
appreciable background rate of GFP expressing malignancies with empty 
vector, this would provide some indication of the extent to which the mutagenic 
activity of proviral integration can contribute and substitute for MYC. Empty 
vector controls were used for the experiments analysing in vitro transformation 
of B cells in the following chapter. 
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Table 3.1 Incidence and timing of lymphoma development after IV injection of 
MYC transduced /~EL Trp538 b1astl8b1ast splenocytes into Rag1KO mice 
The number and timing of lymphoma development (splenomegaly 
macroscopically and a distinct GFP bright population on splenic FACS 
analyses) in recipients is shown. 
3 2 X 106 3.6 X 105 36 2 2 
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3.3 Phenotype of lymphomas 
The FACS phenotype of the lymphomatous outgrowths had been previously 
determined by Dr Lixin Rui in experiments described in Section 1.11.1 above. 
He demonstrated that they were composed of large GFP positive cells -which 
expressed surface B220, lgD, lgM, CD19, CD45 and CD16/32 but were 
negative for CD138, Mac-1 , CD21, CD23, c-kit, CD25, thy1 and AA4.1. This 
phenotype is entirely consistent with a mature B cell without any aberrant 
markers beyond the GFP expression. This broad panel of antibodies was not 
repeated in this work apart from confirmation that the phenotype was that of a 
mature B cell, a representative example being shown in Figure 3.1. The· only 
aberrant surface marker seen in human Burkitt lymphoma is surface CD10 
positivity, the phenotype being otherwise consistent with a mature B cell. CD10 
expression in murine germinal centre B cells, or murine models of Burkitt 
lymphoma is not well described [385] and the murine-specific antibody is not 
readily available so this was not performed. 
The clinical phenotype had been further investigated previously (Lixin, 
unpublished data) showing that this was an aggressive mature B cell tumour, 
infiltrating into the liver, kidney and lung (Figure 3.2). The mitotic figures and 
nucleoli seen in haematoxylin and eosin stained sections suggested rapid cell 
replication. Peripheral blood was not analysed in any of the experiments. 
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Figure 3.1 Representative FACS phenotype of lymphomatous spleen 
Rag1KO mice recipient mice were injected with MYC transduced JgHEL Trp538 b1astl 
Bbtast splenocytes and euthanised 5-8 weeks later. An example of the recipient 
splenic FACS profile (right column) is compared to normal spleen (left column), both 
gated on viable (7 AAD negative) cells. 
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Figure 3.2 Representative haematoxylin & eosin stained paraffin section of a 
lymphoma 
a) Normal murine spleen (x4) 
b) Recipient spleen (x4) 
c) Recipient spleen (x20) 
d) Recipient spleen (x40) 
Photographs taken by Sally Mapp of lymphoma samples from earlier unpublished 
experiments described and illustrated in Section 1.11.1 and performed by Lixin Rui. 
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The invasive nature of the lymphomatous growths suggested a neoplastic 
process, but in the absence of an aberrant F ACS phenotype it was important to 
exclude a polyclonal mature B cell proliferation. Murine B cells mostly express 
the K light chain on their surface [386]. Light chain restriction is thus not as 
useful for determining clonality of murine B cell tumours as it is in human 
tumours, where the K to 'A ratio is more balanced . In murine experimental 
models cldnality is commonly assessed through analysis of immunoglobulin 
gene rearrangements to determine if they are all the same (ie cells are clonal) 
or diverse (ie cells are polyclonal). This was not possible with this experimental 
system because the lgHEL cells used already have rearranged immunoglobulin 
heavy and light chain genes in order to create an immunoglobulin receptor 
specific for the HEL antigen [375]. 
Splinkerette PCR amplification of individual proviral integration junction 
fragments, coupled with cloning of lymphomas in culture by limiting dilution , was 
thus utilised in order to help determine if cells derived from 'lymphomatous' 
spleens were monoclonal, oligoclonal or polyclonal (Figure 3.3). This method 
has many drawbacks [387] but we felt that it could help distinguish an 
oligoclonal outgrowth from a polyclonal outgrowth. Two unique lymphomas 
were assessed and results show that the bands obtained by splinkerette PCR 
(excluding the retroviral vector bands) are the same in most but not all single 
cell clones, demonstrating that most of the malignant cells were clonally related 
with identical integration sites. One example was observed of a subclone with 
one shared and one distinct integration junction fragment (Fig 3-3a). This could 
either reflect an oligoclonal starting population, or the variant may have 
undergone a rearrangement of one integration site . These preliminary results 
indicate that the lymphomas are mono- or oligoclonal rather than polyclonal. 
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Figure 3.3 Clonality assessment using limiting dilution method 
Varying dilutions of a suspension of 'lymphomatous' spleens' cells were plated onto a 
96 well plate and the dilution at wh ich approximately 40% of wells demonstrated cell 
growth was subsequently utilised for clonality assessment. Cell growth theoretically 
follows a Poisson distribution in this setting , which concludes that the majority of wells 
with cell growth ("subclones") post incubation will be derived from a single cell [388]. 
The retroviral integration sites of subclones were thus compared. 
a) Gel photo of splinkerette PCR products from four subclones (left) compared to gel 
photo from original lymphoma number 9 (right) 
b) Gel photo of splinkerette PCR products from eight subclones (left) compared to gel 
photo from original lymphoma number 18 (right) 
(The poor resolution of the subclone illustrations is due to the original electronic images 
being lost). 
a) 
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Since each malignant outgrowth expressed GFP at quite high levels, I 
compared the GFP expression of a malignant outgrowth with the spectrum of 
GFP expression of the input B cells at the time of transplantation into Rag1KO 
mice and at timepoints after transplantation before the clonal/oligoclonal 
outgrowths were detectable. Since this required comparison of GFP 
fluorescence intensity measured days or weeks apart, a standard set of stable 
calibration beads was added to each sample. These beads fluoresce in the 
same wavelength range as GFP and hence are measured by the same 
detector, but the beads can be distinguished by a difference in size using the 
FSC parameter. As shown in Fig 3-4, most of the GFP+ B cells at the time of 
transplantation fluoresced with an intensity range near that of the lower intensity 
calibration bead population (indicated by left hand dashed line). Cells with GFP 
fluorescence as bright as the high intensity calibration bead population (dashed 
line on right of each plot) were rare in the injected inoculum, and in the spleen 
after 11 or 18 days. However, the lymphomatous outgrowth that developed on 
Day 39 exhibited GFP fluorescence brighter than the high intensity calibration 
bead. There are two possible explanations for the high GFP fluorescence of the 
transformed B cells compared to the majority of injected B cells: 1. Cells that 
express the provirus at high levels are preferentially transformed; or 2. 
Transformed cells do not express the proviral vector at a higher level, but these 
growing cells have much more cytoplasmic volume and accumulate much 
higher total amount of GFP. The latter appears unlikely since there is little 
correlation between FSC and GFP in the lymphomatous outgrowth, and there 
are large cells in the transferred inoculum and at earlier time points. 
This question was also approached by asking whether the individual 
lymphomatous outgrowths varied widely in GFP fluorescence or whether there 
was a narrow band of vector expression that was compatible with 
transformation. Figure 3.5 compares GFP intensity in three independent 
lymphomas in different recipients derived from the same pool of injected donor 
B cells. There was only 2-fold difference in median GFP fluorescence. Again 
this is consistent with selection for high MYC/GFP vector expression, although 
one cannot rule out a shared metabolic state that results in high GFP 
accumulation per cell regardless of level of vector expression. 
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Figure 3.4 Representative FACS analysis of cells at various time points post 
retroviral transduction 
GFP expression of MYC transduced /gHEL Trp538 blaSt1 BblaSf splenocytes gated on 
viable (7 AAD negative) cells. Donor mice were euthanized on Day 0, and Day 3 
reflects the time of cell transfer into Rag1KO recipient mice. Cells at subsequent 
time points are from recipient spleen , ie 'Day 11 " reflects 10 days post initial 
retroviral transduction and 8 days post injection into recipients. The gates 
demonstrate the percentage of GFP positive cells, the gate placement being 
determined using non transduced controls (top row). To control for the variable 
sensitivity of the flow cytometer, fluorescent calibration beads were used as an 
internal reference standard in each run (non shaded peaks on histogram) , dotted 
vertical lines showing the same GFP intensity as the calibration beads on the dot 
plots (the calibration beads not being visualised on the GFP/forward scatter plots). 
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Figure 3.5 Lymphomas demonstrated a spectrum of GFP expression 
MYC transduced /gHEL Trp538btaSt1Bblast splenocytes were injected into four recipient 
Rag KO mice. Fifty two days later three of the mice were unwell, were euthanized and 
their spleens were analysed by FACS on the same run. Profiles are gated on viable 
(7 AAD negative) B220 positive cells. The GFP intensity of the GFP high cells (which 
are likely to reflect the lymphoma cells) was thus determined using arbitrary units to 
facilitate comparison. 
Cell 
count 
10° 
GFP 
,.•. is. • 
Ill •,. _. 
• • 0-
·• .. 
.. .. 
•· .. 
·• .. 
•· .... 
:t .,. 
. .. 
. .. 
~ 
• 
+ 
··•· ... 
1 
'1 0 , a 
"'I 
I 
""• 
: • Ii :f)I • 
.. ·fl . ... 
• 11!1 ,.;.. 
..... 
. ... 
,. 11 • 
. . . 
. . . 
·~ ~ 
'
' .... 
\!,: ;; ! ► ~ ~ 
• I • 
I j : 
•.. ,.. 
• I . ~, · : 
·• . 
~. ·• 
r ~' ] 
f : I •· . 
• ♦ 
;, , . i \ : 
I 
3 
1 0 
• 
• 
ff \ : 
. . 
• 
' : •· 
4 
10 
GF p high Ii------... ►
Median GFP intensity of 'GFP high' population 
----- 2258 units 
2848 units 
4744 units 
113 
3.4 Discussion 
Results in this chapter demonstrate that we have developed a reproducible 
method of lymphomagenesis. Correlation of this FACS and morphological 
phenotype with published descriptions of murine and human B cell lymphomas 
demonstrates similarities to the mouse model of Burkitt lymphoma (BL) 
developed by Kovalchuk et al [389] which attempted to replicate BL 
translocation breakpoints by fusing the MYC gene derived from a BL-derivative 
chromosome to elements of the lgK or lgA loci. Both models have 
demonstrated the 'starry sky' pattern in the murine spleen with a diffuse infiltrate 
of large lgM and CD19 positive B cells punctuated by clearings containing 
histiocytes. The main difference between our retrovirus-induced lymphomas 
and those described in this mouse model is that Kovalchuk et al [389] noted 
predominantly lymphadenopathy rather than splenomegaly, while in our model 
splenomegaly was prominent. The FACS profile in both models is consistent 
with a mature B cell phenotype. 
Burkitt lymphoma has not been seen to occur spontaneously in mice, and 
previous attempts to induce lymphoma through overexpression of Myc under 
the control of immunoglobulin promoter regions in mouse models (such as the 
Eµ-myc model [1 O]) have consistently resulted in lymphomas with an immature 
immu nophenotype (surface immunoglobulin negative), or with morphological 
features inconsistent with Burkitt lymphoma. These experimental findings 
confirm the critical importance of the mode of Myc activation in murine 
lymphoma models. 
The presen ce of the internal ribosomal entry site (IRES) in the retroviral 
construct in our model means that the GFP reporter gene and the MYC gene 
are transcribed together, but two separate protein products are produced. In 
general the translational efficiency of both genes depends on the derivation of 
the IRES, the genes within the constructs and intrinsic cellular factors (reviewed 
by Hennecke et al [390]), and thus the translation of the second gene (GFP in 
our case) could potentially be modulated by the nature of the first gene, 
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although the mechanism remains to be defined. Our research assumes that the 
ratio of GFP expression to MYC expression is constant (although not 1 :1 ), so 
that GFP intensity is proportionate to MYC expression, although this has not 
been proven in this system. It must be acknowledged that variations in either 
GFP or MYC expression may alter the translation or catabolism of the other 
protein product, as may the developmental stage or metabolic activity of the 
cell, so the relationship between these two protein levels may not be as 
predictable as assumed. MYC has been shown to be modulated by 
translational control [391,392], altering the direct correlation between mRNA 
and protein concentration , however the relevance of this to a bicistronic vector 
remains unclear. Myc protein levels were not assessed in this research (by 
Western blotting, for example) which would have helped to confirm the 
assumed relationship between GFP expression and MYC levels. This will be 
performed during further work on this model. 
Only small numbers of GFP positive cells were evident in the transferred cells in 
recipient spleen at Days 11 and 18. By day 39 the GFP positive population had 
increased significantly in size and GFP intensity. While it is possible that very 
rare input cells with high GFP expression were not identified through the FACS 
analysis, it seems more likely that up regulation of MYC is part of the 
transformation process. Kovalchuk's model of Burkitt lymphoma [389] 
demonstrated a significant difference in Myc expression between the transgenic 
cells and lymphomatous outgrowth, the group coming to the same conclusion . 
The next logical question is thus which cells undergo transformation . The clonal 
or oligoclonal nature of the lymphomas is consistent with a single or small 
number of cells rapidly proliferating to form the lymphoma. It would seem 
logical to conclude that the intensity of MYC expression in the cell was the 
defining feature. Variations in tumour phenotype as a consequence of 
variations in Myc expression have been reported by Smith et al [393]. This 
group monitored the outcome of varying intensity of Myc expression under the 
influence of regulatory elements which allowed it to be expressed in all 
nucleated haemopoietic cells of all maturity levels. The median survival of the 
mice was inversely correlated to the Myc expression level, and the tumour 
phenotype also varied according to Myc expression, with mice expressing the 
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highest level of Myc developing T cell tumours, and lower expressing ones 
monocytic/macrophage lineage malignancies. Separate research has shown 
that a threshold level of Myc is required for maintenance of Myc-induced T cell 
lymphomas [394]. 
MYC expression would have varied in the input cells depending on the number 
of retroviral integration sites, the location of the retroviral integration sites and 
perhaps also the developmental stage or cell cycle stage of the transduced cell. 
It cannot be assumed that because the lymphoma phenotype in these 
experiments reflects that of a mature B cell that the initial transforming events 
occurred within a mature B cell, as it has been demonstrated that progeny of a 
transformed cell are capable of further maturation [395]. Murine splenic B cells 
are at varying stages of development [396] and the activated pathways within a 
particular cell may determine the degree and effect of MYC overexpression. 
The seminal paper describing the Eµ-myc model of lymphomagenesis [1 O] 
demonstrated different frequency of lymphoma with different regulatory regions 
within the constructs. While this may reflect varying degrees of Myc expression 
altering the incidence of lymphoma (as discussed above), it may also be 
explained by the fact that the different regulatory regions dysregulate Myc 
expression at different stages of B cell maturity or different stages of the cell 
cycle , which may account for the different tumour incidences. 
Although the lymphomatous outgrowth is clearly strongly GFP positive, the GFP 
intensity varies between tumours from the same input cells harvested on the 
same day (Figure 3.5). This suggests that there is a spectrum of tolerated MYC 
expression in the final tumour (but does not necessarily imply that the initially 
transformed cell can tolerate such a breadth of MYC expression). Factors 
which may be influential in determining the GFP intensity of the final tumour 
include those discussed above regarding the variation in MYC expression in a 
single cell (such as number and site of proviral integration), but spontaneous or 
retrovirus-induced co-operating mutations also need to be considered in 
lymphomatous outgrowths that have undergone multiple cycles of replication in 
a p53 defective state. Cell size may contribute to some degree to these 
differences as the GFP intensity will be increased in larger cells even if the 
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concentration of GFP per picolitre of cytoplasm is constant, due to a larger 
volume of cytoplasm. 
Overall this chapter has demonstrated reproducible and rapid formation of 
aggressive mature B cell lymphomas in Rag1 -deficient recipient mice injected 
with Trp53 mutant splenocytes with dysregulated MYC. The high expression of 
GFP in these lymphomas relative to input cells suggests selection for rare 
transduced cells with high MYC expression, and hence this alone may be 
sufficient to explain the clonal or oligoclonal origins of the lymphomatous 
outgrowths. However it cannot be ruled out that transformation itself results in 
high GFP expression and may not relate to MYC expression at all as no input 
cells could be identified with the GFP intensity of the malignant lymphoma. The 
next chapter investigates the additional possibility that the retroviral integration 
site contributes to the neoplastic growth through insertional activation or 
inactivation of co-operating cellular genes. 
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4. Results: Analysis of 
retroviral integration 
sites 
4.1 Introduction 
The results in Chapter 3 provided evidence that only rare cells with high proviral 
expression underwent lymphomatous transformation, so that this factor alone 
could theoretically explain the clonal or oligoclonal nature of the transformed B 
cells. The experiments in this chapter investigated an alternative or additional 
explanation, namely the integration of the MYCIGFP provirus activated cellular 
proto-oncogenes or inactivated tumour suppressor genes, which co-operated 
with MYC overexpression and p53 loss allowing the cell to escape the normal 
growth-regulatory mechanisms. 
The Retrovirus Tagged Cancer Gene Database [94] demonstrates the critical 
role that genes adjacent to retroviral integration sites play in retrovirus induced 
lymphomagenesis. The top ten common integration sites in retrovirus induced 
lymphoid malignancies in this collation include Myc, Pim 1, Notch 1 and Ccnd1 
which are all clearly validated lymphoid proto-oncogenes [397], in addition to 
Myb , which is a validated proto-oncogene and has recently been demonstrated 
to be dysregulated in certain subtypes of T-ALL [238]. The experiments 
described here tested the hypothesis that the retroviral insertion sites in the 
MYC/GFP+ lymphomas would often be near known or suspected proto-
oncogenes or tumour suppressor genes. Insufficient fresh lymphomas were 
available for gene expression analyses using real time PCR (archived 
specimens were used for some insertion site analyses) so the relative 
expression of all important genes near retroviral insertion sites could not be 
determined. 
4.2 Identification of retroviral integration 
sites 
The tumour retroviral integration sites were determined using Splinkerette PCR 
on DNA extracted from cryopreserved murine splenic lymphomas. The method 
is detailed in Section 2.9 and illustrated in Figure 1.1, but the basic principle is 
to cleave lymphoma DNA with a frequent cutting restriction enzyme ( Sau3AI) 
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and amplify junction fragments comprising the 5' end of the provirus and several 
hundred base pairs of flanking host DNA. The size of the junction fragment 
would vary between integration sites, depending on the distance between the 
integration site and the first Sau3AI site 5' in flanking DNA. Amplification of 
these junctions employed a reverse primer complementary to the retroviral long 
terminal repeat, and a forward primer complementary to a synthetic linker that 
was ligated to the nearest restriction enzyme cleavage site upstream of the 
proviral integration. The sequence to which the primer binds in the retroviral 
long terminal repeat was not found in the mouse genome using a University of 
California Santa Cruz Genome Browser Blat search although the splinkerette 
PCR protocol was not performed on non transduced cells to confirm a lack of 
amplification. The PCR products were then separated by gel electrophoresis 
(Figure 4.1), cut out and sequenced (separately detailed in the Appendix). The 
sequence of the flanking host DNA was then located in the mouse genome 
using the UCSC (University of California Santa Cruz) Genome Browser Blat 
search genome function (July 2007 assembly). RefSeq genes encoding mature 
mRNA transcripts (ie starting with the 'NM' prefix), both provisional and 
validated, could thus be collated, initially 10 and subsequently 100 kb either 
side of the insertion site. Forty six unique integration sites were amenable to 
being sequenced, representing an average frequency of 1.9 integrants per 
lymphoma. These results are summarised in Table 4.1, the lymphoma 
specimen numbers and insertion site labels in this table corresponding to the 
labels in Figure 4.1. 
One limitation in this study was unavoidable amplification of an internal vector 
fragment from each lymphoma, which will obscure detection of unique junction 
fragments of similar size. This internal fragment arises because in the vector 
the 3'L TR is identical to the 5'L TR, providing a second priming site for the 
reverse primer, and an internal Sau3AI site occurs 75 bp 5' to the 3'L TR priming 
site. It is possible to modify retroviral vectors so that no internal proviral 
fragments are amplified, however this had not been anticipated. Despite the 
presence of a consistent 75bp internal fragment, this limitation proved to be 
minor as it was still possible to identify numerous flanking fragments that were 
larger than the internal fragment. 
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Figure 4.1 Agarose gel photographs post splinkerette PCR 
Splinkerette PCR was performed on the set of 24 lymphomas to amplify the 5' junction 
fragment at each retroviral integration site. The PCR products were separated by 
agarose gel electrophoresis with molecular weight markers. All unique bands 
visualised under ultraviolet light after staining with ethidium bromide (denoted by 
lymphoma number and a unique letter) were cut out and sequenced, with the exception 
of the small internal retroviral fragment (marked "vector"). Unlabelled bands in this 
figure reflect sequences that could not be identified in the mouse genome, duplicate 
sequences within the one lymphoma (due to incomplete restriction enzyme cleavage of 
DNA) or in rare cases contamination from previously amplified fragments in other 
lymphoma samples. 
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Table 4.1 Unique integration sites and adjacent genes 
The genomic sequence of the 46 unique integration sites identified in the set of 24 
lymphomas was located in the mouse genome using the UCSC (University of California 
Santa Cruz) Genome Browser Blat search genome function (July 2007 assembly). The 
location of each integration site and adjacent genes are summarised below. The 
integration site labels correspond to those on the agarose gels in Figure 4.1 . 
Integration Chromosomal location 
site 
lntragenic Nearest 
gene 
1d chr8:3,653,584-3,654,293 Retn 
2c chr10:80,874,047-80,874,544 Nfic Nfic 
3b chr5:36,895,679-36,895,952 Tbc1 d14 Tbc1d14 
4b chr4:130,469,507-130,470, 144 Laptm5 Laptm5 
7a chr13:42, 196, 785-42, 197,040 Hivep1 Hivep1 
Ba chr2: 103,735, 7 40-103, 735,900 Lmo2 
11 b chr19:29,444,583-29,445,081 Cd274 Cd274 
12b chr3:88,314,524-88,314,861 Lmna 
12d chr10:20, 793,496-20, 794,112 Ahi1 Ahi1 
13b chr3:96,357,957-96,358,372 Txnip 
14b chr2: 118,553,802-118,554,267 Plcb2 Plcb2 
Genes within 
10kb 
Stxbp2, Retn 
Nfic 
Tbc1d14 
Laptm5 
Hivep1 
Cd274 
Lmna 
Ahi1 
Txnip 
Plcb2 
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Integration Chromosomal location 
site 
lntragenic Nearest 
gene 
15b chr4 : 133,676 ,096-133 ,676 , 170 Ubxd5 Ubxd5 
16a chr11 :8,586 ,082-8,586,458 Tns3 
17a chr11 :54, 772 ,810-54 , 772,858 Tnip1 Tnip1 
17c chr3 :21 ,849,100-21 ,849,374 
19a chr3 : 136,405,342-136,405 ,516 Ppp3ca Ppp3ca 
19c chr3 :95, 773, 774-95 , 773 ,915 Plekho1 
19e chr5 : 149, 790 ,016-149, 790,534 Katnal1 
20b chr3 :60,247, 139-60,247,376 Mbnl1 
20d chr3 :52 ,701 ,066-52 ,701,441 Cog6 
23a chr11 : 12,534 ,246-12 ,534 ,393 
24a chr4: 135,587,257-135 ,587,343 Tceb3 
24c chr12: 87,027 , 122-87,027,450 Batf Batf 
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Genes within 
10kb 
Ubxd5 
Tnip1 
Ppp3ca 
Tceb3 
Batf 
Chapter 4: Analysis of retroviral integration sites 
4.3 Analysis of genes within 10kb 
From the 46 unique proviral integration sites identified above, the 33 genes 
within 10kb of the insertion site were initially analysed (results summarised in 
Table 4.2). Such a narrow window was defined, despite a much wider potential 
window over which proviral L TRs can dysregulate adjacent genes, in order to 
provide a stringent test for selection of potential oncogenes near integration 
sites. 
The set of genes was correlated with a peer-reviewed online database of known 
oncogenes, the Atlas of Genetics and Cytogenetics in Oncology and 
Haematology (http://AtlasGeneticsOncology.org) [397]. This atlas lists genes 
relevant to all cancers, not solely B cell lymphoma, and utilises data from 
human and animal studies, dividing cancer genes into two categories: 
'annotated genes' and 'other genes possibly implicated in cancer.' 
Two of the genes in the set of 33 closely flanking genes were documented as 
'annotated genes' (overall 6.06%). This percentage is not significantly higher 
than expected by chance: there were 840 annotated cancer genes in the Atlas 
drawn from a total of approximately 25000 human NCBI RefSeq genes (3.36%), 
the difference not being statistically significant (two tailed p value 0.39 utilising 
Chi square test). The remaining 31 closely flanking genes were, however, 
significantly over-represented in the category of 'other genes possibly 
implicated in cancer,' with 15 (48%) of them in this category compared to a 
7280/25000, or 29% background rate (p=0.017 utilising Chi square test). This 
provided suggestive evidence for an enrichment of proto-oncogenes near the 
proviral integration sites, but was by no means convincing. 
The closely flanking genes were then reviewed to determine if they represented 
common insertion sites within the Retroviral Tagged Cancer Gene Database 
(RTCGD) (http://rtcgd.abcc.ncifcrf.gov) July 2007 build (all tumours, not just 
lymphoid). This database defines common insertion sites (CIS) as 30kb regions 
containing 2 insertion sites, 50kb regions with 3 insertion sites or a 100kb region 
with 4 or additional insertion sites, although definition is somewhat subjective, 
127 
with gene orientation and function being taken into account along with the total 
number of integrations in the database. Seven of the 33 closely flanking genes 
(21 %) were found to be in common insertion sites , an apparently high 
percentage , although the expected rate by chance alone is unknown because 
the total number of genes in CISs cannot be quantified in RTCGD. 
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Table 4.2 Analysis of genes within 10kb of retroviral insertion sites 
The 33 genes within 10kb of the retroviral insertion sites were correlated with the Atlas 
of Genetics and Cytogenetics in Oncology and Haematology [397] and the Retroviral 
Cancer Gene Database (RTCGD) [94], results of which are summarised below. 
Gene Annotated cancer 
Tbc1d14 no 
BC017612 no 
Plcb2 
Ubxn11 no 
Wdr26 no 
Possible cancer 
no 
no 
N/A 
no 
Common insertion site in 
RTCGD 
no 
no 
no 
no 
no 
129 
4.4 Genes and recurrent sites of 
insertion in cancer within 100kb 
The propensity of the genes within 10kb of retroviral integration site to be 
categorised as a 'possible cancer gene' and to be located in a common 
insertion site as detailed above suggests that this is a non-random set of genes. 
These analyses were then extended to the genes within 100kb of the insertion 
sites. The cut off of 100kb was used as it has been demonstrated that retroviral 
long terminal repeats can influence of the expression of genes greater than 250 
kb away [31 0], although it remains unclear if this is always the case. The 
Retroviral Tagged Cancer Gene Database was interrogated for these genes 
and a brief literature review of gene function was undertaken if one such gene 
was within a RTCGD common retroviral insertion site as it was a 'gene of 
interest'. 
The figures and tables below detail the key features surrounding each unique 
integration site. The UCSC Genome Browser Blat search genome function 
(July 2007 assembly) windows show the insertion site I identified (bold arrow) in 
the context of RefSeq genes (labelled with gene orientation indicated) and other 
integration sites in RTCGD (small vertical bars). The only windows illustrated 
are those where the integration site fell within a RTCGD-defined common 
integration site. The numbers of integrations within defined regions is 
enumerated in brackets after the gene name, using the summed incidence of 
integrations in RTCGD and the sites identified in this work. The lymphoma 
numbers and insertion site labels correspond to those in 
Table 4.1 and Figure 4.1. 
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4.4.1 Lymphoma 1 
Genes within 100kb 
Ptp4a2 
Genes within 100kb 
Stxbp2 Trappc5 
Retn Fcer2a 
Xab2 Clec4g 
Pcp2 Cd209a 
Genes of interest 
No gene of interest 
Genes of interest 
No gene of interest 
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4.4.2 Lymphoma 2 
Genes within 100kb Gene of interest 
Gng7 Gadd45b Gng7 (3 integrations in 50kb) 
Tmprss9 
Timm13 
Lmnb2 
Oiras1 
Slc39a3 
Sgta 
This gene is of interest as another distinct intragenic 
integration site was identified in a separate experiment. 
The significance of this gene is considered in the 
discussion. 
The bold arrows show the two intragenic insertion sites in this research in the 
context of schematically illustrated neighbouring genes. The sites of the other 
retroviral insertions in the region (from the RTCGD) are illustrated with a vertical 
line in the row labelled 'retrovirus. ' 
Nfic 
Pip5k1c 
Tbxa2r 
Gipc3 
18058 8000 
(: .. : .· 
Bruno/5 
Nein 
S1pr4 
180450000 
ret'rov i rus i nser·'t i ans 
Your Selence rrom Blat search 
RefSetenes 
_ ,: ._. 
•. . ., . , . ~ . : 
. . + .. ;. .• .. ..•.... 10 ··•'· 
• ··'•·•· ·• •,• ... , •. , •._ ·.• .. -:- -·-y..❖ ·;. ··-~:-.-:•: -----v-•:. ;~:--;.;:;:; . --~----;-:;--·-... 
180480000 
~: : . :I 1.1i. 
Gene of interest 
,sca le 
188350000 i :chr 10 
1111 H 11 11111111 I 
.. 
jret'rov i rus 
jYourSeq 
[» ;3110056003R i k 
:Tmprss9 
T;mm13 
1Lmnb2 
:GadcH5b 
1Gng7 
'Gng7 
:o;ras1 
ls 1 c39a3 
:sgta 
Hmg20b Nfic (nuclear factor 1/C) (5 integrations in 
Gna15 30kb) Deletion of this gene has been shown 
Fzr1 to contribute to tooth root defects in mice [398]. 
No role in neoplasia has been published to 
date. 
~~Ql~r~ .,:4~lll; ' . B]a~'.~g~rc:n:!!m§Yl!!s::·.'.li;Q~tj;;~:!fHm·' ·.,_ •. ,,d~;ll!iE1!,i!§g;rJ1Rll!I:§:~ ...•·.· ·· y , 
The bold arrow shows the intragenic insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the other retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the 
row labelled 'retrovirus .' 
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position/search chr1 0:B.0, 774.294-B0.974.293 1 jump ]I dear 1 size 200,000 bp. ! con.figure I 
180950000 I 8 0900000 I 80858008 
r e-trov i rus i nse- r~t ions 
I I II 
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H ~>< 
retrovirus 
llt-~ P ip5K1c 
~Pip5 k1C 
IH-i 25 1 0012J06Ri k 
Tbx a2r 
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F63011 0N24Rik 
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CelFS 
Ne ln 
S ipr..; 
Gna 1s 
.•,. 
·< 
·•:• 
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4.4.3 Lymphoma 3 
Genes within 100kb Genes of interest 
Zfp362 A3galt2 No gene of interest 
Phc2 Trim62 
Genes within 100kb Genes of interest 
Tbc1d14 Ccdc96 No gene of interest 
Grpe/1 05Ertd579e 
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4.4.4 Lymphoma 4 
~1§1~11~r 
Genes 
within 100kb 
Zdhhc18 
Nude 
Nr0b2 
Gpatch3 
Gpn2 
Sfn 
Pigv 
Arid1a 
~~~l~,~g~~:~i,R.JJ (§~,~1:~~111,a:ijg;;(ggjjL .. 
Genes of interest 
Zdhhc18 (zinc finger, DHHC domain containing 18) (5 
integrations in 100kb) 
This is a validated protein-coding gene but its function is not well 
described. 
Arid1 a (AT rich interactive domain 1 A (SWl-like)) (5 
integrations in 100kb) 
Deficiency in embryos causes developmental arrest [399]. 
Mutations have been identified in ovarian clear cell and 
endometriod carcinomas , suggesting a role as a tumour 
suppressor gene [400]. 
);ii"~';Ql~l!!~;~~~-5;;:~(' 
The bold arrow shows the intragenic insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the other retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the 
row labelled 'retrovirus. ' 
position/search chr4:133.079.777·133.279.776 I jump I[ clear I size 200,000 bp. I cq(lfigure ] 
4q81 · • 
\133250000 \133200000 \133150000 
retrovirus inse rtions 
11 I I I 
Your Sequence f'rom B lat Sear ct, 
RefSeienes 
• i · I : . · : \#+j,o 
+·n---· -:-: -¾+IH·+!~ 
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100 Ko 
H 
Chr4 ( q02,3-q03) 
lsca le 
\133100000 i : chr4 
[re"trov ir·us 
'a lat: S equence 
fffN>+11810019J16R i K 
fl-l{:l>f \1810019J16R i k 
\~+.,-++ff INud c 
,Nr002 
\Gpat:ch3 
\Gpn2 
\Sfn 
'2dhhc18 
\p;gv 
\p;gv 
\Pigv 
iAr idla 
Genes 
within 
100kb 
Laptm5 
Sdc3 
Matn1 
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Genes of interest 
Laptm5 (5 insertions in 30kb) encodes a lysosomal transmembrane 
protein which appears to have a role in ubiquination [401], but which has 
not been well characterised . It is initially expressed in embryonal stem 
cells, and with cell maturation is predominantly expressed in the spleen, 
thymus, bone marrow and lymph nodes [402]. It was previously called 
Clast6, E3. It is down regulated on B cell or T cell activation [403] 
including CD40 ligation and has been shown to be up regulated by retinoic 
acid in a promyelocyte cell line [404]. During normal B cell maturation 
Laptm5 expression is high in the earliest stages, drops during intermediate 
stages of development, and is again abundantly expressed in mature B 
cells and B cell lymphomas [405]. Laptm5 enhances degradation of 
antigen receptors in Band T cells [403,406] . 
Sdc3 (syndecan 3) (5 insertions in 100kb) deficient mice are 
characterised by a unique type of muscular dystrophy [407], and 
polymorphisms have been associated with obesity [408]. 
:IIIBEi1i~lllliiDEliDDllilEll 1l lllliili 
The bold arrow shows the intragenic insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the othe[ retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the 
row labelled 'retrovirus.' 
position/search chr41 30,3£9,823-13G,569.S22 ············ u~.~P .. ll.~.1=~~1 size 200,000 bp. L .. ~?.~~9.~~.: J 
1 -------------------<1100 f:b 
I 130550000 [ 130500000 I 130450000 
r etrovirus insertions Ii I Your s eauence om Blat search 
RefSe Genes 
~-+HHI+~· 4 
,sea le 
I 130400000 , : chr4 
I !ret'rov irus 
.,.+H{rsac3 
\L aptm5 
'Matnl 
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4.4.5 Lymphoma 6 
Genes within 100kb 
Nil 
Genes of interest 
Nil 
4.4.6 Lymphoma 7 
Genes within Gene of interest 
100kb 
Hivep1 Hivep1 (human immunodeficiency virus type I enhancer 
binding protein 1) (2 insertions in 30kb) 
There is no published literature linking this gene to malignancy 
or cell proliferation. 
The bold arrow shows the intragenic insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the other retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the 
row labelled 'retrovirus.' 
position/search chr13:42.096.900-42.296.399 ----- l}~;~~~J[~~i.~~] size 200,000 bp-. [ configure 1 
13 q= , • qR2 Chr13 ( qR4 ) 
100 kb :sea le 142250000 142200000 142150000 I \: c11r13 
retrov irus inlt ions 
Your Sequence fro lat Searer, 
,r-etrov i rus 
RefSeq Genes 
: ~ . : : :: -++---< \Hivepl 
[ ,~;§l~;l~~1.~ +Ih~§r1§§; o~~~i!.~§lakl.i.li,1! 1~ta11 ; 
Genes with in 100kb Genes of interest 
BC017612 No gene of interest 
Ccdc67 
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4.4.7 
Genes 
within 
100kb 
Caprin1 
Lmo2 
Chapter 4: Analysis of retroviral integration sites 
Lymphoma 8 
Genes of interest 
Lmo2 (6 insertions in 100kb) is widely expressed (particularly in 
haemopoietic organs) but its precise function is still unclear, although it 
has been demonstrated to be important in early haemopoiesis [409]. It 
has two domains and is involved in protein-protein interactions, with 
LMO2-associated complexes being able to bind DNA and influence gene 
expression. 
Enforced expression predisposes to T cell tumours in mice [41 0]. From a 
clinical perspective, LM02 is dysregulated by nearby integrations of 
gene-therapy retroviral vectors in multiple cases of T-ALL that developed 
several years after transplantation of gene-corrected haemopoietic stem 
cells into children with common gamma chain severe combined 
immunodeficiency [296]. Breakpoints near the LM02 gene have also 
been demonstrated in spontaneous cases of T cell acute lymphoblastic 
leukaemias [411 ]. Expression of LM02 is high in germinal centre B cells, 
and their progeny [412], and its expression in human Diffuse Large B cell 
Lymphoma has been demonstrated to be associated with prolonged 
survival [50]. 
Caprin1 (3 insertions in 100kb) encodes cytoplasmic 
activation/proliferation-associated protein-1. Knock-down experiments in 
lymphocyte cell lines have demonstrated that it influences cell division 
[413]. It has also been shown to be a target of the regulatory miR-16 
[414] which has been implicated in the pathogenesis of Chronic 
lymphocytic leukaemia. 
The bold arrow shows the insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the other retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the 
row labelled 'retrovirus.' 
position/search chr2:l03.635,812-1G3,335,311 ............... fi~;i;·1r:~i-~-~·i··1 size 200,000 bp. r····~;;~ig:~·~~:····1 
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I 103800000 I 103750000 
retrovirus insertions 
II I 
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I 103700000 
t:(:!i· C<1pr n1 
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Lrno2 
Lrno2 
Lrno2 
Lrno2 
··• 
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4,4.8 Lymphoma 10 
Genes within 100kb 
Nil 
Genes of interest 
Nil 
4.4.9 
~~~:[_ 
Genes 
within 1 00k 
Cd274, 
Jak2, 
lns/6, 
Rln1, 
Pdcd1/g2 
Lymphoma 11 
'::~~1~'~p~~:~~~:i .. 
Gene of interest 
Cd274 (also called PDL 1) (3 insertions in 30kb) is one of the 
ligands of programmed death-1 (PD-1) receptor. This pathway 
sends inhibitory signals to T cells to modulate their activity in the 
setting of a chronic antigenic stimulus (reviewed in [415]). The 
downstream pathways from PD-1 are best characterised in T 
cells , although this receptor is also expressed on B cells. 
···.·· ...... ·,:•1i~::~~~,~$1&:1;~~§P:~~~111aqg;~:§i!:~i1tae;;;;:;l;\;;;;:T,;;~F+ · 
The bold arrow shows the intragenic insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the other retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the 
row labelled 'retrovirus. ' 
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4.4.10 Lymphoma 12 
Genes within 100kb 
Rps17 
Cpeb1 
PdeBa 
Genes within 100kb 
Lmna Rab25 
Slc25a44 Rob/d3 
Sema4a 
Mex3a 
Ubqln4 
Ssr2 
Genes within 100kb 
Nat15 C/uap1 
Olfr15 
Zfp174 
Zfp597 
Nlrc3 
Btbd12 
.. ,i~IIIDlRll eEt::, 
Genes of interest 
No gene of interest 
Genes of interest 
No gene of interest 
Genes of interest 
No gene of interest 
Genes within 
100kb 
Gene of interest 
Ahi1 
Myb 
Myb (63 insertions in 200kb). This gene is discussed in detail in 
Section 1.8. 
The bold arrow shows the intragenic insertion site in Ahi1 in this research in the 
context of schematically illustrated neighbouring genes. The sites of the other 
retroviral insertions in the region (from the RTCGD) are illustrated with a vertical line 
in the row labelled 'retrovirus .' 
1208~0000 
100 k l:::i :sea l e !? 
I 20800000 I 20750000 I ! : chrl 0 ? .. 
I I retrov irus inse rt ions 
: ii:!; 
11 I II 1 11 II II I I I iretrov irus Your Sequence om Blat s e arch j 
~l~t sequence i 
Refs Jenes j r-~1 I --<c:++:--:tr-~-+ ..• ~-• -+-+<-,-H+,-.,j-++4-+-+-f-+-++-+H-+-KY-- ~~ ~; 
:Myb 
'Myb 
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4.4.11 Lymphoma 13 
ii~,§, ,h ;~ii~ijiii ~~:ijl11u1.,~,§~1 , -
Genes Gene of interest 
within 
100kb 
lkbkb 
Okk4 
Polb 
Plat 
Ap3m2 
Jkbkb, despite a lack of retroviral insertions nearby, due to its selective 
expression in haemopoietic cells , particularly lymphocytes and its 
known pivotal role in the NF-KB pathway this has been designated as a 
gene of interest. lkbkb encodes a protein product called inhibitor of 
kappaB kinase beta (abbreviated as lkbkb, IKK~, IKK-8, or IKK2 in 
scientific literature). lkbkb forms a part of the IKB kinase complex in 
conjunction with IKKa and IKKy (NEMO). The critical nature of this 
pathway in normal B cell function and differentiation is discussed in 
Section 1.4.2, and its role in B cell lymphoma is discussed in Section 
1.5.6. 
ii!Dlgr,J!liii:: .. A .. --!.~'-· .. ,_~~11~i@a1s§J1~~; , +:~,~.;;; 
The bold arrow shows the insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the other retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the 
row labelled 'retrovirus .' 
position/search chr823.724.006-23.924.005 ·················· [ jump H clear I size 200,000 bp . I configure j 
123900000 
1-1-++.;-H-~ 1+--++---t+~ 
~1-i-H-<ill - 11 . :i 
Genes within 100kb 
Txnip Lix1 I 
Hfe2 RbmBa 
Polr3gl Pex11 b 
Ankrd34a 
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100 kb 
123850000 123800000 
r e trovirus insertions 
Your Se quence-r am Bla't S e arch 
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i• · : · -II 1· ·. II 1- 1111111¼+-fil 
Genes of interest 
No gene of interest 
123750000 
~iH 
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-
~ ca l e 
: : chrS 
t etrovirus 
~B lat Sequence i]]~ 
Dkk4 
\Polb 
:·· 
.i9930013F 10R ik Et 
)kbklo 
: r kbko 
\p1a1: 
' 
(Aro3m2 
•Ap3m2 
4.4.12 Lymphoma 14 
Genes within 100kb 
Elov/6 
Genes within 100kb 
Plcb2 Pak6 
Gm1337 Phgr1 
Bub1b Disp2 
Genes of interest 
No gene of interest 
...... llll!ill! 
Genes of interest 
No gene of interest 
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4.4.13 Lymphoma 15 
Genes within 100kb 
Gnptab, Sycp3, 
Oram 1, Chpt1 
[~!g,"' 
Genes within 
100kb 
Ubxn 11 Ccdc21 
Sh3bgrl3 Aim 11 
Cd52 
Genes of interest 
No gene of interest 
Genes of interest 
Cd52 (7 insertions in 100kb) is expressed on the surface of 
B and T lymphocytes and in the male genital tract. Its role in 
lymphocytes is poorly defined, although it is a target for the 
monoclonal antibody alemtuzumab. 
Ubxn11 (also called Ubxd5) (7 insertions in 100kb) 
encodes Colon Antigen 1 which has been demonstrated to 
elicit a T cell response in colorectal patients with metastatic 
disease [416] , but the function of this gene remains unclear. 
_J~J;;!-~~:;Fg.111 ~~11: T " · " " 
The bold arrow shows the intragenic (in Ubxn11) insertion site in this research in the 
context of schematically illustrated neighbouring genes. The sites of the other 
retroviral insertions in the region (from the RTCGD) are illustrated with a vertical line 
in the row labelled 'retrovirus. ' 
position/search chr4:133.576.305-133.776.3D4 ·············· !"Jump If cl~~-~ size 200,000 bp. L configurn ! 
I 133750000 I 1133700000 113365 0000 
t'ett'ov i t'LlS insert i ans 
II 111 
Your SeqLience ,- -om B lat s ear ct1 
Rerse Genes 
IHI I II.I~ 
Ii 
ii H·+-+i+#'--H+-·•i 
: I= : I? , : ? I II ~ H · : : I f"+l11 
Genes within 100kb 
Sh3bp5 Capn7 
Dnahc1 Mett/6 
142 
Genes of interest 
No gene of interest 
I 1336000 0 0 
;Sea le 
:s113bgr 13 
,Ccdc21 
'Gm753 4 
\catsper 4 
:catsper 4 
..... 
.,. 
4.4.14 Lymphoma 16 
Gene within 100kb 
Tns3 
Gene with in 100kb 
Tgfbr2 
Genes of interest 
No gene of interest 
Genes of interest 
No gene of interest 
4.4.15 Lymphoma 17 
Genes within 100kb 
Tnip1 Gpx3 
Lyrml Anxa6 
Hint1 Ccdc69 
Genes within 100kb 
B4ga/t5 
S/c9a8 
Spata2 
Genes of interest 
No gene of interest 
Genes of interest 
No genes of interest 
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Gene with in 100kb 
Nil 
Genes of interest 
No gene of interest 
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4.4.16 Lymphoma 18 
Gene with in 100kb 
Ogkz Mdk 
Ambra1 
Chrm4 
Creb3l1 
Genes of interest 
No gene of interest 
4.4.17 Lymphoma 19 
11,i;tlll".••····· ']~i 1ill!¾~.~·.,;L.L, 
Gene within 100kb 
Ppp3ca 
. ,,, 11li n~e~io:~;;~;[ J~a,l!~Q' 
Genes of interest 
No gene of interest 
p;9,Jg1~:11~f~:s;1~,~1;;,{3~11, ···••··· ...... ,. ;~rns~~•q~ii~§:1, , J~,~11~,o/ 1 
Gene with in 100kb Genes of interest 
Siglec15 S/c14a 1 S/c14a2 No gene of interest 
ii~ll,ll!l~~a · · .; +,1 J~Q.i*j~li~~1ii11~~!i1~ftf:11iig~;g~%§llfii1,i,r,~~1~~~~ 
Gene with in 100kb Genes of interest 
Mrps21 Gm129 No gene of interest 
Aph1a Car14 
Anp32e Plekho 
Vps45 
;ra61er4.37 GehesMrtl~i: ins~r£1<i,Ji:~1~Elll l~i1115nc1 'g~il~. · "Jl!int~·test 
Gene within 100kb Genes of interest 
Dnajb9 PnplaB Nrcam No gene of interest 
f:Ii~§,le:;~~38 Geoe~:1ae~t inser:t,io'iil, '.ii!1111~~~!!an8ii1§i6i~llfflll,il'l~:(~§i 
Gene within 100kb Genes of interest 
Katna/1 Hmgb 1 No genes of interest 
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4.4.18 Lymphoma 20 
Gene within 100kb 
Gng7 Slc39a3 
Tmprss9 Sgta 
Timm13 
Gadd45b 
Diras1 
Thop1 
Creb3/3 
Lmnb2 
Gene of interest 
Gng7 because another unique integration site has been 
identified in this gene in this small number of lymphoma 
samples. The significance of this gene is expanded in 
thia chapter's discussion. 
The bold arrows show the two intragenic insertion sites in this research in the context 
of schematically illustrated neighbouring genes. The sites of the other retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the row 
labelled 'retrovirus.' 
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'T'ourSeq 
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Gng7 
Gng7 
Dirasi 
S1c39a3 
Sgt21 
Tt1op ! 
Cret-313 
magr ·•········ ·•· r ;11;1111,111 .·· 
Gene with in 100kb 
Mbn/1 
804500001 
retrovirus insertions 
'T'our seln ce , - -om B 121t se21r er, 
RefSe Genes 
lllllt►- -+-+-+-+-=-~~~-':'"-+-+-+-+-+tt~ 
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80500000 1 
.. ·...... aliDillDD••·•···· •·•••i••· iil~llli 
Genes of interest 
No gene of interest 
1-++t!HII (:ti 
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-~:~n;~i11;B~'~illi i;l.§@jigl~:· · . .... :dlfi,: . .. > .· :;~~ii~f;j;]'.iilri1ii!il. 
Genes within Genes of interest 
100kb 
Lta 
NF-KB i/1 
Bat4 
Bat3 
Bat2 
Atp6v1g2 
Batta 
Aif1 
Ltb 
Odx39b 
H2-01 
Ly6g5b 
Csnk2b 
Gpank1 
Apom 
Bag6 
Prrc2a 
Lst1 
Tnf 
Lta, Ltb and Tnf (5 insertions in 100kb). This integration site 
is also of interest as it is near (less than 100kb away from some 
of the genes) the site of the histocompatibility locus genes. 
Tnf (tumour necrosis factor superfamily, member 2) encodes 
the pro-inflammatory cytokine TNFa which is mainly produced 
by macrophages, and has a broad spectrum of activities 
including cellular survival, proliferation and differentiation. TNF 
can activate a plethora of downstream pathways including the 
NF-KB pathway, MAPK pathway and death signalling pathways. 
It frequently acts in concert with other cytokines. Tnf single 
nuclear polymorphisms have been associated with increased 
risk of lymphoma [417] 
Lta (lymphotoxin alpha (TNF superfamily, member 1) gene) 
produces lymphotoxin b which is also known as TNF~. It is 
overexpressed in Burkitt lymphoma cell lines and B 
lymphoblasts. Lta is produced by lymphocytes and has a role in 
inflammation, lymphoid organ development, B cell stimulation 
and inhibition of tumour angiogenesis. 
Ltb (lymphotoxin beta (TNF superfamily, member 3) is 
overexpressed in the above lines and also in T cells and B cells 
in addition to tonsil , lymph node and thymus (but not bone 
marrow). It anchors Lta to the cell surface. Ltb is important for 
early lymphoid organogenesis. 
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The bold arrow shows the insertion site in this research in the context of schematically 
illustrated neighbouring genes. The sites of the other retroviral insertions in the region 
(from the RTCGD) are illustrated with a vertical line in the row labelled 'retrovirus.' 
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4.4.19 Lymphoma 22 
Gene with in 100kb 
Pds5a N4bp2 
Genes of interest 
No gene of interest 
4.4.20 Lymphoma 23 
Gene within 100kb 
nil 
Gene with in 100kb 
Wdr26 Nvl Cnih4 
Genes of interest 
No gene of interest 
Genes of interest 
No gene of interest 
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4.4 .21 
Gene 
within 
100kb 
Tceb3 
Fuca1 
Hmgcl 
Lyp/a2 
Rp/11 
Gale 
(/d3 
just 
beyond 
100kb) 
Lymphoma 24 
Gene of interest 
Id3 (inhibitor of DNA binding 3) (8 insertions in 50kb) encodes a 
dominant negative helix loop helix protein that can bind to members of the 
basic helix loop helix family of transcription factors , inhibiting their activity 
[4 18] . It has been found to function as an E protein antagonist, E protein 
transcription factors being critical for a~ T cell development. ld3 is also a 
modulatory factor in yo T cell development, although the mechanism 
remains to be well clarified [419]. Interestingly, mice with deleted ld3 
develop an aggressive lymphoma resembling human hepatosplenic yo T 
cell lymphoma [420] . More recently its deletion has been demonstrated to 
impair the production of T regulatory cells and promote the development of 
TH17 cells [42 1]. Less has been published regarding its role in B cell 
maturation and proliferation , although it has been shown to inhibit B cell 
development [422] . Most importantly, ld3 inactivating mutations have been 
discovered to be very frequent in Burkitt lymphoma [5] . 
The bold arrow shows the insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the other retroviral 
insertions in the region (from the RTCGD) are illustrated with a vertical line in the row 
labelled 'retrovirus .' 
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13 5 7000001 
Gene within 
100kb 
Baff 
Jdp2 
Mfsd7c 
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········•·1,. 1) ....... ·.· 
Gene of interest 
Batt (4 insertions in 50kb) encodes basic leucine zipper transcription 
factor, ATF-like, which is highly expressed in haemopoietic cells. It 
has increased expression in T helper cells compared to other T cell 
subsets, with knockout mice demonstrating defective differentiation of 
IL-17-producing T helper cells [423]. Interestingly, a small study by 
Lorenzo et al [424] demonstrated that the expression of Baff 
discriminates between normal individuals, those with a history of 
Burkitt Lymphoma, and the latter who have had a secondary 
malignancy, however the significance of these findings remains 
unclear. 
·········1a11·····•·•····· 
The arrow shows the intragenic insertion site in this research in the context of 
schematically illustrated neighbouring genes. The sites of the other retroviral insertions 
in the region (from the RTCGD) are illustrated with a vertical line in the row labelled 
'retrovirus.' 
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4.4.22 Candidate oncogenes within common retroviral 
integration sites 
Based on the combined incidence of integrations in RTCGD and the sites 
identified in this work , many of the unique integration sites fulfilled the 
classification of recurrent sites of integration and the genes in these locations 
were either known oncogenes or established regulators of B cells (Table 4.49). 
Among the best known oncogenes at these sites were Myb (Section 4.4.10) and 
Lmo2 (Section 4.4.7) , both of which are well known for being dysregulated by 
nearby proviral insertions. A number of the genes at these recurrent sites of 
integration affect the same process. or pathway, notably G-protein signalling for 
chemotaxis , TGF~ signalling (an important anti-proliferative signal in B cells), 
and NF-KB signalling (a major growth pathway in normal and neoplastic B cells). 
Laptm5 is one such gene (Section 4.4.4) shown to negatively regulate antigen 
receptor expression and signalling in B cells and T cells [403 ,406]. In addition, 
one of the integrations was immediately adjacent to /kbkb, encoding a key 
kinase activating the NF-KB pathway, although recurrent integrations near /kbkb 
were not found in RTCGD (Section 4.4.11 ). 
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Table 4.49 Candidate oncogenes within common integration sites 
Many oncogenes, proto-oncogenes and B cell regulators are located within regions 
fulfilling the definition of a common integration site (using the combined incidence of 
integrations in RTCGD and the sites identified in this work). Based on our 
experimental findings, the number of retroviral insertions in the region and the 
published literature the most important genes within approximately 100kb of our 
retroviral insertion sites are summarised below. 
Candidate Retroviral 
oncogene insertions 
/window 
Candidate 
process 
Known functions of 
candidate oncogene 
Lmo2 6/100kb Anti-
differentiation 
Inhibition of differentiation, 
inhibition of E-box basic helix-
loop-helix transcription 
Nfic 5130kb 
Gng7 3150kb 
Hivep1 2130kb 
DNA replication 
G proteins & 
chemotaxis 
NF-KB, TGF~ 
response 
DNA replication, transcription 
Heterotrimeric G protein 
signals, chemotaxis, growth 
Pim complementation group, 
NF-KB signalling, TGF~ 
response 
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4.5 Discussion 
The results in this chapter provide suggestive evidence for enrichment of P rota-
oncogenes or tumour suppressor genes flanking the retroviral integration sites. 
A higher than expected percentage of nearby flanking genes corresponded to 
"other genes possibly implicated in cancer" in the Atlas of Genetics and 
Cytogenetics in Oncology and Haematology. A high fraction of identified 
integration sites were in recurrent sites of proviral integration in a database of 
these sites identified in a variety of retrovirus induced lymphomas and other 
cancers, although it was not possible to determine if the fraction of CIS near the 
identified insertions was greater than expected by chance. Review of the 
function of genes flanking these insertion sites identified a number of known 
proto-oncogenes, a significant proportion of which are known to be 
dysregulated in haemopoietic malignancies. 
These features are consistent with the possibility that the transformed 
MYCIGFP+ Trp53-mutant B cells had acquired their neoplastic phenotype as a 
consequence of their retroviral integration serving as a third mutagenic hit, the 
retroviral promoter and enhancer elements facilitating dysregulation of adjacent 
pro-oncogenes, precipitating the development of lymphoma. While the results 
are consistent with this possibility, they are equally compatible with a null 
hypothesis that the integration sites play no role in transformation and are 
selected simply as preferred retroviral integration sites or permissive loci for 
high MYC/GFP proviral expression. In the remainder of this discussion I will 
consider some of the best candidates for flanking proto-oncogenes that may 
have been activated by the integrated provirus. In the next chapter, I tested this 
hypothesis experimentally by deliberately introducing a dysregulated version of 
the flanking gene as a third mutagenic hit. 
The list of potential co-operating genes cannot be neatly categorised into a 
specific function or cellular pathway. This may be because the integration sites 
identified only represent a fraction of those present and the majority may 
I 
represent 'passenger' mutations. It is not possible to ascertain whether 
retroviral integrations cause gain or loss of function in this model. It has been 
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assumed that the genes identified were potentially overexpressed due to their 
proximity to the retroviral promoter or enhancer, but there may be instances 
where the identified gene is in fact down regulated or even mutated as a 
consequence of the retroviral integration. The broad association of potential co-
operating genes with pathways that have recently been shown to be 
dysregulated in Burkitt lymphoma (as detailed in Section 1.12) was thus of 
interest. Candidate oncogenes within common integration sites listed in Table 
4.49 and their products have been underlined in the discussion below to 
emphasize the relationship of the discussion to our research results . 
Recent publications [5, 14] have highlighted the importance of the Pl3K pathway 
in the pathogenesis of Burkitt Lymphoma. 103, the negative regulator of TCF3, 
has been recently reported [5,425,426] to be recurrently mutated in Burkitt 
lymphoma, enhancing the activity of B cell receptor signalling through the Pl3K 
pathway and promoting cell proliferation. Suppression of the NF-KB pathway 
has also been recently characterised in Burkitt lymphoma, as discussed in 
Section 1.12. Despite not being found in a common retroviral integration site in 
the RTCGD, lkbkb was of interest due to its key role in the NF-KB pathway. Lta 
and other tumour necrosis factor-related cytokines stimulate the NF-KB pathway 
(reviewed in [427]), and both lymphotoxins have been shown to be NF-KB target 
genes in lymphocytes [428,429]. 
Myb has been demonstrated to be critical to the development and maintenance 
of follicular B cells [271 ], the authors of this research suggesting that this 
mechanism may be through modulation of B cell receptor signalling. Lauder et 
al [430] reviewed the role of Myb in T cell activation and survival, finding that 
Pl3K and its effector molecular AKT are activated by the interleukin 2 receptor 
and that Myb is a downstream effector of this pathway, helping to protect cells 
from apoptosis. In contrast Watanabe et al [431] found that miRNA-150 (a 
potent suppressor of Myb) overexpression in NK/T-cell lymphoma cells resulted 
in reduced levels of phosphorylated AKT. It is tempting to speculate that an 
analogous link between Myb and the Pl3K pathway is found in B cells. Thomas 
et al [271] showed that Myb-deficient mature B cells have normal proliferation 
but increased apoptosis with some preliminary data supporting aberrant B cell 
receptor signalling in these mutant mice. 
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With regards to the significance of MYB in Burkitt lymphoma, recent findings 
(Louis Staudt personal communication) confirm that MYB is consistently 
overexpressed in Burkitt lymphoma compared to DLBCL. MYB silencing has 
been shown to reduce proliferation and increase apoptosis in a Burkitt 
lymphoma cell line [432 ,433] . 
Other potentially co-operating genes are difficult to assign to a specific pathway. 
Gngl is such an example , its second intron being a recurrent integration site in 
two separate experimentally induced lymphomas (Table 4.1 ). In addition to 
this , Hummel et al [199] and more recent research (Louis Staudt personal 
communication) found that it was differentially expressed in Burkitt lymphoma. 
The full name of this gene is guanine nucleotide binding protein (G protein), 
gamma 7 and it is one of the twelve known members of the gamma subunit 
family . These subunits combine with alpha and beta subunits to form 
heterotrimeric G-proteins which transduce receptor signals across the cell 
membrane , activating downstream signalling pathways. The only publication 
regardi ng this protein in mice [434] reports that knockout mice had behavioural 
changes associated with altered focal regulation of cerebral adenylyl cyclase 
activity. Two publications specifically relating to the human gene in the setting 
of solid tumours demonstrate reduced expression of this protein in pancreatic 
malignancies [435] compared to normal pancreas and that low Gngl expression -
was associated with poorer survival in oesophageal cancer [436] . An 
interesting recent publication [437] looked at homozygous deletions in Hodgkin 
Lymphoma cell lines using array-Comparative Genomic Hybridisation. Gngl 
was one of 7 potential new tumour suppressor genes identified in this 
publication . The significance of this gene was not further pursued 
experimentally due to time and resource limitations and the absence of 
substantial literature to support its role in B cell lymphoma at the time. Its role · 
as a tumour suppressor gene is of particular interest from the literature and as 
both retroviral insertions were intragenic and may have caused 
haploinsufficiency, contributing to lymphomagenesis. This could not be pursued 
with the current research model which focuses on potential proto-oncogenes 
but models such as those using short hairpin RNA suppression, gene 
sequencing looking for mutations or promoter methylation pattern differences in 
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normal and lymphomatous tissue may have been helpful to try to further define 
this gene's role. 
Lmo2 was another gene of interest, but its role in B cell homeostasis and 
neoplasia remains to be clearly elucidated. It is within a common retroviral 
insertion site and is reviewed in Section 4.4.7. LM02 is known to be 
overexpressed in germinal centre lymphocytes and germinal centre-type 
DLBCL but surprisingly its expression is markedly suppressed in Burkitt 
lymphoma [344,438]. Recent work by Cubedo et al [439] did not implicate MYC 
or p53 in the LM02 interactome. 
Laptm5 is another gene of interest, although its role in B cell lymphoproliferative 
disorders is still being defined. Its normal role in B cells is reviewed in Section 
4.4.4. There is no literature to date regarding the relationship between this 
gene and MYC, p53 or Burkitt lymphoma. 
There was not an absolute correspondence between the bands sequenced and 
distinct integration sites identified for several reasons. On some occasions the 
sequence corresponded to internal vector sequences only (the splinkerette 
method uses primers that anneal to both of the viral long terminal repeats and a 
restriction enzyme cleavage site so some of the sequences obtained will be 
internal viral sequences without crossing the viral-DNA junction), at other times 
the sequence was not able to be matched with confidence to the murine 
genome and on other occasions the same sequence was evident from distinct 
bands within the same lymphoma, presumably due variable restriction enzyme 
cleavage. The most common reason, however, for this discrepancy was cross-
contamination, where that the exact insertion site had been previously identified 
in a distinct lymphoma. This is most likely to reflect PCR product contamination 
of DNA despite physical separation of the different stages of the DNA extraction 
and PCR reactions. Despite this, most samples contain multiple other unique 
bands, and further analysis was still possible. 
Technical issues aside, there are several reasons why results are not definitive. 
The splinkerette method of identification of retroviral insertion sites is likely to 
significantly underestimate the number of insertion sites, with more recent 
155 
methods commonly identifying approximately 20 retroviral insertion sites per 
tumour [313,384], while this analysis detected an average of 1.9 unique 
insertion sites per lymphoma (and this difference will reflect the use here of a 
single round of transduction with a replication defective vector). It is thus 
possible that genes dysregulated as a consequence of several retroviral sites 
within the same B cell may co-operate and facilitate transformation or that key 
genes have been overlooked. While the identification of common integration 
sites could suggest selection for integration sites that activate nearby 
oncogenes or inactivate tumour suppressor genes and thus potentiate 
neoplasia, the biased propensity for retroviruses to insert into certain niches 
within the genome could also contribute to this enrichment. In addition, while 
the analysis using the Atlas of Genetics helped to strengthen the argument, this 
database accepts contributions from external sources, which are reviewed by 
the editorial board. The precise definition of these two categories of cancer 
genes is not listed on the website , nor in the group's publications, and is likely to 
reflect to some degree the individual interests of contributing authors rather than 
an objective review of the literature. Most of the data in this database, however, 
is not from retroviral experiments. 
Review of the retroviral insertion sites on the USCS browser does not 
thorough ly map the sites of micro RNA genes. The location of the insertion sites 
was thus correlated with the genomic location of the known micro RNA gene as 
detailed in the Sanger miRBase microRNA database Release 13.0 March 2009 
[440](http://microrna.sanger.ac.uk). One insertion site was located within 100 
kb of a known microRNA gene. The insertion site was localised to chromosome 
3:88314504-88314699 and MI0008315 mmu-mir-1905 is on the same 
chromosome at 88340223-88340304, ie approximately 25kb away. This 
micro RNA was identified by He et al [441] by screening non-protein coding 
RNAs for conservation between mouse and rat and a sequence encoding a hai·r 
pin structure, its expression subsequently being confirmed by microarray. In 
this article , prior to being allocated a name, the predicted mi RNA is called 
Nmir_027. As yet there have been no further publications about this microRNA, 
so its function remains uncertain. 
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The concept of the key role of the retroviral insertion site in the transformation 
process is not necessarily at odds with the hypothesis at the conclusion of 
Chapter 3 that the intensity of MYCIGFP proviral expression was likely to 
determine if a cell was transformed. Four of the genes that were adjacent to a 
MYCIGFP provirus integration site in the set of lymphomas were selected for 
further study: Myb, lkbkb, Lmo2 and Laptm5. The number of genes was 
capped due to time and resource limitations. The biological significance of the 
retroviral insertion site was tested in Chapter 5 by dysregulating these proto-
oncogenes under the control of a retroviral L TR in conjunction with MYC 
overexpression to determine if this facilitated B cell transformation. 
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5. Results: Testing the 
'Third Hit' 
Hypothesis 
5.1 Introduction 
The experiments in Chapter 3 established an efficient experimental system to 
induce malignant transformation by a single round of retroviral mutagenesis in a 
finite number of mature B cells. It was noted that proviral GFP expression in the 
malignant B cells was higher than in the majority of transferred B cells, raising 
the possibility that malignancy was associated with selection of rare B cells 
where the proviral GFP and MYC proteins were highly expressed. 
The question of selection of B cells in the resulting malignancies was 
investigated in Chapter 4, where the number and sites of proviral integration in 
each lymphoma were analysed. These studies revealed that the lymphomas 
were mono- or oligo-clonal with only a few detectable proviral integration sites. 
Therefore strong selection for rare clones of B cells appeared to underlie 
formation of the malignant lymphomas, since more than 100,000 proviral 
MYC/GFP-expressing B cells were transferred into each recipient mouse yet 
only one or several of these had typically grown out as a lymphoma over the 
ensuing 5-8 weeks. A substantial proportion of the proviral integration sites in 
the lymphomas corresponded to sites of recurrent proviral integration in a large 
database of retrovirus-induced tumours. Among these were proviruses that had 
integrated near the promoters of lymphoid proto-oncogenes such as Myb and 
Lmo2 that are well known for being activated by retroviral integrations in other 
mouse models and in human gene therapy trials. These results raised the 
possibility that the rare clones of MYCIGFP transduced Trp538 b11Bbt B cells that 
underwent malignant transformation did so because the strong retroviral 
enhancer dysregulated the expression of a nearby proto-oncogene, providing a 
third mutagenic "hit" needed for spontaneous growth of the B cell clone. 
The hypothesis tested in this chapter was that dysregulated expression of Myb, 
Lmo2, Laptm5 or lkbkb , caused by the strong enhancer/promoter of the 
retrovirus , would be sufficient to promote growth of mature B cells in concert 
with MYC overexpression and Trp53 inactivation. To create an experimental 
setting where a large number of MYC/GFP transduced Trp538 b11Bbt B cells also 
had retrovirally dysregulated Myb, Lmo2, Laptm5 or /kbkb, cDNAs (derived from 
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normal murine spleen) encoding each of these proteins were engineered into a 
separate retrovirus expression vector based on the pMXs-lG backbone from the 
Kitamura [377] laboratory but replacing the GFP sequence with a OsRed 
sequence (see Figure 2.1 for vector maps). Like the M YCIGFP vector, these 
vectors were also bicistronic and replication defective. Thus, the experimental 
strategy was to co-transduce mature Trp538 bllBbt B cells with the MYC/GFP 
vector an~ independently integrated vectors encoding Myb/OsRed, Lmo2-
DsRed, Laptm5-DsRed or lkbkb-OsRed. If any of the latter were sufficient to 
transform mature B cells into spontaneous growth, in concert with MYC 
dysregulation and Trp53 mutation, then the majority of doubly-transduced B 
cells should proliferate spontaneously, as opposed to the one singly-transduced 
B cell in two hundred thousand that grew out in vivo (Chapter 3). The results 
below show that this appears to be the case for Myb, whereas Lmo2, Laptm5 
and lkbkb were an insufficient 'third hit'. 
In designing an assay to measure co-operation between mutations in Trp53, 
MYC and a third retrovirus-borne gene for B cell growth in the absence of the 
normal exogenous growth factors, a key consideration was whether to test the 
effects of the three mutations after adoptive transfer in vivo or i·mmediately 
following transduction in tissue culture. The advantage of the in vivo assay was 
that it would employ the conditions that had been used to identify the candidate 
co-operating third hits. The disadvantage of the in vivo assay was the logistical 
difficulty of obtaining the large numbers of cells per mouse necessary to track 
the growth of doubly-transduced cells after transfer, the loss of most of the 
injected cells shortly after injection, the outgrowth of rare clones of singly MYC-
transduced p53-mutant cells over time, and the ethical issues of potentially 
inducing lymphoma in large numbers of mice when it could be replaced by a 
tissue culture alternative. Each of these limitations could be overcome by 
analysing the growth of small numbers of doubly transduced B cells in tissue 
culture, and hence the latter approach was pursued as a first step. Analysis in 
vitro would also allow accurate analysis of the effects of the individual and 
combined mutations to be measured on other growth-factor governed 
processes that precede cell proliferation or death. 
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5.2 Measuring single and double-
transduced B cells 
Splenic B cells were activated into cell cycle by exposure to antigen (HEL) in 
vivo prior to harvest from the mice (Day 0) and stimulated in culture for 24-36 
hours with CD40 antibody. They were subsequently transduced with the 
various retroviral vectors (Day1). After transduction, the B cells were cultured in 
RPMI complete medium without additional growth factors. Normal B cells are 
absolutely dependent for their metabolism and nutrient uptake upon receipt of 
exogenous growth and survival stimuli through receptors including BCR, CD40, 
BAFFR or TLR. Absence of these stimuli, by culturing B cells in RPMI without 
any of these factors, precipitates autophagy, gradual decrease in cell size, and 
subsequently apoptosis. Flow cytometry was performed when removing anti-
CD40 (Day 3), and at various time points after withdrawal of growth stimuli 
(Figure 5.5, Days 7, 11, 15). A schematic of the experimental approach is 
shown in Figure 5.1. 
Using the two retroviral systems, cells expressing each vector could be 
independently visualised using FACS. The GFP expression vector was 
detected in the FL 1 channel and the DsRed expression vector in the FL2 
channel of the four channel BO FACS CaliburTM without the addition of further 
fluorochromes (Figure 5.2). Gate positions were determined by the 
simultaneous analysis of cultures that were singly transduced or not transduced 
as negative controls. The labelling of the various gated regions is shown in 
Figure 5.3. 
The percentage of transduced B cells varied according to the cDNA that was 
introduced upstream of the IRES:DsRed element in the vector (Figure 5.4), with 
much lower percentage of DsRed positive cells obtained when the vector 
contained either Myb or /kbkb cDNA inserts. With the latter two inserts, it was 
· also observed that the intensity of DsRed fluorescence among DsRed positive 
B cells was shifted to lower levels closer to the cell autofluorescence 
background (data not shown). The lengths of the different inserts were: Myb 
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2290 bp, lkbkb 2469 bp, Laptm5 2402 bp, LM02 1779 bp, with the DsRed 
empty vector having no insert. Consequently there appeared to be no direct 
correlation between the length of the insert and the transduction efficacy of 
either vector (Figure 5.4). Modifications of the volumes of the retroviral 
supernatant added prior to spinoculation also failed to significantly alter the 
transduction efficiency. One possibility is that each cDNA sequence creates a 
unique secondary structure in the transcribed vector RNA, influencing the 
efficiency of recognition of the packaging sequence 5' to the cDNA insert and 
hence the efficiency of packaging vector RNA into retroviral particles. Equally, it 
is likely that the lower percentage of DsRed+ cells with the Myb or lkbkb inserts 
is due to a larger fraction of transduced cells expressing too little DsRed to be 
detected above the background of cell autofluorescence. The Myb or lkbkb 
inserts may alter the mRNA secondary structure in such a way that the IRES 
element is less efficiently recognized for translation of the Os Red protein. 
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Figure 5.1 Timeline representation of the experimental design. 
B cells were activated into cycle with antigen and anti-CD40 on Day O and spinoculated 
with bicistronic retroviruses the next day. Two days after spinoculation anti-CD40 was 
washed off, the cells were analysed by flow cytometry and either injected into recipient 
mice or continued in culture. Further analysis timepoints are detailed subsequent . 
figures. 
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Figure 5.2 Flow cytometric detection of B cells expressing two retroviral 
vectors 
Antigen and anti-CD40-activated B cells were split into four parallel aliquots, and 
spinoculated with GFP or DsRed encoding defective ecotropic retroviruses as 
indicated. Two days after spinoculation the cells in each culture were analysed by 
flow cytometry without the addition of antibody-coupled fluorochromes but following 
addition of a DNA dye that is only taken up by dead cells (7 AAD). GFP expression 
was detected in the FL 1 channel and OsRed expression in the FL2 channel of a four 
channel BO FACS Calibur™. The plots shown were gated on viable cells by 
excluding 7 AAD positive cells. The percentage of viable cells in each gated region is 
shown. 
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Figure 5.4 Transduction efficiency varied according to retroviral vector 
Percentage of viable Trp53 mutant cells expressing GFP from the MYC/GFP vector 
and/or DsRed from vectors with the indicated cDNA inserts or empty vector (EV). 
Gating strategy for single and double positive cells as in Figure 5.2. Data from two 
different experiments are shown by adjacent bars for each vector, analysed either 
(a) 2 days after spinoculation , or (b) 6 days after spinoculation. Day 7 data is the 
mean of triplicate cultures for each vector. 
D GFP vector 
■ DsRed vector 
■ Both vectors 
a) Day 3 30 ~--
------
-- ---
-----
-----
-------1 I---
% of cells ' 20 ~ ------
expressing 
each vector 
10 ____ _ 
DsRed gene 
b) Day 7 30 
% of cells 
expressing 20 
each vector 
10 
I 
I 
I 
Non 
transduced 
-
1 
EV 
I""' 
' 
-
-
-
-
DsRed gene Non EV 
transduced 
166 
-
1 
Myb lkbkb Laptm5 Lmo2 
~ 
-
-
r 
r, 
-
-
12 
I""' 
u "' 
.( 
-
-
-
.. ' 
. 
~ 
,_ ,_ 
-
-J, ~ I I I I I 
Myb lkbkb Laptm5 Lmo2 
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5.3 Effect of single and double 
transduction on cell size 
Cell cycle progression is accompanied by an increase in cell size as a 
consequence of the synthesis of increased cellular organelles, cytoplasm, and 
the doubling of chromosomes prior to cell division. Quiescent B cells are mostly 
in GO phase of the cell cycle and are thus characteristically smaller than 
activated cells in G1 phase, which are in turn smaller than B cells with more 
than 2n DNA content in S, G2 and M phases. These increases in cell size 
result in corresponding increases on the flow cytometer in the amount of laser 
light scattered at low angles in the forward direction (Forward Scatter, FSC). 
Cell size can also vary with alterations in cellular metabolism, apoptosis and 
autophagy [442,443] (reviewed by Mason and Rathmell [444]) . Of relevance to 
this study, the apoptotic threshold is reached later if cells constitutively 
overexpress the Bax-Bak inhibitors Bcl-2 or Bel-XL [445,446] so that autophagy 
is prolonged, resulting in lymphocytes with very small volume~. In contrast, 
exogenous growth factors like antigen, CD40 stimulation, or enforced Myc 
expression promote glycolysis, ribogenesis and nutrient uptake and cell 
enlargement [442,447]. By comparing the size of transduced B cells when they 
were cultured in the absence of exogenous growth factors I sought to detect 
any anabolic or catabolic effects of Myb, lkbkb, Lmo2 or Laptm5 alone and 
combined with MYC. Specifically, I wished to test the hypothesis that these 
candidate proto-oncogenes would stimulate B cell enlargement either on their 
own or in Trp53-mutant cells doubly transduced with the MYCIGFP vector. 
On Day 3 most viable cells in each culture had high FSC indicating that they 
were large cells that had not yet exited cell cycle nor initiated an autophagic 
decrease in cell volume. After 4 days culture without anti-CD40 (Day 7), the 
majority of viable cells remaining (most of which have not been transduced with 
either vector) had greatly decreased FSC. By Day 15 (12 days without anti-
CD40) all of the cells were small except cultures containing Myb and MYC 
doubly-transduced B cells where a population of intermediate FSC persisted. 
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Figure 5.5 Representative FSC/SSC plots post dual transduction with various 
retroviral combinations 
p53 mutant splenic B cells were activated into cell cycle by exposure to antigen (HEL) 
in vivo prior to harvest from mice (Day 0) . They were then stimulated in culture for 24-
36 hours with anti-CD40 antibody, spinoculated with the indicated vector combinations , 
and cultured for at least 24 hours with anti-CD40 antibody to allow retroviral integration 
into dividing B cells. Cells were subsequently washed and either analysed by flow 
cytometry immediately (Day 3) , or incubated in RPMI complete medium without 
additional growth or survival stimuli for 4 days (analyses on Day 7) , 8 days (Day 11) or 
12 days (Day15) before flow cytometric analysis . Plots were gated on viable cells (7-
AAD negative) , but remain open gated with respect to GFP and DsRed fluorescence to 
include non-transduced and transduced cells. 
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Chapter 5: Testing the 'third hit' hypothesis 
Having established the conditions for single and double transduction of mature 
B cells and subsequent analysis of cell size without further exogenous growth 
stimulus, the next analyses focused on comparing the size of cells that were 
singly or doubly transduced (expressing one or both of the GFP and OsRed 
vectors respectively) with each other and with non-transduced cells in the same 
culture. 
5.4 Effect of MYC on cell size 
First, the effect of MYCIGFP retroviral transduction on cell size was assessed 
compared to non-transduced cells or cells transduced with a GFP/Empty vector 
(Figure 5-5). When cultures were analysed on Day 3, before removal of anti-
CD40, GFP-negative non-transduced cells exhibited fewer large cells than 
GFP+ cells expressing the MYCIGFP vector (Figure 5-6a), but there was no 
difference in the FSC distribution of GFP+ cells expressing the MYCIGFP vector 
compared to GFP+ cells expressing the GFP/Empty vector (Figure 5-6b). The 
difference between transduced and non-transduced cells in Figure 5-6a can be 
explained by the absolute requirement for cells to be dividing in order to 
integrate and express the provirus, which will select for larger, actively dividing 
cells in the GFP+ subset. 
By Day 7, when the B cells had been cultured for 4 days without anti-CD40 or 
other growth stimuli, GFP+ cells expressing the MYCIGFP vector had higher 
FSC than control GFP+ cells expressing the empty-GFP vector (Figure 5-5b). 
This is consistent with the known effect of MYC promoting cell metabolism and 
synthesis of proteins, nucleic acids and lipids, and demonstrates the ability to 
detect metabolic effects of oncogenes by this assay. FSC was bimodal in all 
subsets and cultures at this time, which may reflect cells stalled at G1 or G2, 
heterogeneity of catabolic state within the population, or the larger population 
could represent cell doublets. The two peaks of cells, small and large, were 
both shifted to higher FSC in GFP+ cells expressing MYCIGFP compared to 
GFP/Empty vector. 
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Having established an assay that revealed MYC's known metabolic effects, I 
next analysed the effect of the four different cDNAs expressed in the DsRed 
vector. Initially these effects were assessed when these vectors were 
expressed alone in Trp53 wild type cells , and subsequently after dual 
transduction with the MYCIGFP retroviral vector in both Trp53 wild type and 
mutant cells. 
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Figure 5.6 Effect of MYC on size of singly transduced B cells 
Representative analysis of FSC as a measure of cell size in Trp53 wt cells either on 
Day 3, before culture without anti-CD40, or on Day 7, after culture for 4 days without 
anti-CD40. Viable 7 AAD- cells were gated on GFP single positive or GFP-negative as 
shown in Figure 5.2 and Figure 5.3. 
a) Comparison with non-transduced cells. Black histogram, GFP+ cells 
expressing MYCIGFP vector; grey shaded histogram, GFP-negative non-
transduced cells in the same culture. 
b) Comparison with empty vector transduced cells. Black histogram, GFP+ cells 
expressing MYCIGFP vector; grey shaded histogram, GFP+ cells expressing 
GFP/Empty vector. 
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5.5 Effect of Myb on cell size 
In Trp53 wildtype B cells, there was little difference between DsRed+ cells 
expressing OsRed/Myb compared to DsRed/Empty vector on Day 3, 24 hours 
after spinoculation and before removal of anti-CD40 (Figure 5-?b). However, 
after a further 4 days culture without growth factors (Day 7), cells expressing the 
DsRed/Myb retrovirus were shifted to lower FSC compared to those expressing 
the OsRed/EV retrovirus (Figure 5-?b) or to non-transduced B cells in the same 
culture (Fig 5-?a). Although FSC was bimodal as noted above, both the large 
and small peaks of cells were shifted to lower FSC by the DsRed/Myb vector. 
Thus , enforced expression of full-length Myb had the opposite effect to MYC, as 
measured by cell size. 
Interestingly, the presence of Myb in the DsRed vector also caused a decrease 
in FSC on Day 7 in Trp53 wildtype B cells that were doubly transduced to 
express both the DsRed and GFPIMYC vectors (Figure 5-Sa), and this also 
occurred in Trp53 mutant B cells (Figure 5-Sb). 
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Figure 5. 7 Effect of Myb on size of singly transduced B cells 
Representative analysis of FSC as a measure of cell size in Trp53 wt cells either 
on Day 3, before culture without anti-CD40, or on Day 7, after culture for 4 days 
without anti-CD40. Viable 7 AAD- cells were gated on DsRed single positive or 
DsRed-negative as shown in Figure 5.2 and Figure 5.3. 
a) Comparison with non-transduced cells. Black histogram, DsRed+ cells 
expressing DsRed/Myb vector; grey shaded histogram, DsRed-negative 
non-transduced cells in the same culture. 
b) Comparison with empty vector transduced cells. Black histogram, DsRed+ 
cells expressing DsRed/Myb vector; grey shaded histogram, DsRed+ cells 
expressing empty vector DsRed vector. 
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Figure 5.8 Effects of dual MYC/Myb overexpression on cell size. 
Representative FSC histograms of Trp53 wildtype (a) or Trp53 mutant (b) viable 
cells gated as in Figure 5.2 on DsRed single positive, GFP single positive, or 
double positive cells transduced with either GFPIMYC and DsRed/Myb (purple 
histograms) or GFP/MYC and DsRed/Empty vector (black histograms). Cells were 
analysed on Day 3, before culture without anti-CD40, or on Day 7, after culture for 
4 days without anti-CD40. Day 7 results are shown from triplicate cultures for each 
vector combination . 
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A potential explanation for the reduction in cell size seen in cells transduced 
with the Myb-expressing vector is that Myb induced a highly autophagic and low 
metabolic state that was able to resist apoptosis. This occurs in B cells from 
Bc/2 transgenic mice, which even in GO of cell cycle have a characteristically 
smaller size and FSC than normal GOB cells [33]. The t(14;18) classically seen 
in human Follicular Lymphoma which results in the juxtaposition of Bc/2 with the 
immunoglobulin heavy chain promoter locus is similarly associated with an 
excess of small mature B cells. Myb has been demonstrated to positively 
regulate Bc/2 expression through its promoter in T cells [448,449] and other 
MYS family members have been demonstrated to positively regulate Bc/2 in B 
cells [450,451], although no publications detail the effect of Myb itself in B cells. 
To test the possibility that the reduced size of Myb-expressing B cells was due 
to increased expression of Bc/2, the transduction experiments were repeated in 
B cells from a strain of mice with an ENU-induced loss-of-function Bc/2 mutation 
to see if the effect was negated. Bc/2dorian mice have a phenotype of premature 
greying starting as early as weaning age and lymphopenia comparable to that 
seen in Bc/2 knock-out mice [31,32], although the homozygous Dorian mice are 
fertile (on a mixed CBAx86 background) and do not have terminal polycystic 
kidney disease (although their kidneys have not been morphologically 
assessed). The Bc/2dorian allele is a T-C substitution in nucleotide 70 which 
changes a TCA codon encoding serine to a CCA codon encoding praline. This 
amino acid substitution (position 24) is near the C terminal end of the conserved 
BH4 domain of Bcl-2 which is critical for the anti-apoptotic function of the protein 
[452]. As a consequence of these findings it has been assumed that Dorian 
mice harbour a hypomorphic allele of Bc/2, although this has not been fully 
characterised. 
Splenocytes were harvested from Bc/2dorian homozygous mice and wild-type 
control (CBAx86)F 1 mice. Bc/2dorian spleens contained approximately 25% of 
the number of splenocytes seen in the controls. Both cohorts of splenic B cells 
were activated with anti CD40 antibody and transduced with the DsRed/Myb 
retrovirus or the OsRed/Empty vector retrovirus with results shown in Figure 
5.9. As before, DsRed-positive wild-type cells expressing the Myb/DsRed 
vector were shifted to lower FSC by Day 7 compared to cells expressing 
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OsRed/Empty vector. This shift also occurred in Bc/2dorian B cells, and there 
was no statistical difference in the median FSC between wildtype and Bc/2dorian 
B cells expressing the Myb vector (Fig 5-8b). The effect of Myb on cell size was 
therefore not negated by a loss-of-function mutation of Bc/2. 
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Figure 5.9 Effect of the Bc/2dorian mutation on size of cells transduced with 
DsRed/Myb or DsRed/Empty vectors 
a) Forward scatter histograms, and b) Median forward scatter six days post 
retroviral transduction gating on DsRed expressing cells. Error bars represent 
standard deviation. Data is shown in triplicate. p values were calculated using at 
test. 
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Figure 5.10 Effect of lkbkb on size of singly transduced B cells 
Representative analysis of FSC as a measure of cell size in Trp53 wt cells either 
on Day 3, before culture without anti-CD40, or on Day 7, after culture for 4 days 
without anti-CD40. Viable 7 AAD- cells were gated on GFP single positive or 
DsRed-negative cells as shown in Figure 5.2 and Figure 5.3. 
a) Comparison with non-transduced cells. Black histogram, DsRed+ cells 
expressing DsRedllkbkb vector; grey shaded histogram, DsRed-negative 
non-transduced cells in the same culture. 
b) Comparison with empty vector transduced cells. Black histogram, DsRed+ 
cells expressing DsRedllkbkb vector; grey shaded histogram, DsRed+ 
cells expressing OsRed/Empty vector. 
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Figure 5.11 Effect of dual lkbkb/MYC overexpression on cell size 
Representative FSC histograms of Trp53 wildtype (a) or Trp53 mutant (b) viable 
cells gated as in Figure 5.2 on DsRed single positive, GFP single positive, or 
double positive cells transduced with either GFPIMYC and DsRedllkbkb (purple 
histograms) or GFPIMYC and DsRed/Empty vector (black histograms). Cells were 
analysed on Day 3, before culture without anti-CD40, or on Day 7, after culture for 
4 days without anti-CD40. For Day 7 results are shown from triplicate cultures for 
each vector combination . 
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Figure 5.12 Effect of Laptm5 on size of singly transduced B cells 
Representative analysis of FSC as a measure of cell size in Trp53 wt cells either 
on Day 3, before culture without anti-CD40, or on Day 7, after culture for 4 days 
without anti-CD40. Viable 7 AAD- cells were gated on GFP single positive or 
DsRed-negative as shown in Figure 5.2 and Figure 5.3. 
a) Comparison with non-transduced cells. Black histogram, DsRed+ cells 
expressing DsRed/Laptm5 vector; grey shaded histogram, DsRed-
negative non-transduced cells in the same culture. 
b) Comparison with empty vector transduced cells. Black histogram, DsRed+ 
cells expressing DsRed/Laptm5 vector; grey shaded histogram, DsRed+ 
cells expressing empty vector DsRed vector. 
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Figure 5.13 Effect of dual Laptm5/MYC overexpression on cell size 
Representative FSC histograms of Trp53 wildtype (a) or Trp53 mutant (b) viable 
cells gated as in Figure 5.2 on DsRed single positive, GFP single positive, or 
double positive cells transduced with either GFPIMYC and DsRed/Laptm5 (purple 
histograms) or GFPIMYC and DsRed/Empty vector (black histograms). Cells were 
analysed on Day 3, before culture without anti-CD40, or on Day 7, after culture for 
4 days without anti-CD40. For Day 7 results are shown from triplicate cultures for 
each vector combination. 
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Figure 5.14 Effect of Lmo2 on size 
Representative analysis of FSC as a measure of cell size in Trp53 wt cells either 
on Day 3, before culture without anti-CD40, or on Day 7, after culture for 4 days 
without anti-CD40. Viable 7 AAD- cells were gated on GFP single positive or 
DsRed-negative as shown in Figure 5.2 and Figure 5.3. 
a) . Comparison with non-transduced cells . Black histogram, DsRed+ cells 
expressing DsRed/Lmo2 vector; grey shaded histogram, DsRed-negative 
non-transduced cells in the same culture. 
b) Comparison with empty vector transduced cells. Black histogram, DsRed+ 
cells expressing DsRed/Lmo2 vector; grey shaded histogram, DsRed+ 
cells expressing empty vector DsRed vector. 
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Figure 5.15 Effect of dual Lmo2/MYC overexpression on cell size 
Representative FSC histograms of Trp53 wildtype (a) or Trp53 mutant (b) viable 
cells gated as in Figure 5.2 on DsRed single positive, GFP single positive, or 
double positive cells transduced with either GFPIMYC and DsRed/Lmo2 (purple 
histograms) or GFPIMYC and DsRed/Empty vector (black histograms) . Cells were 
analysed on Day 3, before culture without anti-CD40, or on Day 7, after culture for 
4 days without anti-CD40. For Day 7 results are shown from triplicate cultures for 
each vector combination. 
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5.5.1 Effect of lkbkb, Laptm5 or Lmo2 on cell size 
The decrease in cell size in B cells expressing the Myb/OsRed vector was 
unique to that vector. Not only was it not observed in OsRed/Empty vector 
transduced B cells (as shown above), but the other cDNA inserts tested in 
parallel either increased cell size (/kbkb) or had no effect (Laptm5, Lmo2). 
DsRedllkbkb transduction alone into Trp53 wildtype B cells resulted in a subtle 
but consistent increase in cell size on Days 3 and 7 compared to cells 
expressing OsRed/Empty Vector (Fig 5-9). In cultures of Trp53 wt or Trp53 
mutant cells B cells co-transduced with DsRed vector and GFPIMYC vector, 
cells expressing the DsRedllkbkb vector, with or without expression of the 
GFPIMYC vector, were considerably larger than their control counterparts 
expressing the OsRed/Empty Vector on Day 3 and Day 7 (Fig 5-10). The effect 
was similar in Trp53 wt and Trp53 mutant cells, and was statistically significant 
(Fig 5-16). 
Laptm5 and Lmo2 transduction did not substantially alter cell size either with 
dual GFPIMYC transduction or in Trp53 wild type or mutant cells. These results 
are summarised in Figure 5.16 and Figure 5.17. 
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Figure 5.16 Comparison of cell size post single retroviral transduction 
The bar graphs show the mean forward scatter at Day 7 of Trp53 wild type cells 
that have been singly transduced (on Day 1) with various DsRed vectors (labelled 
'transduced gene'). The gating strategy is as for Figures 5.2 and 5.3, gating on 
cells expressing a DsRed vector alone, 
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Figure 5.17 Mean forward scatter post dual retroviral transduction 
The bar graphs show the mean forward scatter at Day 7 of Trp53 mutant cells 
that have been doubly transduced (on Day 1) with various DsRed vectors 
(labelled 'transduced gene') in addition to the GFP/MYC vector. The gating 
strategy is as for Figures 5.2 and 5.3 with a) showing cells expressing a DsRed 
vector alone, and b) showing cells expressing both the DsRed vector and the 
GFPIMYC vector. The experiment was performed in triplicate. The p value was 
determined using a two-tailed unpaired t test. Error bars reflect standard 
deviation. The experiment was repeated (in triplicate) and similar results were 
obtained. 
a) 600 
p=0.050 
p<0.0001 
Mean 
forward 400 
scatter 
200 
0 
Transduced gene: Red EV Myb lkbkb Laptm5 Lmo2 
b) 600 p=0.002 
p=0.012 
Mean 
~00 
forward 
scatter 
200 
0 
Transduced gene: Red EV Myb lkbkb Laptm5 Lmo2 
186 
5.6 
Chapter 5: Testing the 'third hit' hypothesis 
Effect of single and double 
transduction on B cell growth in vitro 
The experiments above measured effects on B cell size that would integrate 
changes in the cells' metabolic activity that may or may not result in cell 
proliferation. To investigate if enforced expression of Myb, /kbkb, Laptm5 or 
Lmo2 could actually trigger proliferation of mature splenic B cells in the absence 
of exogenous growth factors, either alone or combined with MYC expression 
and Trp53 inactivation, cells from Trp53 mutant and wild type mice were co-
transduced with GFPIMYC and one of the four OS-Red vectors and then 
washed to remove anti-CD40 and cultured in medium alone as above (RPMl-
1640 medium supplemented with penicillin, streptomycin, L-glutamine, HEPES, 
2-mercaptoethanol solution and 10% heat inactivated Fetal Calf Serum and 
incubated at 37°C with 5°/o CO2). In these experiments cultures were harvested 
at longer times after washing out anti-CD40, and the percentage and number of 
viable cells expressing DsRed or GFP or both in each culture was measured by 
integrating data from the haemocytometer and flow cytometer. 
The analyses focus on the GFP and DsRed expressing cells as expression of 
these fluorescent proteins implies simultaneous expression of the proto-
oncogenes also encoded by these bicistronic vectors. Experiments were 
duplicated several times. These experimental design features were 
incorporated to optimise the likelihood that any changes were due to the 
expression of the proto-oncogene rather the random acquisition of growth 
enhancing mutations, the chance of the latter being high due to the p53 
mutation and DNA mutations produced by retroviral transduction. 
In Figure 5.18 parallel cultures of Trp53 wildtype or mutant B cells were 
transduced with the different vector combinations, and harvested and analysed 
before washing out anti-CD40 on Day 3 or after being placed back in culture 
without anti-CD40 for 4, 8, 12 or 22 days. 
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On Days 3 and 7 there was little detectable difference in the frequency of cells 
expressing the different DsRed vectors, with the exception that the frequency of 
DsRed/Myb single positive and double positive cells was lower than with the 
other DsRed vectors, and the positive cells had lower DsRed fluorescence as 
had been noted earlier. By Day 11 there were few viable cells remaining in all 
the cultures, with the exception of cultures of Trp53 mutant dual transduced with 
DsRed/Myb and GFPIMYC where a distinct population of GFP'; DsRednegative 
cells was present. This population of GFP'; DsRednegative cells increased in 
frequency to account for 83% of viable cells on Day 15, and 96% of the cells by 
day 25. No distinct population of GFP'; DsRednegative cells consistently 
developed in Trp53 wildtype cells transduced with the same Myb + MYC 
combination, nor did any single or doubly transduced B cells increase in 
frequency in cultures of Trp53-mutant B cells transduced with any of the other 
vector combinations. Equivalent results were obtained in three independent 
experiments comparing the different vectors. 
I concluded from these experiments that retroviral expression of /kbkb, Laptm5 
or Lmo2 was not sufficient to induce B cells to proliferate in the absence of 
exogenous growth stimuli, even as a "third hit" paired with enforced MYC and 
inactive Trp53. By contrast, the DsRed/Myb vector triggered spontaneous 
proliferation of a substantial subset of B cells only when combined with MYC 
and mutant Trp53. These observations were pursued in more detail as 
described below. 
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Figure 5.18 Representative flow cytometric plots at various time points 
Antigen-activated tifEL B cells with wild type or inactive p53 were transduced 
with the indicated vectors and cultured for up to 24 days in RPMI complete 
medium. Profiles are gated on viable (7 AAD negative) cells and show the 
percentage that are singly positive for GFP or DsRed or double positive. The 
non transduced and control cells (top panels at each time point) were used to 
determine gate position and were not in culture for the same duration as the 
transduced cells. 
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5.6.1 Enumerating total number of transduced B cells 
over time in culture without growth stimulants 
To extend the findings above, triplicate cultures with each vector and cell 
combination were harvested at each timepoint and the numbers of viable cells 
per ml in each well was counted using a haemocytometer and integrated with 
the flow cytometric analyses to calculate the total number of cells expressing 
the different vectors. The results for the Myb+MYC combination are shown in 
Figure 5.19 and Figure 5.20, and for the other vector combinations in Figure 
5.21 and Figure 5.22. 
As before, a prominent population of GFPhi DsRednegative B cells began to be 
detectable by Day 11 and accounted for 20-40% of viable cells in cultures 
transduced with Myb and MYC, but only if the B cells were Trp53 mutant. 
GFP10w DsRednegative B cells were increased as a percentage in two of three Day 
15 cultures of Trp53 wildtype cells transduced with Myb and MYC (Fig 5-18). 
However when absolute numbers of GFP+ cells per culture was calculated (Fig 
5-20b) , these numbers steadily declined over time in control cultures with 
wildtype Trp53 or with DsRed/Empty Vector in place of DsRed/Myb. In 
contrast, in the Myb+MYC Trp53 mutant cultures the total number of GFP+ cells 
stopped declining by Day 11 and began to increase by Day 15. This appeared 
to result from gradual proliferation of initially rare GFPhi DsRednegative B cells, 
and this was confirmed and extended as described later. 
Analysis of triplicate cultures with the GFPIMYC and either DsRed/Lmo2 or 
DsRed/Laptm5 (Figure 5.21 and Figure 5.22) revealed a steady decline in the 
total number of DsRed- single positive and DsRed+ GFP+ dual positive cells 
over the timecourse from Day 3 when anti-CD40 was withdrawn, through Days 
7, 11 and 15. The progressive loss of single and double-transduced B cells with 
these vectors paralleled that of single and double-transduced cells with 
DsRed/Empty Vector and GFPIMYC (Fig 5-22b and c). This reinforced the 
conclusion above that enforced expression of Laptm5 or Lmo2 was not 
sufficient to induce B cell proliferation alone or combined with overexpressed 
MYC and mutant Trp53. 
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By contrast, in cultures transduced with the DsRed/lkbkb vector and GFPIMYC, 
there was a 5-10 fold increase in the percentage and absolute number of 
DsRed- single positive and DsRed+ GFP+ dual positive cells between Day 3, 
when anti-CD40 was withdrawn, and Day 7 (Figure 5.21 and Figure 5.22b and 
c). This result, together with the evidence in the preceding section that the 
DsRed/lkbkb vector caused an increase in cell size, indicates that enforced 
expression of lkbkb was sufficient to induce B cells to proliferate in the absence 
of anti-CD40, both on its own and in cells doubly transduced with GFPIMYC. 
However the proliferation did not continue after Day 7, and instead the numbers 
of DsRed- single positive and DsRed+ GFP+ dual positive cells expressing 
lkbkb steadily declined on Days 11 and 15 (Figure 5.22b and c). I conclude 
from this that retroviral expression of lkbkb induces a transient burst of B cell 
proliferation that is self-limiting after 4 days. As discussed later, this conclusion 
has been confirmed in independent studies of B cells retrovirally transduced to 
express a constitutively active lkbkb by another PhD student Yogesh Jeelall 
[101]. 
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Figure 5.19 Consequences of overexpression of Myb and MYC 
Antigen-activated /ifEL B cells with wild type or inactive p53 were transduced with the 
indicated vectors and cultured for up to 12 days in RPMI complete medium. Profiles are 
gated on viable (7 AAD negative) cells and show the percentage that are singly positive 
for GFP or DsRed or double positive. The non transduced and control cells (top panels 
at each time point) were used to determine gate position and were not in culture for the 
same duration as the transduced cells. Data is shown in triplicate after Day 3. 
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Figure 5.20 Cell counts with time 
Cells described in Figure 5.19 were counted using a haemocytometer (in triplicate) 
and results were correlated with the FACS results to determine a) the percentage of 
GFP positive cells of total cells b) the number of GFP positive cells per ml culture 
medium c) the number of non transduced (not expressing a fluorescent protein) cells 
per ml in wells with varying dysregulated gene combinations. Error bars reflect 
standard deviation . 
Legend: 
a) 
b) 
c) 
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The effect of dysregulation of the lkbkb, Laptm5 or Lmo2 in conjunction with 
MYC overexpression were less striking so only the results in p53 defective cells 
are shown in triplicate in Figure 5.21. Differences in cell counts with time 
(Figure 5.22) similarly focused on p53 defective cells, attempting to dissect out 
initial variations in cell proliferation prior to the inevitable cell death seen in 
these cells when deprived of growth factors. 
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Figure 5.21 Consequences of overexpression of lkbkb, Laptm5 or Lmo2 in 
conjunction with MYC compared to Empty vector (EV) 
Antigen-activated tf11EL B cells with inactive p53 were transduced with the indicated 
vectors , washed to remove anti-CD40 on Day 3 and cultured for up to 12 days in RPMI 
complete medium. Profiles are gated on viable (7 AAD negative) cells and show the 
percentage that are singly positive for GFP or DsRed or double positive. The non 
transduced and control cells (top panels at each time point) were used to determine gate 
position and were not in culture for the same duration as the transduced cells. 
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Figure 5.22 Cell counts with time 
Cells harvested at different times after removal of anti-CD40 from triplicate cultures 
transduced with the indicated vector combinations, as analysed by flow cytometry in 
Figure 5.21 , were counted using a haemocytometer (in triplicate) to calculate the mean 
number per culture and standard deviation of: (a) GFP single positive cells; b) GFP + 
DsRed dual positive cells ; c) DsRed single positive cells ; d) GFP + DsRed double 
negative cells. 
a) GFP positive cells 
b) Dual positive cells 
c) DsRed positive cells 
d) Non transduced cells 
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5.6.2 Phenotype of MYC/Myb dual transduced B cells 
The results above indicated that Myb and /kbkb both had the capacity to induce 
B cell proliferation in cultures lacking B cell mitogens, but the proliferation 
induced by each had fundamentally different characteristics. The retroviral 
vector encoding lkbkb was sufficient on its own (without MYC/GFP) to induce a 
transient burst of proliferation of most of the transduced DsRed+ B cells, which 
peaked 4 days after removing anti-CD40 (Day 7) and then ceased. By contrast, 
the DsRed retroviral vector encoding Myb induced sustained proliferation but 
only by a subset of B cells with an initially rare GFPhi phenotype. Paradoxically, 
these DsRed/Myb-transformed B cells did not express detectable levels of 
DsRed itself. This unusual subset of proliferating B cells were undetectable on 
Day 7, when the lkbkb-induced proliferation had peaked, and only became 
frequent in the cultures on Days 11-15. Additional experiments were therefore 
performed to characterize the proliferating cells in Myb-MYC co-transduced 
Trp538 bllBbt cultures and test if they would continue proliferating for long periods. 
After 30 days in culture without anti-CD40, the GFPhi DsRed- population 
continued to increase in frequency and number and when compared to non-
transduced B cells that had been activated but then cultured without anti-CD40 
for 4 days, the Myb-induced outgrowths displayed moderately increased FSC, 
equally high levels of cell surface B220 and increased cell surface lgM (Figure 
5.23). This analysis identified them as mature B cells. As before, the levels of 
GFP fluorescence were uniformly high, while there was negligible DsRed 
fluorescence above the background autofluorescence of activated B cells. 
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Figure 5.23 Abbreviated phenotype of cells persisting at Day 30 
Antigen-activated tf11EL B cells with mutated p53 were doubly transduced with the 
MYCIGFP and Myb/OsRed vectors and cultured for 30 days in RPMI complete 
medium. The profiles are gated on viable (7 AAD negative) cells. The control cells (left 
column) were viable non transduced splenocytes 7 days post activation of the B cell 
receptor and 4 days after removal of anti-CD40 from the culture. 
The median forward scatter for transduced and non transduced cells is shown with a 
dashed line (320 units for non transduced, 376 units for Myb/MYC transduced). 
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Growth kinetics of MYC/Myb dual transduced B 
cells 
Myb/MYC doubly-transduced Trp53 mutant B cells continued to grow in culture 
for at least 8-12 weeks without added B cell growth stimulus, provided that the 
cultures were split intermittently (guided by visible acidity of cultures, on 
average every 4-8 days) to dilute the cells (approximately 1/10) in fresh media. 
This confirmed that the combination of the Myb and MYC vectors and p53 
inactivation were sufficient to transform a subset of mature B cells into 
continuous, mitogen-independent mature B cell lines in culture with high 
reproducibility. The growth kinetics of these B cell lines (Figure 5.24) after sub-
culture revealed that the cell numbers quadrupled in the first 4 days and 
doubled again by 8 days, implying an initial doubling time of approximately 2 
days if there was no loss due to apoptosis. The actual doubling time may be 
faster, as it is likely that daughter cells are lost due to apoptosis. In the future, it 
would be useful to obtain more accurate measures of division rate using CFSE 
labelling and dilution. By comparison, the proliferative rate of well-studied 
Burkitt cell lines similarly grown in RPMI supplemented with fetal calf serum and 
penicillin, streptomycin and glutamine is approximately 24 hours [445,453]. 
As noted previously, very few GFPhi DsRed- cells comparable to the 
transformed cell lines were present in the first 6 days of culture, but these 
progressively increased after 10 days, implying that they derived from relatively 
rare transformed precursors in the initial transduced population. Limiting 
dilution was used to estimate the frequency of B cells that were transformed into 
spontaneously proliferating B cell lines in culture. Trp538bllBbt spleen B cells 
were dual-transduced with Myb and MYC vectors as before, and on Day 3 (day 
2 post spinoculation) the number of viable B cells and percentage expressing 
GFP or OsRed was determined by flow cytometry, and 1000 viable B cells were 
plated out in each of 9 separate 2ml culture wells. On Day 3 21 % of the plated 
cells were GFP+, so that each culture was seeded with 210 GFPIMYC 
transduced B cells, and 0.08% were DsRed+ GFP+ double positive (but this 
number may be an underestimate of dual transduced cells if many DsRed 
transduced B cells express too little DsRed to detect by flow cytometry). 
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Twenty days later, each culture was harvested and the cells counted and 
analysed by flow cytometry (Figure 5.25). In 4 of the 9 cultures, large GFPhigh 
cells had increased to more than 20,000 cells per culture, representing 100 
times the input number of GFP+ B cells , resulting in populations ranging from 
37,475 cells to 80,640 GFP+ cells per culture. Three other wells had much 
smaller expansions of 1413, 2698, and 4 724 large GFPhigh cells (Figure 5.25). 
Based on limiting dilution calculations derived from the Poisson distribution 
[388], the occurrence of highly proliferating B cells (increased more than 100 
fold over starting GFP+ numbers) in 44% of the wells is consistent with the 
majority of wells with cell growth being derived from a single cell. Thus, a 
minimum estimate of the frequency of transduced B cells transformed into 
highly proliferating lines is 1 cell in 210, based on each culture having been 
seeded with 210 GFP+ cells. This represents very efficient transformation of 
mature B cells , and is likely to be an underestimate of the transformation 
efficiency since each culture was seeded with many fewer doubly transduced B 
cells. The observation that OsRed was expressed weakly from the I RES-
DsRed vector containing Myb compared to Empty-lRES-DsRed vector 
(described in Section 5.2 above) means that the measured input frequency of 
DsRed+ GFP+ cells (0 .08%) is likely to underestimate the actual frequency of 
double-transduced B cells. An upper estimate for the actual number of double-
transduced cells at the start of each culture is 50, based on the percentage of 
cells doubly transduced with the empty DsRed vector, which is more highly 
expressed. Consequently, a minimum estimate is that one in fifty Myb-MYC 
dual transduced p53 mutant B cells are transformed into a spontaneously 
growing clone. This represents a very efficient transformation of mature B cells. 
If these cultures were indeed monoclonal , the formation of 32,768 or 65,536 
GFP+ progeny would require 16-17 cell doublings , assuming no loss from cell 
death. Since these populations were formed in 20 days , it can be inferred that · 
the transformed B cells divided approximately once per day. 
In future studies, it would be interesting to repeat this experiment with flow 
sorted cells selected either for GFP single positive or DsRed & GFP double 
positivity, to more accurately determine the phenotype of the precursor cells 
and their transformation efficiency. 
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Figure 5.24 Growth rate in wells containing proliferating Myb+MYC co-
transduced Trp538 biisb, cells 
Trp53 mutant B cells that had been transduced with Myb and MYC vectors and 
maintained for greater than 3 weeks in culture without anti-CD40 by serial passage 
were subcultured in triplicate into fresh medium on Day 0. The number of cells per 
ml was counted using a haemocytometer on the indicated days. Data is shown in 
triplicate with the line joining the mean numbers at each time point. 
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Figure 5.25 Gauging transformation efficiency 
Two days post dual retroviral transduction with the Myb/DsRed and MYCIGFP 
retroviruses 1000 viable p53 defective B cells were plated out in each of 9 separate 
2ml culture wells and incubated at 37°C in RPMI-CM without the addition of 
exogenous growth factors. Twenty days later the number and percentage of GFP 
high cells in each of these wells was measured by FAGS. 
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5.6.4 Myb Expression in transformed B cells 
In contrast to the high expression of the GFPIMYC vector in Myb+MYC doubly 
transduced Trp53 mutant B cell outgrowths, it was remarkable that there was no 
measurable expression of DsRed from the OsRed/Myb vector despite the fact 
that the outgrowths only occurred in wells where the B cells had been 
transduced with both vectors. As noted earlier, the range of DsRed 
fluorescence intensity was clearly much lower in OsRed/Myb singly-transduced 
cells than the range exhibited in OsRed/Empty vector singly or doubly-
transduced B cells (Figure 5.18). 
To measure Myb mRNA directly, real time PCR with primers complementary to 
the 5' end of the Myb coding sequence was performed on RNA from the 
spontaneously proliferating Myb+MYC dual transduced B cells and from 
activated B cell controls (Figure 5.26). The calculated relative amount of Myb 
mRNA in the transformed Myb/MYC dual transduced cells was much higher 
than any of the control activated B cell populations. This conclusion was 
corroborated by independently comparing Myb mRNA levels on Affymetrix 
GeneChip®Gene 1.0 ST Array System for Mouse (Table 5.1 ). In the microarray 
analysis, two Myb+MYC transduced outgrowths could be best compared to a 
sample of sorted GFPIMYC singly-transduced B cells. These three samples 
had comparable levels of PCNA and Cyclin A2 mRNA, providing evidence that 
they were comparably activated into cell cycle. By contrast, the dual-
transduced B cells had 15-fold or 32-fold more Myb mRNA than the MYC singly 
transduced B cells. 
The results above do not resolve whether the large amounts of Myb mRNA 
present in the transformed B cells are derived from the OsRed/Myb provirus or 
from the endogenous Myb gene. However since they expressed much higher · 
Myb mRNA levels than actively dividing B cells transduced with MYC alone, the 
simplest interpretation of the data is that this Myb mRNA derives from the 
integrated provirus. If this was the case, the proviral mRNA either has lost the 
IRES-OsRed element or that element is not translated into protein. I did not 
have time to investigate this key issue further, but future studies will need to 
analyse the sequence and structure of the integrated provir_us and its mRNA in 
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these transformed B cell lines to confirm that the Myb mRNA is of proviral origin 
and test whether or not the IRES-OsRed sequence is still present. This could 
be done by amplification of cDNA using primers that selectively amplify proviral 
Myb mRNA or endogenous cellular Myb RNA, taking advantage of the fact that 
the 5' and 3' untranslated sequences of the proviral and cellular mRNAs differs. 
The resulting products could be measured both in quantitative PCR and by gel 
electrophoresis and sequencing. 
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Figure 5.26 Relative Myb expression 
Relative Myb expression in four different cell types was determined using real time 
PCR. The dual MYCIGFP and Myb/DsRed transduced cells had been stably growing 
in culture for several weeks . Each well contained approximately 33% viable GFP 
positive cells . The singly transduced cells were not cell sorted , the populations 
containing between 10 and 30% transduced cells at the time of RNA extraction (Day 
3). Activated non transduced cells were activated in vivo and in vitro on Day 0. RNA 
was extracted 2 days later. Both singly transduced and activated non transduced 
cells were still in anti-CD40 at the time of RNA extraction. RNA was extracted and 
cDNA was produced using an oligo (dT) primer-based method . Real time PCR 
pri mers annealed to the Myb gene at its 5' end and f3 Actin was the reference gene. 
Non transduced (activated) cells were arbitrarily assigned a relative Myb expression 
value of 1. The experiment was performed in duplicate , the bars reflecting the mean 
value, the dots the individual values. 
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Table 5.1 Relative expression of selected genes using microarray 
Microarray analyses of oligo-dT primed RNA were performed using the Affymetrix 
GeneChip®Gene 1.0 ST Array System for Mouse. Full methodological details are 
found in Chapter 2. Cytoplasmic RNA was isolated from the following: 1. "Activated 
cells", p53 wild type splenocytes 24 hours after harvest from antigen stimulated mice 
and culture with anti-CD40 antibody; 2. "MYC transduced cells", Trp53 mutant anti-
CD40 activated B cells flow cytometrically sorted for GFP+ cells 2 days after 
spinoculation with GFPIMYC retrovirus with CD40 still in culture; 3 and 4, "Outgrowth 
one and two", two independent outgrowths of Myb+MYC dual transduced B cell lines 
stably growing in culture for several weeks, each containing approximately 33% viable 
GFP positive cells. Normalised relative expression of the indicated mRNAs in each . 
sample is shown in arbitrary Affymetrix units 
Gene 
CD19 
CD20 
CD79a 
CD79b 
Bruton's 
tyrosine 
kinase 
Cyclin D1 
Cyclin A2 
Proliferating 
cell nuclear 
antigen 
Activated 
cells 
2593 
7494 
5278 
4508 
665 
91 
910 
4536 
MYC 
transduced 
cells 
3283 
8000 
6395 
6224 
1226 
51 
2256 
3883 
Outgrowth Outgrowth 
one two 
856 2505 
195 1518 
1902 5276 
1818 4197 
629 1022 
621 1204 
2695 3002 
2649 4918 
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5.6.5 Dysregulated MYC and Myb must occur in the 
same B cell for spontaneous proliferation. 
As OsRed expression was not evident in the spontaneously proliferating B cells 
yet only the Myb/OsRed vector could induce their proliferation, it remained 
possible that MYC singly transduced Trp53 mutant B cells were reprogrammed 
to proliferate with the assistance of a secreted factor from Myb singly 
transduced cells in the same culture well. To test this possibility, an experiment 
was performed where the proliferation of mixtures of MYC singly transduced 
and Myb singly transduced spleen B cells was compared with proliferation of 
identical B cells that had been co-transduced, so that the two proviral vectors 
would either be restricted to separate B cells in the culture or would co-exist in 
the same B cell (Figure 5.27). As before proliferating populations of GFPhi large 
B cells developed by Day 15 in the cultures containing co-transduced B cells. 
By contrast, in mixed co-cultures of singly-transduced B cells, there were no 
more GFPhi large B cells than in control cultures transduced with the MYC 
vector alone. This result indicates that co-existence of the MYC and Myb 
vectors in the same Trp53 mutant B cell is required to transform it into 
spontaneous proliferation. Taken together with the high Myb mRNA observed 
in the previous section, the simplest explanation for the lack of measurable 
DsRed in the transformed B cells is that the Myb/OsRed proviral mRNA is 
expressed in these cells but has either lost the IRES or OsRed sequence or 
fails to translate it efficiently. 
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Figure 5.27 The GFPhigh outgrowth did not occur in wells containing both Myb 
singly transduced and MYC singly transduced Trp53 mutant cells 
Trp53 mutant splenocytes were activated and either singly transduced with MYCIGFP 
or Myb/OsRed retroviruses, or co-transduced. After transduction triplicate cultures 
were established of each of these combinations and, in parallel, triplicate cultures were 
established comprising a 50:50 mixture of the singly transduced cells (MYB+MYC co-
culture ). Cells were cultured for 12 days in RPMI complete medium with no added 
exogenous growth factors. a) Representative FACS plots at Day 15 showing the 
percentages of GFPhigh cells in each well. b) Percentage of GFPhigh cells in each well 
type at Day 15 and mean value for each group. 
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5.7 Growth of Myb-MYC dual-
transduced Trp53 mutant B cells in 
• 
VIVO 
The experiments above suggest that dysregulated Myb may be sufficient as a 
"third oncogenic hit" for mature B cells with dysregulated MYC and defective 
Trp53 to proliferate autonomously without the need for growth stimuli such as 
anti-CD40. I did not have time to extend these studies to determine if the 
transformed B cell lines, once established in culture, could continue growing as 
malignant lymphomas in vivo. However, as an initial pilot experiment, a 
preliminary in vivo study was performed to test whether Myb+MYC doubly 
transduced Trp538bllBbt spleen B cells could generate lymphomas in Rag1 null 
mice if they were injected on Day 3 of culture, two days after spinoculation and 
before any transformed line had grown out in culture. In these initial studies, 
200 000 viable cells (representing approximately 30,000 GFP+ cells) were 
intravenously injected to each of four recipient mice. This is ten-fold lower than 
the 2-6 million cells MYC-singly transduced splenocytes (containing typically 
200,000 GFP+ cells) that were injected into each recipient in the studies in 
Chapter 3. After 46 days two of the four mice were unwell, euthanised, and 
found to have gross hepatosplenomegaly with large numbers of GFPhigh mature 
B cells in their spleen (Figure 5.28). The third mouse died suddenly before it 
could be examined, and the fourth was euthanized at Day 65, although clinically 
well , revealing splenomegaly upon necropsy, and a distinct but relatively 
infrequent GFP high B cell population in the spleen (Figure 5.29). The results of 
this pilot experiment indicate that it will be valuable to pursue this question 
systematically in future studies. One line of experiments will need to repeat the 
pilot design above, transplanting recently transduced B cells but including 
recipients of single-transduced controls and larger numbers of recipients in 
each experimental group. Another line of experiments will need to establish 
multiple independent Myb+MYC transformed B cell lines in culture, and then 
inject different numbers of these cells' into Rag1 null or wildtype mice. 
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Figure 5.28 Phenotype of spleen cells from a Rag1 KO recipient mouse 
displaying malaise 45 days post transfer of MYC+Myb doubly-
transduced Trp538 btlBbt cells 
Two hundred thousand Trp538bitsbi cells two days post MYC+Myb dual transduction 
were intravenously injected into each Rag1 KO recipient mouse. The recipient mice 
were regularly checked for signs of illness. After 46 days this mouse appeared unwell 
with prominent abdominal distension and was thus euthanised. Splenocytes were 
assessed by FAGS and compared to splenocytes from a control C57BL/6 mouse 
harvested on the same day. 
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Figure 5.29 Splenic phenotype of a 'healthy' Rag1KO recipient mouse 65 days 
post injection of 200 000 dual transduced Trp538 bl1Bbl cells. 
Experimental details are as per Figure 5.28. This recipient did not appear unwell at 
Day 65 post cell transfer but brief a FACS analysis of splenocytes was performed to 
detect the expression of the fluorescent proteins. 
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5.8 Discussion 
The most striking finding in this chapter was the efficient transformation of 
activated mature B cells into continuously growing, mitogen-independent B cell 
lines by co-transduction of p53 mutant cells with a retrovirus expressing MYC 
and a second retrovirus expressing Myb, but not when the second retrovirus 
expressed DsRed alone, lkbkb, Laptm5 or Lmo2. This is informative in 
addressing the initial research questions of the number of oncogenic 'hits' that a 
B cell requires to become neoplastic and may help address the specific 
pathways that need to be dysregulated in B cells to induce neoplasia. The way 
in which Myb, MYC and p53 may cooperate in oncogenesis is discussed in 
detail in Chapter 7. 
The results clearly reveal a powerful co-operation between dysregulated Myb, 
MYC and inactive p53, but a key issue is whether or not one can conclude from 
these results that these three oncogenic "hits" are alone sufficient to transform 
mature, activated mouse B cells into continuously growing, mitogen-
independent B cell lines. Uncertainty about this conclusion cq_mes from two 
chief sources. First, the limiting dilution analysis indicates that as few as 1 
GFP+ B cell in 210 was transformed into a highly dividing clone. Second, the 
transformed B cells that grew out after 10 days displayed an unusual phenotype 
with respect to expression of the GFP and DsRed markers when compared to 
the majority of B cells present in the first 6 days of culture. Their GFP intensity 
was much higher than the majority of transduced B cells on Day 3 or Day 7 of 
culture, and they lacked measurable expression of DsRed. 
Possible explanations for high GFP in transformed cells: The unusually 
high GFP expression in the Myb+MYC transformed B cells recapitulates the 
observations in Chapter 3, where very few of the MYCIGFP transduced p53-
deficient B cells transferred into Rag1-deficient hosts had GFP expression as 
high as the level observed in the rare clones of malignant B cells that 
spontaneously proliferated in the recipient animals. One simple explanation for 
the high GFP in the Myb+MYC transformed cells is that the three oncogenic hits 
are sufficient, but only in rare B cells where one or more copies of the MYC 
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provirus have integrated in highly permissive chromosomal loci that support 
very high MYC expression. 
Another possibility is that Myb increases the transcription or translation of the 
MYCIGFP vector so that cells that start out GFP medium are boosted to 
become GFPhigh as Myb "rewires" their transcriptional status in concert with 
MYC overexpression and Trp53 deficiency. This implies that both the GFP 
intensity (discussed in Chapter 3) and the retroviral insertion site (discussed in 
Chapter 4) are critical in the transformation process. Alternatively, the GFP 
intensity itself may not be critical in determining which cells are transformed and 
may merely reflect post-transcriptional processes such as increased translation 
of GFP from the IRES or increased accumulation and stability of the GFP 
protein due to the stage of differentiation or activity of the B cell, both of which 
are likely to be important in the transformation process. 
These alternative explanations for the selection for high GFP in the transformed 
B cells could perhaps be resolved using knock-in mice where MYC was 
activated in B cells by Cre-Lox recombination from a single locus (eg Rosa26) 
to provide uniform expression. 
Possible explanations for lack of DsRed in transformed cells: Several 
possible explanations are apparent. First, I have not formally demonstrated that . 
the Myb/OsRed provirus is present in these cells. The possibility remains that 
the observed Myb overexpression may be a consequence of endogenous rather 
than retroviral Myb. While the experiments showed that dual retroviral 
transduction of the same cells was necessary for the outgrowths to develop, it is 
conceivable that the provirus was lost as part of the transformation process. 
Future experiments will therefore require Southern blotting or Splinkerette PCR 
to identify the integrations of the Myb/DsRed provirus, and real time PCR 
experiments with one primer complementary to the 3' end of the Myb gene and 
the other to the 5' end of the IRES (or 5' primer complementary to L TR and 3' 
primer complementary to the 5' end of the Myb coding region), and thus only 
retroviral Myb would be amplified. Alternatively, an epitope tag could be 
incorporated in the retroviral construct enabling proviral-derived Myb to be 
specifically detected by Western blotting. PCR to document the presence of the 
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. MMLV retrovirus in the outgrowth could have also been performed but clearly 
alone would not exclude possible silencing of the MMLV long terminal repeat. 
These experiments were planned but time limitations precluded their 
completion. 
Assuming that the Myb mRNA was provirally derived, a second explanation for 
lack of DsRed is that the transformed state was less permissive for translation 
of the bicistronic pMX DsRed vector than the initial transduced cells, or 
down regulated the transcription of the provirus itself. It has been reported that 
while pluripotent haemopoietic stem cells can be transduced with the Moloney 
Murine Leukaemia Virus (MMLV) (the virus upon which the pMX OsRed vector 
is based), expression of this virus reduces with cell division. The viral 
integration sites are still evident in subsequent generations, but mRNA 
expression was markedly reduced, associated with and probably due to 
increased proviral methylation [454]. Other studies, however, have 
demonstrated persistent retroviral expression many months after transduction of 
bone marrow cells, with constructs based on the same virus, consistent with 
sustained expression in a haemopoietic progenitor [455,456]. Expression of 
this vector at different stages of B cell development has not been thoroughly 
investigated to our knowledge. In contrast, the Murine Stem Cell Virus (MSCV) 
vector expressing the MYC/GFP mRNA has clearly not been inactivated during 
transformation, but the different L TR in this vector is reported to be less prone 
to methylation and inactivation in hemopoietic cell types. 
Another possible explanation for the lack of demonstrable OsRed expression is 
that the cellular reprogramming required for the cells to acquire the potential for 
autonomous growth has resulted in post translational modification or catabolism 
of the red fluorescent protein. Similarly, post translational modification of Myb in 
the non physiological conditions of cell culture may prolong its half life, reducing 
the ongoing need for transcription and translation, and thus uncoupling its 
protein level from that of DsRed. Another potential explanation for the 
discrepancy between Myb and DsRed could be microRNA expression or other 
post transcription modulation which influences the translation of one but not the 
other open reading frame. 
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A particularly intriguing possible explanation for high Myb mRNA but lack of 
detectable DsRed protein would be that the proviral mRNA occasional 
undergoes an internal splicing event in the packaging cell line , so that a minority 
of the resulting retroviruses carry a variant vector containing the 5' part of the 
Myb coding region , but have deleted the C-terminal negative regulatory domain 
of Myb and the IRES and some or all of the DsRed coding regions. Such an 
event would result in a subset of the transduced B cells expressing a protein 
resembling v-myb or experimentally truncated c-Myb enhancing its oncogenicity 
[229,255] (and reviewed by Ramsay and Gonda [216]) but lacking detectable 
DsRed. This would not have been detected using the real time PCR primers 
used for quantification of Myb expression in Figure 5.26 as these were 
complementary to the 5' end of the gene. Real time PCR primers could have 
been designed that annealed to the 3' end of the gene and the relative 
expression of the two ends of the Myb gene could have been compared. It 
would also be useful to PCR amplify cDNA from the transformed B cells using a 
5' primer at the start of the Myb coding region and oligo-dT or different 3' 
primers corresponding to the IRES, OsRed coding region , or 3' L TR of the 
vector, to detect truncated mRNAs in transformed B cells compared with acutely 
transduced Myb/DsRed+ B cells . Also , one could repeat the dual transduction 
experiments with variant Myb/OsRed vectors where Myb was truncated to 
remove the C-terminal negative regulatory domain. If truncation of Myb is 
indeed a "fourth hit" required for transformation of mature B cells , one would 
observe efficient continuous proliferation of all of the Os Red/truncated Myb and 
MYC/GFP dual transduced B cells. 
Effect of Myb and other genes on cell size and growth: Cell size variations 
may reflect alterations in cellular pathways , giving a potential insight into 
downstream pathways influenced by specific gene dysregulation. The mTOR 
(targets of rapamycin) protein is thought to be a central regulator of cell growth · 
through multiple mechanisms [457]. 4EBP1 and S6K1 are effectors that 
modulate cell growth, with overexpression of either increasing cell size, 
expression of both being regulated by mTOR [458]. Myc overexpression in B 
cells has also been shown to increase cell size [459], although a direct 
downstream link to the mTOR pathway has not been established to date. Myc 
overexpression in Eµ-Myc mice, although selectively increasing the percentage 
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of less mature B cells, results in increased size (and protein synthesis) of B 
cells at all maturation phases and all cell cycle stages without an increase in 
cell cycle progression [460] which the authors conclude is likely to be due to the 
downstream signalling pathways activated by Myc overexpression. 
It was initially postulated that the size reduction seen in cells transduced with 
the Myb expressing retrovirus was Bc/2-mediated, but Figure 5.9 demonstrated 
that both Dorian and wild-type cells expressing the DsRed/Myb retrovirus had a 
similar reduction in size, suggesting that the Bc/2 gene was not a downstream 
target of Myb. An alternate explanation is that Myb overexpression may delay 
activation of the mitochondrial pathway of apoptosis through induction of other 
anti apoptotic or suppression of pro apoptotic Bcl2 family members. Rathmell et 
al [445] demonstrated that overexpression of the antiapoptotic homolog of Bc/2, 
Bel-XL was able to prolong survival at the expense of cell size in a proB cell line 
deprived of growth factor support. Alternatively, this size reduction may relate 
to Myb-mediated modulations in cellular metabolism and ribogenesis, a concept 
that was not further pursued. 
Despite review of retroviral insertion sites (Chapter 4) suggesting a possibility of 
co-operation with MYC, dual overexpression of lkbkb, Lmo2 or Laptm5 with 
MYC did not lead consistently to uncontrolled cell growth in our model. A failure 
to identify other critical factors in the transformation process such as a specific 
cell cycle stage, maturation stage or cellular environment may explain the 
difficulty of in vitro validation of the potentially co-operating genes. 
Experimental investigation of other genes identified near retroviral insertion 
sites (particularly Gngl and Lta) may have been more fruitful, but limitations of 
time and resources necessitated that a finite number of genes were pursued. 
While /kbkb did not give the same spectacular results as Myb when dual 
transduced with MYC in Trp53 defective cells, the results suggest it may be a 
growth enhancer, although insufficient as a third hit for spontaneous 
proliferation. As demonstrated in Figure 5.22 cells dual transduced with 
MYC/lkbkb were more abundant than cells transduced with any of the other 
gene combinations at Day 7. This may either reflect that cells readily express 
this retroviral construct, or that cells expressing it have an early but non-
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sustained growth advantage. The increase in cell size seen in cells transduced 
with lkbkb in conjunction with MYC (Figure 5.11) is another factor suggesting a 
growth modifying effect. NF-KB pathway activation is not a characteristic of 
MYC-driven Burkitt lymphoma, and its activation has been shown to enhance 
Fas-mediated apoptosis in a Burkitt lymphoma cell line [345], and thus it may be 
postulated that in cells overexpressing Myc that the NF-KB pathway is 
suppressed with time to maintain cell viability. 
Alternatively, these findings may indicate the need for a fourth hit in addition to 
the dysregulation of MYC, Trp53 and lkbkb for autonomous cell growth. The 
other genes within 100kb of the retroviral integration sites near lkbkb were 
Okk4, Polb, Plat, and Ap3m2. DKK-4 encodes a protein whose normal role 
remains unclear, but which is known to inhibit the Wnt/~-catenin signalling 
pathway and has been noted to be overexpressed in some malignancies [461]. 
Polb encodes DNA polymerase ~ which is involved in DNA repair and 
replication. Polymorphisms in Polb (and more commonly in other DNA repair 
genes) have been demonstrated to modify risk for various tumours such as 
bladder cancer [462] and colorectal cancer [463]. Plat (plasminogen activator, 
tissue) encodes an enzyme that facilitates breakdown of blood clots. It is not 
known to play a role in cellular proliferation or transformation. Ap3m2 (adaptor-
related protein complex 3, mu 2 subunit) forms part of a protein complex which 
has a role in intracellular protein trafficking, but a role in cellular proliferations 
remains to be defined. The genes within 100kb of the other retroviral insertion 
identified in the same lymphoma were Txnip, Hfe2, Polr3gl, Ankrd34a, Lix1I, 
RbmBa, and Pex11 b. Txnip (thioredoxin interacting protein) is not known to 
have a role in B cell proliferation. The overexpression of Hfe2 precipitates 
haemochromatosis (iron overload). Polr3gl (polymerase (RNA) Ill (DNA 
directed) polypeptide G (32kD)-like), Ankrd34a (ankyrin repeat domain 34A) 
and Lix1 I (Lix1-like) have not been well characterised. RbmBa (RNA binding 
motif protein SA) is a nuclear protein that binds to RNA, but has not defined role 
in neoplasia. Pex11 b controls with abundance of peroxisomes ( organelles 
within which various metabolic pathways occur) in cells. While none of the 
above genes are known to cooperate ,with the NF-KB pathway, this possibility 
could be tested by overexpressing the four genes in the same B cell and 
observing consequential cell size and growth. 
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The transient proliferation and thus cell size increase seen in cells transduced 
with the lkbkb expressing retroviral vector is consistent with the published 
literature. Sasaki et al demonstrated that constitutive activation of the canonical 
NF-KB pathway through lkbkb kinase overactivity leads to increased numbers of 
mature B cells (marginal zone cells particularly) through increased cell survival 
rather than cell cycle progression [28]. In this publication these cells were 
predominantly resting B cells, although the addition of anti lgM, cross linking the 
B cell receptor, increased cell proliferation. The process of retroviral 
transduction requires cell activation, which was performed using intraperitoneal 
HEL to ligate B cell receptors and supplementary anti CD40 in our model. 
Jeelall et al [101] confirmed that overactivity of the canonical NF-KB pathway 
due to constitutively active lkbkb protein, in conjunction with the complex 
cascade initiated by CD40 activation and antigen binding, was sufficient to 
increase B cell proliferation in vitro. 
Laptm5 did not substantially alter B cell size in both singly transduced cells and 
cells co-transduced with the GFPIMYC retroviral vector and had not apparent 
effect on B cell growth. In subsequent studies of OsRed/Laptm5 vector singly 
transduced mature splenic B cells, it was shown that the DsRed-positive cells 
exhibited exaggerated down regulation of surface lgM in response to antigen 
binding (Helen Richards, Hons thesis, ANU). This result is consistent with 
recently published work showing that Laptm5 promotes endosome-lyososome 
traffic and degradation of antigen receptors in B and T cells [403,406]. While 
antigen receptor downregulation was not measured in the experiments in this 
chapter, the subsequent studies establish that the Laptm5 vector does increase 
a known activity of Laptm5. As the downstream pathways modulated by 
Laptm5 remain to be defined, the way in which it modifies B cell size is 
uncertain, but the principles discussed above remain relevant. 
While Laptm5 dysregulation is implicated as a co-operating "third hit" based on 
the proviral integration in one of the lymphomas in Chapter 4 and recurrent 
proviral integrations in lymphoid neoplasms in RTCGD, the lack of an effect of 
the Laptm5 vector on B cell growth may indicate that this is not the case 
because it is in fact a simple 'passenger mutation' in the lymphomas where its 
promoter is flanked by a proviral integration, or that it is a "driver mutation" 
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along with MYC and Trp53 defects but only in the context of a "fourth hit". With 
respect to the latter possibility the other genes within 100kb of this integration 
site were reviewed. Neither Sde3 nor Matn1 are known to have a role in cellular 
proliferation. One other proviral integration site was identified in the lymphoma 
bearing the Laptm5 integration. Genes within 100kb of this insertion site were 
Zdhhe18, Nude, Nr0b2 , Gpateh3, Gpn2, Sfn, Pigv and Arid1 a. This second 
insertion site was within the Zdhhe18 (zinc finger, DHHC domain containing 18) 
gene, but the function of this gene is not well described in the literature. Nude 
(nuclear distribution gene C homolog (Aspergillus)) regulates nuclear movement 
and has been described as a tumour suppressor gene in prostate cancer 
through inhibition of cellular proliferation [464]. Nr0b2 (nuclear receptor 
subfamily 0, group B, member 2), also known as small heterodimer partner 
(SHP) encodes a protein that inhibits the activation of some hormone receptors 
[465]. Gpateh3 (G patch domain containing 3) and Gpn2 (GPN-loop GTPase 2) 
are not well characterised in the literature. Sfn (stratifin), also called 14-3-3a, is 
thought to be a tumour suppressor gene with a role in differentiation and cell 
cycle progression [466]. Pigv (phosphatidylinositol glycan anchor biosynthesis, 
class V) has no known role in cellular proliferation. Arid1 a (AT rich interactive 
domain 1A (SWl-like)) has been described as a tumour suppressor gene [400] 
in gynaecological cancer. Overall , none of these genes seem a likely 
cooperative proto-oncogene with Laptm5. 
The lack of any effect of Lmo2 on B cell size or growth may have been a 
consequence of the retroviral construct being defective, or it may not have 
facilitated the correct degree of gene overexpression at the required critical time 
in the cell cycle or cell maturation phase. It would be important in future studies 
to examine known biochemical or transcriptional targets of Lmo2 (which to date 
are not well defined [467]) to confirm that Lmo2 activity was dysregulated in the 
transduced B cells. No other unique retroviral insertion sites were identified in · 
this lymphoma specimen using splinkerette PCR, although there are likely to be 
others detected with more sensitive techniques. The other gene with 100kb of 
the insertion site near Lmo2 was Caprin 1 ( cytoplasmic activation/proliferation-
associated protein-1 ), a cytoplasmic phosphoprotein. Its expression has been 
shown to correlate with splenic B cell activation status, and knock-down 
experiments in a lymphocyte cell line have demonstrated that it negatively 
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influences cell division, although over expression experiments have shown 
inconsistent results [413] and the implicated pathways remain to be defined. It 
is possible that overexpression of Caprin 1 co-operates with Lmo2 
overexpression to promote cell growth and proliferation, the cooperative effect 
being lost when Lmo2 alone was over expressed in conjunction with MYC and a 
pS3 defect in our model. 
The lgM+ 8220+ GFPhigh phenotype of the lymphomas developing in recipient 
mice was comparable to that seen in the in vitro proliferating MYC/Myb dual 
transduced cells. Additional markers were also consistent with a mature B cell 
phenotype, including positivity for CD19, lower levels of lgD, and CD138 and 
CDS negativity. CD138 (syndecan 1) is a relatively specific marker for plasma 
cells, and although it may be demonstrated on some immature B cells [468] it is 
not usually expressed on mature B cells. CDS expression is also uncommon in 
mature murine B cell neoplasms, being found predominantly in mouse models 
of Mantle cell lymphoma [9] and Chronic lymphocytic leukaemia [469], although 
rare reported cases of B cell lymphomas derived from B-1 cells may also 
express CDS [470]. 
Investigation of the growth kinetics of the in vitro outgrowths (Figure S.25) 
demonstrated that not all wells seeded with dual Myb/MYC transduced cells 
contained GFP positive cells after 20 days incubation. This suggests that not 
every doubly transduced p53 deficient B cell is transformed to spontaneous 
growth, although these results are limited by the lack of quantifiable DsRed/Myb 
expression by flow cytometry. Limiting factors may include the level of proviral 
expression (which Figure 5.4 demonstrates varies with the retroviral construct), 
autocrine/paracrine growth factors, acquired deleterious genetic defects, 
concentration of local substrates such as glucose, lactate, glutamine, cell 
density, cell cycle stage or maturation stage at transduction. An alternate 
explanation is that the doubly transduced cells that grow autonomously in 
culture are carrying a fourth hit. It is possible that prior to harvesting the B cells 
there has already been some in vivo enrichment for B cells that have 
accumulated one more somatic mutations that are still insufficient to transform 
them until the MYC and Myb vectors are also introduced. Alternatively, 
spontaneously acquired mutations or those due to non-productive or non-
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detected retroviral integrations into the murine DNA may occur in dual 
transduced cells giving the cells an additional critical growth advantage. 
The preliminary in vivo results support the conclusion that dysregulation of Myb 
may be sufficient to provide the third oncogenic hit needed for B cell growth 
both in culture and in vivo. However, from these data the possibility cannot be 
excluded that the lymphomas arose independently of the Myb vector from 
GFPIMYC singly transduced B cells, since a similar type of lymphoma arose in 
many Rag1 knock out recipients that received ten times more cells singly 
transduced with the MYC/GFP retrovirus alone (Chapter 3). Further 
experiments would ideally use a different model with inducible gene expression 
or suppression. An example would be a Cre-Lox system, deleting Trp53 at a 
specific time point or stage of B cell maturation in an effort to minimise the 
accumulation of genetic defects prior to the experimental genetic alterations. 
Inducible gene expression or suppression could be used to examine both the 
propensity of the cells to develop lymphoma in the setting of dysregulation of 
specific genes, but could also assess the degree of oncogene addiction of the 
lymphoma (and thus the potential of specific gene targeting to be of therapeutic 
utility). 
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6. Results: Gene 
expression analyses 
6.1 Background 
The previous chapter revealed a potent co-operation between retroviral vectors 
encoding Myb and MYC in transforming a subset of mature Trp53-mutant B 
cells into continuously growing B cell lines. While flow cytometric profiling 
showed that the transformed cells continued to express B220 and surface lgM, I 
wished to determine whether the global gene expression program in these cells 
resembled activated B cells , germinal centre B cells , or corresponding human 
lymphoma subsets. To begin addressing this question this chapter describes 
the findings from a preliminary microarray analysis comparing Myb+MYC 
transformed B cell lines with activated B cells and B cells that had recently been 
transduced with MYC alone. It was performed as a pilot study, with the plan to 
extend the pilot study and follow up specific genes in a statistically significant 
number of samples but I did not have time to pursue the follow up studies. 
Nevertheless, the results of the pilot study are presented here , together with a 
discussion of key observations. 
RNA from two transformed B cell lines ('Outgrowth 1' and 'Outgrowth 2') were 
used as test samples. Both lines were derived from a pool of Trp53 mutant B 
cells dual-transduced with Myb and MYC at the same time but grown in 
separate wells for several weeks. Each outgrowth contained approximately 
33% viable GFP positive cells. To provide a control sample of dividing, 
MYC/GFP-transduced Trp53 mutant B cells that was as closely matched to 
these cell lines except lacking retroviral Myb expression , RNA was isolated in 
parallel from Trp53 mutant B cells that had been activated with antigen and anti-
CD40, transduced with the MYC/GFP vector alone, grown in anti-CD40 for two 
days , and flow cytometrica lly sorted for GFP+ cells ("MYC transduced"). For 
comparison , RNA was isolated from Trp53 wild type splenocytes that had been . 
activated by antigen and cultured for 24 hours with anti-CD40 ("Activated B 
cells"). The latter would be expected to be less well matched with the 
transformed B cells because the B cells were only beginning to divide and had 
normal MYC and Trp53, but would display a gene expression profile of normal, 
I 
activated B cells for comparison to the other three samples. 
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Poly-A+ mRNA in each of the samples was converted to cDNA using oligo-dT 
priming, and then to biotinylated cRNA that was hybridized to Affymetrix 
GeneChip® 1.0 ST Arrays for mouse as per the manufacturer's protocol, these 
steps being performed by the Australian Cancer Research Foundation (ACRF) 
Biomolecular Resource Facility (BRF) at the John Curtin School of Medical 
Research. This system focuses on 28 853 well annotated genes with 
approximately 26 perfect match 25 nucleotide-long exon probes spanning each 
gene (770 317 distinct probes). Gene sequences were based on NCBI build 36 
mouse genome sequence, February 2006 and cover 100% of NM sequences 
(mature messenger RNA transcripts) in the April 2007 RefSeq (NCBI Reference 
Sequence) database. Results from these probes were collated using Partek® 
software by staff at the ACRF BRF. 
6.2 Markers of cells in S-G2-M phase of 
cell cycle 
As noted above it was expected that the activated B cell sample would contain 
fewer B cells in cell cycle than the outgrowths or the MYC transduced B cells, 
and this difference alone would be reflected in substantial differences in gene 
expression. To test this I compared the expression of 11 murine homologues of 
a set of human genes that are validated markers of B cell cycle described by 
Shaffer et al [4 71] in the two outgrowths and in the MYC transduced B cells 
relative to their expression in the activated B cell sample (Table 6.1 ). Of the 11 
cell cycle genes tested, 10 were increased between 2 and 7 fold in MYC 
transduced B cells and the two outgrowths, compared to the B cells that had 
simply been activated by anti-CD40 for 24 hours. Taking the set of 10 
increased genes as a group, there was no consistent elevation in this gene set 
in the outgrowths relative to the MYC -transduced cells, indicating that the 
Myb+MYC transformed cells appeared relatively well matched to the MYC-
transduced cells with respect to cell cycle status. The one gene in this set of 11 
that was further elevated in both outgrowths relative to the MYC transduced 
cells was Ccnb 1. While this apparent difference will need confirmation in 
independent samples, it is notable that Ccnb1 is a validated target of Myb [472]. 
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Table 6.1 Expression of cell cycle genes in outgrowths and MYC transduced 
cells compared to Activated B Cells 
Murine homologues of the human cell cycle gene set described by Shaffer et al [4 71] 
were used. RNA was extracted from two Trp538b1 Myb/MYC transformed B cell lines 
(labelled Outgrowth 1 and Outgrowth 2), Trp538b1 antigen-activated B cells 2 days after 
transduction with MYC/GFP vector alone and flow cytometrically sorted for GFP+ cells 
(labelled MYC transduced) and Trp53witdtype antigen activated B cells 1 day after 
activation with cognate antigen and CD40 ligand ("Activated B cells"). The 
corresponding cRNA was analysed on Affymetrix 1.0 ST Mouse Array chips. Fold 
changes of the indicated genes in each B cell line compared to activated B cells are 
shown. Relative gene expression is depicted using the following colour scale: 
■ >2 fold increase 
D -2<fold increase<2 
-2>fold increase 
Cell cycle gene 
Ccnb1 
Bub1 
Cenpf 
Mad2l1 
Top2a 
Aurka 
Plk1 
Birc5 
Kif23 
Plk4 
Cenpe 
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Outgrowth 1 
5.68 
3.52 
4.53 
2.04 
2.74 
4.84 
3.91 
3.35 
· 2.62 
Outgrowth 2 MYC transduced 
-6.10 
~~~~~~ ----· ---·----------------
3.87 
6.73 
- -- - - - - - .... - - ::. . - -
1.64 - ' 1.-58 ° - -
-- - - - - -
3.54 
5.80 
-5.87 
3.84 
3.69 
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6.3 Markers of germinal centre 
differentiation 
MYC dysregulation and Trp53 inactivation are primarily observed in Burkitt 
lymphoma, which consistently displays cell surface markers and a gene 
expression program corresponding to rapidly dividing germinal centre 
centroblasts [344] - a distinct differentiation state from activated B cells. 
therefore asked whether the Myb+MYC -transformed Trp53 mutant B cells had 
differentiated into germinal centre cells by analysing expression of 22 genes 
that are strongly upregulated in germinal centre B cells relative to other B cells 
in the lmmGen database of sorted mouse lymphocyte subsets analysed by 
Affymetrix microarray profiling (www.lmmgen.org). The relative expression of 
these genes in the Myb+MYC-transformed outgrowths was compared to the 
single MYC transduced B cells (Table 6.2). Only one of the 22 genes 
demonstrated a greater than 2 fold increase in expression in both of the 
outgrowths (843041 0A 17Rik), and the most widely used markers of mouse 
germinal centre differentiation were either decreased (Aicda, ~as) or not 
different ( Gcet, Rgs13, Myb/1). Comparison of the Activated B cells with the 
MYC-transduced B cells also showed little difference in expression of the set of 
22 germinal centre genes, confirming that the MYC-transduced Trp53 mutant B 
cells themselves had not differentiated into germinal centre B cells. Thus, the 
two transformed B cell samples did not exhibit evidence of having differentiated 
into germinal centre cells. 
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Table 6.2 Expression of germinal centre-specific genes in Myb+MYC 
transformed B cell lines and Activated B cells relative to MYC-
transduced B cells. 
Relative expression of 22 genes that are highly expressed selectively in mouse 
germinal centre B cells in the lmmGen database. Fold changes of the indicated genes 
in each B cell line compared to Day 3 MYC-transduced Trp53 mutant B cells is shown. 
Specimens as per Table 6.1. Relative gene expression is depicted using the following 
colour scale: 
■ >2 fold increase 
D -2<fold increase<2 
-2>fold increase 
Germinal centre gene Activated 8 
Aicda 
Fas 
-1.7848094 
1.13929393 
-1.2063345 
Outgrowth 1 
-1.0792282 
lldr1 
ArhgapB 
Basp1 
Ctnna/1 
Gcet2 
Ccr/1 
Ehf 
Rgs13 
Mbd4 
Zdhhc2 
Stau2 
Phf19 
Efnb1 
Rassf6 
Myb/1 
Gm600 
H1fx 
Ohfr 
Gatm 
-1 . 0084 783 - -1 . 035-2649 
843041 OA 17 Rik 
230 
1.0407 4022 . 1.07177346 
-1.0033118 
1.44917317 
1.19551315 
·-1.2289191 
1.21067363 
.;.1.2737128 
1.05317122 
1.01892651 
; . . •. ~. 
~ . ·---· ~·. - . , - -- --- -· 
.. . 
-1.0210121 
-1.5368752 
-1.0139595 
-1.051018 
-1.2657566 
1.43395525 
· -1.0942937 
1.14869835 
-1.0~97167 
1.2397077 
1.53687518 
3.48220225 
4.11245531 
Outgrowth 2 
-1.2141949 
-1.1250585 
-1.0497167 
-1.0210121 
-1.0942937 · 
1.00695555 
1.55832916 
1 .18099266 . 
1.2397077 
1.49484925 
--1.1407637 
1.41421356 . 
1.2141948& 
3.45814893 
1.38510947 
1.58008262 
1.85317612 
9.06307108 
Chapter 6: Gene expression analyses 
6.4 NF-KB pathway 
As described in Section 1.12 gene expression profiling has revealed that many 
NF-KB responsive genes show diminished mRNA expression in Burkitt 
Lymphoma compared to Germinal Centre-type Diffuse Large B cell Lymphoma 
[344]. The expression of the mouse orthologues of this set of NF-KB regulated 
genes was compared in the Myb+MYC transformed outgrowths with the single 
MYC transduced B cells (Table 6.3). Of the 25 genes in this set nearly half 
were decreased between 4 and 50-fold in both Trp538 b1 Myb+MYC transformed 
B cell lines compared to MYC singly transduced B cells. Two of these genes, 
Traf1 and Nfkb1, have been shown to both bind and be repressed by Myb [473], 
and the repression of Nfkb 1 could have a secondary effect on many other NF-
KB target genes. By comparison, only 4% of the total probe sets tested (1156 of 
the 29,221) were decreased 4-fold or more in the outgrowths. Using a Chi 
square test there is a statistically significant increase in the number of NF-KB 
target genes with a 4 fold or greater reduction in expression in Outgrowth 1 
compared to MYC-transduced Trp53 mutant B cells (two tailed p<0.0001 ). The 
p value for the same analysis for Outgrowth 2 was similarly significant. 
The B cell surface proteins CD21 (Cr2), CD23 (Fcer2), CD25 (//2ra), 
Lymphotoxin beta (Ltb), EBV-induced receptor 2 (Ebi2), and CD95 (Fas) are 
encoded by genes that are well validated to be directly induced by NF-KB 
[28,42, 101 ]. When mRNA expression of these genes in Trp538 b1 Myb+MYC 
transformed B cell lines was compared to Trp538 b1 MYC singly transduced B 
cells, all six of these genes were decreased (Table 6.4). Recent data from Y 
Jeelall and J Rayner, current students in Prof Goodnow's laboratory, has begun 
to validate these gene expression differences by independent approaches. 
Antigen-activated 8 cells with wild-type Trp53 were singly transduced with a 
Myb-EGFP retroviral vector or an empty EGFP vector and analysed by flow 
cytometry to compare CD21, CD23, CD25 and CD95 expression on the surface 
of GFP+ and GFP- cells (Jeelall, personal communication). Analysis of 
independent triplicate transduced samples revealed that the expression of each 
of these proteins was specifically and significantly decreased in Myb-transduced 
B cells compared to non-transduced or empty vector transduced B cells. 
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Table 6.3 Relative expression of NF-KB responsive genes known to be 
suppressed in Burkitt lymphoma 
Analysed are the mouse orthologues of a set of genes identified by Staudt and 
colleagues [344] as being NF-kB induced in B cells, and decreased in Burkitt 
lymphoma compared to GC-type Diffuse Large B cell lymphoma. Fold changes of the 
indicated genes in each B cell line compared to Day 3 MYC-transduced Trp53 mutant 
B cells is shown. Specimens as per Table 6.1. Relative gene expression is depicted 
using the following colour scale: 
■ >4 fold increase D -4<fold increase<4 
-4>fold increase 
Gene 
Cc/22 
Traf1 
Ebi3 
Cd83 
Cd40 
Tnf 
6330500O04Rik (C16Orf32) 
Lta 
Nfkb1 
Nfkb2 
Tnfaip3 
Bc/2a1a 
Smarca2 
Bc/2a1d 
ld2 
Bc/2a1d 
Nfkbia 
Cxc/10 
Cxc/9 
Birc3 
Gadd45b 
Cd44 
lrf4 
Pim1 
Dusp2 
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Outgrowth 1 Outgrowth 2 
-1.453972517 
-3.655326801 
-2.549121255 
1.1096694 72 
-2. 713208655 
-1.494849249 -1. 705269784 
-1.172834949 -1.042465761 
-
-3.386981249 1.231144413 
-1.569168196 1.028113827 
1.101905116 -1.214194884 
1.443929196 1._526259209 
1.337927555 1.827662.9 
-
1.140763716 2.620786808 
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Table 6.4 Relative expression of NF-kB-induced genes encoding B cell surface 
proteins 
Fold changes of the indicated genes in each B cell line compared to Day 3 MYC-
transduced Trp53 mutant B cells is shown. Specimens as per Table 6.1 . Relative gene 
expression is depicted using the following colour scale: 
■ >4 fold increase 
-4<fold increase<4 
■ -4>fold increase 
Gene 
Fcer2a (CD23) 
Cr2 (CD21) 
l/2ra (CD25) 
Ltb 
Ebi2 
Fas 
Outgrowth 1 Outgrowth 2 
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6.5 Most highly increased genes in 
Myb+MYC-transf armed B cells 
As an additional preliminary analysis of the pilot data , the 25 most increased 
mRNAs in the transformed B cell lines relative to the MYC-singly transduced B 
cells were considered (Table 6.5) . Notably, the 12th highest was Myb 
(approximately 20-fold increased). Twelve of the remaining 24 genes represent 
genes that Myb has been shown to bind in Chip or EMSA assays (Spp1 , Acta2, 
Lyz1, Sox4, Cd93, Gstm1, Plk2, Akap12, Slc40a1, Dab2, Mrc1 and Ccnd1 
[474,475]) and a further 4 are known to be induced by Myb or B-Myb (Fn1 , 1/lr, 
Cdkn2a, Uch/1 [27 4,4 76-4 78]). As exemplified by Cd93 and 1/lr, the majority of 
these genes are normally restricted within the B cell lineage to expression in 
progenitor, pre-Band immature B cells [479]. 
While these pilot data are preliminary, the high fraction with independent 
evidence of being Myb-target genes makes it reasonable to pursue these, and 
other induced genes in the dataset, in follow up studies. A cell surface protein 
encoded by one of these highly upregulated genes, CD93, has been tested in 
single Myb-transduced B cells in the follow up studies by Y Jeelall noted in the 
previous section, and was confirmed to be strongly and specifically induced 
selectively in Myb-transduced B cells within 2 days, without the need for MYC or 
Trp53 mutations (Y Jeelall personal communication). Notably, the Cd93 gene 
contains multiple sites shown to bind Myb [475]. 
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Table 6.5 The 25 most highly increased genes in Myb+MYC transformed Trp53 
mutant B cells compared with MYC-transduced Trp53 mutant B cells. 
Fold difference in mRNA expression in each sample relative to day 3 MYC-transduced 
Trp53 mutant B cells. Asterisks mark Myb-target genes defined in the literature. Myb 
itself is noted by the double arrow. Relative gene expression is depicted using the 
following colour scale: 
■ >4 fold increase 
Gene 
Uch/1 
Ccnd1 * 
C3ar1 
Cdkn2a 
Mrc1 * 
Dab2 * 
Slc40a1 * 
Akap12 * 
C1qa 
Plk2 
Atp1b1 
Trf 
Gstm1 
Myb<< 
Timp2 
1/lr 
Cd93 * 
C1qc 
Sox4 * 
C1qb 
Lyzs 
Acta2 
Gpnmb 
Fn1 
Spp1 * 
-4<fold increase<4 
-4>fold increase 
Activated B cell Outgrowth 1 
18.25221945 . 
58.89200964 
Outgrowth 2 
16.67945217 
23.58830748 
14. 72300241 
22.94328397 
7.568461174 
13.547925 
2.496661098 
26.17286587 
18.50701094 
32 
30.90996253 
11.87618857 
27.09585 
14.52030649 
8.75434961 
15:34822591 
24.25146506 
22 ~ 00866909 
32.2225776 
26.90868529 
31 .34144952 
30.2738447 
15. 77972327 
29.85705573 
50.56264396 
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6.6 Broader pathway analysis 
Given the encouraging results from focussed analysis of specific gene sets 
above, pathway analysis was subsequently performed on the microarray 
dataset as a whole. This was undertaken to guide hypothesis generation 
regarding dysregulated pathways in the cellular outgrowths , and thus guide 
further research to follow up these preliminary findings. Data were analysed in 
two different ways , each with their own advantages and disadvantages as 
discussed below. 
6.6.1 Differential gene expression - Method One 
The first analysis method was simply identifying genes (for pathway analysis) 
that were overexpressed or underexpressed at least 2 fold compared to both 
the MYC singly transduced control and the activated B cell control. Only those 
genes encoding mature messenger RNA transcripts (ie with an 'NM' prefix in 
the NCBI Reference Sequence database) were considered. I identified 281 
genes with increased expression and 262 genes with reduced expression 
(Table 6.6) from the total of 15 981 genes encoding mRNA on the Affymetrix 
GeneChip® 1.0 ST Array. 
The significance of several of the overexpressed genes has been discussed in 
Section 6.5. With regards to the underexpressed genes , Myc is notable. My 
experimental system used a bicistronic retrovirus encoding human MYC while 
the microarray probes detect murine Myc sequences which are similar but not 
identical. It is likely that endogenous murine Myc expression is suppressed in 
this experimental system due to the high expression of human MYC, the latter 
not being detectable with the murine-specific probes. 
Results from this analysis method (both specific genes and dysregulated 
pathways) were then compared to a second analysis method (Section 6.6.2) in 
Section 6.6.3 to determine whether th,e results obtained were reproducible. 
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Table 6.6 Genes that had greater than two fold increased (281 genes) or 
decreased (262 genes) expression in both outgrowths compared to 
both controls - Method One. 
The outgrowths are two Trp538 b1 Myb/MYC-transformed B cell lines. The controls are 
Trp538 b1 antigen activated B cells 2 days after transduction with MYC/GFP vector alone 
and flow cytometrically sorted for GFP+ cells and Trp538 b1 antigen activated B cells 1 
day after activation with cognate antigen and CD40 antibody. Partek® software was 
used to analyse raw data so that differential gene expression between each of the four 
cell populations could be compared, calculating a fold change for each gene on the 
array. Only genes that clearly coded for mRNA (RefSeq name starting in NM) were 
further analysed. The background gene set was all genes coding for mRNA on the 
chip. Duplicates were removed. 
Genes expressed >2x in outgrowths Genes expressed <-2x in outgrowths 
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Genes expressed >2x in outgrowths 
E2f3 
tBiflip," 
Dstn 
C1qc 
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Genes expressed <-2x in outgrowths 
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Genes expressed >2x in outgrowths Genes expressed <-2x in outgrowths 
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Genes expressed >2x in outgrowths 
Sdc1 
llr~!/iJ$di~':2-" 
Sri 
Fbln2 
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Genes expressed >2x in outgrowths Genes expressed <-2x in outgrowths 
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Genes expressed >2x in outgrowths Genes expressed <-2x in outgrowths 
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Genes expressed >2x in outgrowths 
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6.6.2 Differential gene expression - Method Two 
Analysis of Variance (AN OVA) was the second data analysis method. The 
initial part of the analysis (Figure 6.1) entailed ensuring that this statistical tool 
was appropriate for these samples, and identifying excess 'noise' using a 
Principal Component Analysis and a Sources of Variati.on graph respectively 
(Figure 6.1). The Principal Component Analysis (PCA) was used to ensure that 
the controls were more similar to each other than the test samples and showed 
that the two outgrowth specimens cluster together while the two controls are 
less similar to each other (as expected given that the activated B cells had only 
been activated for 24 hrs and have fewer B cells in cycle), but are also distinct 
from the outgrowths. 'Sources of Variation' graphs were also created to 
compare the variation within groups (ie between the two controls or between the 
two outgrowths), which partly reflects background 'noise' due to subtle 
differences in array chip manufacture, technique of RNA production, processing 
date etc, to the variation between groups (ie controls versus outgrowths). 
Higher variation between groups than within groups suggests that results are 
more likely to be due to biological variation than error ('noise'). The results from 
our data suggested that the ANOVA method of analysis was appropriate for this 
data. 
Microarray outputs from 15 981 genes encoding mRNA on the Affymetrix 
GeneChip® 1.0 ST Array were thus analysed with the assistance of the ACRF 
BRF using an ANOVA analysis on Partek® software with a view to pathway 
analysis . Interestingly, Myb overexpression and Myc suppression did not 
features in this analysis. Results from this analysis method (both specific genes 
and dysregulated pathways) were subsequently compared to a first analysis 
method (Section 6.6.1) in Section 6.6.3 to determine whether the results 
obtained were reproducib le. 
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Figure 6.1 ANOVA analysis - Validation 
a) Principal component analysis. Gene expression data from each cell type has been 
transformed using Partek® software into three sets of linearly uncorrelated variables 
called principal components, as shown on separate axes, highlighting similarities and 
differences between groups. 
b) and c) Sources of Variation graph showing mean and median F ratios respectively 
were generated using Partek® software. The F ratio compares 'between group 
variation' to 'within group variation,' the higher the value obtained the more likely 
differences between two groups is due to the factor being tested, and not just the natural 
variation within a group. 
a) 
b) 
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Table 6.7 Genes in outgrowths that had greater than two fold increased (125 
genes) or decreased (88 genes) expression than controls - Method 
Two 
The outgrowths are two Trp538b1 Myb+MYC-transformed B cell lines. The controls are 
Trp538 b1 antigen activated B cells 2 days after transduction with MYC/GFP vector alone 
and flow cytometrically sorted for GFP+ cells and Trp53wt antigen activated B cells 1 
day after activation with cognate antigen and CD40 antibody. ANOVA analysis on all 
15 981 genes encoding mRNA on the Affymetrix GeneChip® 1.0 ST Array was 
performed using Partek® software. p<0.01 
Genes expressed >2x in outgrowths Genes expressed <-2x in outgrowths 
Gene RefSeq Fold Gene RefSeq Fold Symbol change Symbol change 
Spp1 NM 009263 33.60 Gimap4 NM 174990 -65.66 
C1qc NM 007574 27.36 Cr2 NM 007758 -51.27 
Sox4 NM 009238 22.85 lgj NM 152839 -37.53 
Acta2 NM 007392 22.65 Stat4 NM 011487 -31.40 
Uch/1 NM 011670 18.05 Kynu NM 027552 -26.05 
C1qa NM 007572 16.43 l/9r NM 001134458 -25.16 
Oab2 NM 023118 15.72 Sema7a NM 011352 -22.22 
My/4 NM 010858 14.80 Dusp4 NM 176933 -17.89 
Nt5dc2 NM 027289 13.60 ltgal NM 008400 -16.95 
Feris NM 030707 12.66 St8sia6 NM 145838 -15.88 
Ehd2 NM 153068 12.44 Plbd1 NM 025806 -14.96 
Thbd NM 009378 12.10 Fas NM 007987 -12.73 
lgf2bp3 NM 023670 11.47 Setbp1 NM 053099 -12.49 
Cdkn2a NM_00104065 10.82 Ebi3 NM 015766 -11.96 4 -
Timp3 NM 011595 10.27 CdB0 NM 009855 -10.21 
Cpe NM 013494 9.59 As3mt NM 020577 -9.56 
Otub2 NM 00117784 9.52 GimapB NM 001077410 -7.43 1 
Enpep NM 007934 8.69 Tgtp1 NM 011579 -6.84 
Ryk NM 013649 8.58 Gimap6 NM 153175 -6.46 
Sertad4 NM 198247 8.57 Trim? NM 053166 -6.31 
Ptprs NM 011218 6.72 Pglyrp1 NM 009402 -6.05 
Camkv NM 145621 6.61 Cnn2 NM 007725 -5.88 
Bgn NM 007542 6.47 Dock10 NM 175291 -5.63 · 
Em/1 NM_00104333 6.45 l/4ra NM 001008700 -5.59 5 
-
Arhgap29 NM 172525 6.23 Hmgn3 NM 026122 -5.45 
Cenpv NM 028448 5.79 Bmyc NM 023326 -5.35 
Lgals1 NM 008495 5.68 Arap2 NM 178407 -4.85 
Tspan4 NM 053082 5.60 Man1a NM 008548 -4.60 
Cfh NM 009888 5.50 I Ctsw NM 009985 -4.43 
Pf4 NM 019932 5.28 Bmp2k NM 080708 -4.40 
Lgr5 NM 010195 5.15 Mef2c NM 001170537 -4.27 
Nfib NM 00111320 5.11 H2-gs10 NM · 001143689 -3.99 
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Genes expressed >2x in outgrowths Genes expressed <-2x in outgrowths 
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Genes expressed >2x in outgrowths Genes expressed <-2x in outgrowths 
Ppi/1 
Cc/25 
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Genes expressed >2x in outgrowths 
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6.6.3 Similarities between groups of differentially 
expressed genes obtained with different statistical 
methods 
The Venn diagram (Figure 6.2) and table (Table 6.8) below illustrate and detail 
the common genes identified in the two analysis methods. The modest fraction 
of similarly differentially expressed genes with the two analysis methods reflects 
both the small number of samples and controls used in this experiment, and the 
difficulties and limitations of microarray analyses in general. 
On the whole genes shown to be dysregulated in Burkitt lymphoma compared 
to Diffuse Large B cell Lymphoma [199,344] did not features prominently which 
is likely to reflect the different control populations in these publications 
compared to this research and limitations of this pilot microarray analysis, 
among other factors. 
Pathway analysis was performed to review the data in terms of general trends 
rather than on a gene-by-gene basis. 
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Figure 6.2 Enumeration of common genes in the two data sets 
This figure illustrates the number of genes a) overexpressed and b) underexpressed 
two fold in the two Trp538 b1 Myb/MYC-transformed 8 cell lines compared to controls 
(Trp538 b1 antigen activated 8 cells 2 days after transduction with MYC/GFP vector 
alone and flow cytometrically sorted for GFP+ cells, and Trp53wt antigen activated 8 
cells 1 day after activation with cognate antigen and CD40 antibody) using each 
microarray analysis method and the number of genes common to both analyses. 
a) 
b) 
Ov erexpressed first method 
N=213 
Underexpressed first method 
N=210 
¼," 
\ 
\ 
•·• ·~ 
nderex pressetl 
econd rnetho 
=36 
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Table 6.8 List of common genes in the two data sets 
List of genes overexpressed and underexpressed two fold in outgrowths compared 
to controls in both microarray analysis methods. The outgrowths are two T,p538 b1 
Myb/MYC-transformed B cell lines. The two controls are Trp538 b1 antigen activated 
B cells 2 days after transduction with MYC/GFP vector alone and flow cytometrically 
sorted for GFP+ cells , and Trp53wt antigen activated B cells 1 day after activation 
with cognate antigen and CD40 antibody. 
Genes expressed >2x controls Genes expressed <-2x controls 
l Nf!tat4 
Rab31 
}l~-TlrJlp 1 
lgf2bp3 
Cyb5r1 
Cpe "' 
Dab2 
Ppi11 
B4galt6 
Cr-af2-
~\~1t ~ ·: . . - . 
Ryk 
Msh2 
''P laf13 
Cdca7 
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6.7 Significantly altered pathways 
Functional annotation was performed using the Database for Annotation, 
Visualization, and Integrated Discovery (DAVID) resource 
(http://david.abcc.ncifcrf.gov) from National Institute of Allergy and Infectious 
Diseases (NIAID), NIH [480] version 6.7. Pathway analysis was performed for 
the two gene sets obtained using the two different methods of microarray 
analysis (Table 6.9 and Table 6.10) and for the gene set in common to both 
analysis methods (Table 6.11 ). These gene sets were individually mapped to 
cellular pathways defined by the Kyoto Encyclopaedia of Genes and Genomes 
(KEGG) atlas from Kanehisa Laboratories, Japan [481]. Those pathways in 
which these differentially expressed genes were over represented compared to 
the background list of all the mRNAs on the GeneChip® were thus determined. 
Less than 50% of the differentially expressed genes were able to be mapped to 
KEGG atlas pathways, reducing the power of this analysis. In addition, some 
further information was potentially lost by only analysing mRNA-encoding genes 
detailed in RefSeq, without including recently discovered but incompletely 
described genes. Discrepancies in gene labelling between DAVID and the 
KEGG atlas , including the fact that the KEGG atlas often represents multiple 
genes of highly related family members as a single gene in their pathways , 
means that the statistics from this pathway mapping are imprecise. 
Several 'pathways' identified in the broader analysis deserve particular mention. 
It must be recalled that as the KEGG pathways contain genes that both promote 
and inhibit a given pathway, and the genes mapped to the pathways are either 
over or under expressed in the data analysis , enrichment of a certain pathway's 
genes does not necessarily mean that that pathway is more active in that cell . 
population , but rather that it is likely to be differentially regulated. 
Natural killer cell mediated cytotoxicity 
This 'pathway' has been highlighted, but most of its dysregulated genes are not 
, 
specific to NK cells, including MHC class I genes and interferon genes which 
are widely expressed. There are unlikely to be many NK cells in either control 
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or the autonomously growing cells population, although their numbers were not 
specifically counted. 
Cell adhesion molecules 
As illustrated in Figure 6.3 'Cellular adhesion molecules' is not a single 
pathway, but rather sets of genes involved in different types of intercellular 
adhesion. Adhesion molecules specific to the immune system were the most 
common subcategory identified, which will be at least partially due to 
differences in activation status and numbers of contaminating T cells between 
the autonomously growing cells and controls. It is possible that this result may 
also reflect true differences in the requirement for adhesion molecules between 
control lymphocytes (predominantly B cells) and autonomously growing cells, 
but this requires further research. 
Allograft rejection I Graft versus host disease/ Antigen processing and 
presentation I Viral myocarditis / Type 1 diabetes mellitus / Systemic 
lupus erythematosus / Autoimmune thyroid disease/ Asthma 
These pathways have been highlighted predominantly due to the differential 
expression of major histocompatibility complex (MHC) genes and tumour 
necrosis factor (TNF) family genes which, as mentioned above, are not specific 
to these physiological/pathological processes. 
Toll-like receptor signalling pathway 
As discussed in Section 1.4.2, toll-like receptors are found on many cells and 
have a role in innate immunity. Their antigens are components of 
microorganisms and their downstream pathways vary with the receptor subtype 
but include some pathways in common with downstream signalling from the B 
cell receptor. It is of interest that this pathway was highlighted, although the 
significance of this finding is unclear. 
Relevance of pathways not significantly over represented 
It is also important to consider the pathways that were not found to be enriched 
in these an·alyses. KEGG pathways describe a 'B cell receptor signalling 
pathway', and, as described above, the genes within this pathway were not over 
represented in our outgrowth. This 'pathway', however, includes, among other 
255 
components , the MAPK signalling pathway, NF-KB signalling pathway, and the 
Pl3K signalling pathways. Focussed pathway-specific gene analyses (such as 
detailed for the NF-KB pathway above) are required to better define these 
components. 
Also of interest, the DAVID analyses do not highlight apoptotic pathways or cell 
cycle pathway genes in general as being dysregulated in autonomously 
proliferating cells compared to control populations. This may indicate that 
altered activity of these pathways is not a feature of this rapidly proliferating 
population but, as described in this chapter, many factors limit these analyses. 
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Table 6.9 Pathway analysis from microarray analysis method one 
The over and under expressed genes from Table 6.3 were mapped to cellular pathways 
using the DAVID resource. Over represented pathways, the number and percentage of 
total genes implicated, fold enrichment and p value are listed below. Only pathways that 
contained at least five differentially expressed genes were considered. The p value 
was calculated by the DAVID program and was calculated using a modified Fisher 
Exact test. Those pathways with p<0.01 are shown. 
Term Count 
Type I diabetes 10 
mellitus 
Graft-versus-host 9 
disease 
Antigen 
processing and 
presentation 
Toll-like receptor 
signalling 
pathway 
Hematopoietic 
cell lineage 
12 
1 1 
10 
% p Value Fold Enrichment 
1.8 0.000062 5.4 
1.7 0.000083 5.9 
2.2 0.000137 4.0 
2.0 0.003441 3.0 
1.8 0.003848 3.1 
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Figure 6.3 Pathway analysis for microarray analysis method one 
The figures below are graphical representations of the location of the dysregulated 
genes/gene groups listed in Table 6.9 in cellular pathways. The figures are modified 
from the DAVID website, the under or overexpressed gene in this dataset being 
highlighted in black boxes. Not all genes in pathways are included in KEGG pathways 
and some 'gene' names reflect families of genes rather than detailing all the members. 
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Table 6.10 Pathway analysis from microarray analysis method two 
The over and under expressed genes from Table 6.7 were mapped to cellular 
pathways using the DAVID resource. The over represented pathways, number and 
percentage of total genes implicated, fold enrichment and p value are listed below. 
Only pathways that contained at least five differentially expressed genes were 
considered. The p value was calculated by the DAVID program and was calculated 
using a modified Fisher Exact test. Those pathways with p<0.01 are shown. 
Term 
Complement and coagulation 
cascades 
Count % p 
Value 
5 2.4 0.0071 
Fold 
Enrichment 
6.3 
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Figure 6.4 Pathway analysis from microarray analysis method two 
The figures below are graphical representations of the location of the dysregulated 
genes/gene groups listed in Table 6.10 in cellular pathways. The figures are modified 
from the DAVID website , the under or overexpressed gene in this dataset being 
highlighted in black boxes. Not all genes in pathways are included in KEGG pathways 
and some 'gene' names reflect families of genes rather than detailing all the members. 
The legend is detailed in Figure 6.3 . 
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Table 6.11 Pathway analysis for gene set common to both analyses 
The over and under expressed genes from Table 6.5 were mapped to cellular 
pathways using the DAVID resource, the over represented pathway, number and 
percentage of total genes implicated, fold enrichment and p value are listed below. 
Only pathways that contained at least five differentially expressed genes were 
considered. The p value was calculated by the DAVID program and was calculated 
using a modified Fisher Exact test. The single pathway with p<0.05 is shown. 
Term Count % p 
Value 
Fold 
Enrichment 
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6.8 Discussion 
The challenge with microarray data analysis is to differentiate the real 
differences from those that are statistical outliers ('false discovery rate') as a 
consequence of the large numbers of genes being analysed. Because of the 
cost of the method, only small numbers of independent samples within each 
treatment group can be analysed , and the very large number of questions 
asked (the number of genes measured) weakens any conclusions that can be 
drawn due to the problem of multiple testing. The studies described above are 
a preliminary pilot experiment performed to guide further research, which was 
particularly limited because only two samples of Myb+MYC transformed Trp53 
mutant B cells were analysed and compared with a single, well-matched 
counterpart of MYC-transduced Trp53 mutant B cells. Consequently, no 
conclusions can be drawn from analysis of single genes, and lists of 
upregulated or downregulated genes in one sample versus another may have a 
high fraction of false positives. 
The limitations above can be minimized by performing analysis of sets of genes 
that have been selected based not on the microarray data here but from 
independent information, as was done for cell cycle genes, germinal centre B 
cell genes, or NF-kB induced genes inhibited in Burkitt lymphoma. Effectively, 
these allow comparisons within a single dataset: for example the chi-squared 
comparison of the fraction of the set of 25 NF-kB induced genes inhibited in 
Burkitt lymphoma decreased more than 4-fold with the fraction of all the genes 
on the array decreased more than 4-fold in the same sample. This provided 
statistical evidence that the high fraction of NF-kB induced genes repressed in 
each sample of Myb+MYC transformed B cells would be unlikely to have been 
observed by chance. Follow up by a subsequent student confirmed that Myb . 
does indeed suppress expression of cell surface proteins encoded by 4 out of 4 
NF-kB induced genes that were repressed in the microarray analysis. 
Having recognized the limitations of this microarray analysis, it is notably that 
I 
among the 25 genes ranked as most highly induced in the Myb+MYC 
transformed B cells relative to MYC-singly transduced B cells, two thirds have 
268 
Chapter 6: Gene expression analyses 
been shown to be Myb target genes in independent studies, as discussed in 
Section 6.5. Moreover, one of these encoding the cell surface protein CD93 
has subsequently been tested using independent methods and independent 
replicate samples, confirming that it is indeed reproducibly and specifically 
induced by Myb in activated B cells. While this does not mean that all genes in 
the lists of upregulated or down regulated genes will be validated by 
independent follow-up, this provides some degree of confidence that the 
preliminary data in this chapter are a useful starting point for developing 
hypotheses about how Myb cooperates with MYC overexpression and Trp53 
defects to transform activated B cells into continuously growing B cell lines. 
An ideal control in experiments to determine the effect of over expression of 
Myb in the setting of MYC overexpression would be a stable in vitro outgrowth 
derived from MYC singly transduced B cells. Unfortunately most MYC singly 
transduced cells cease dividing and die in culture after several days as 
illustrated in Figure 1.2, without the development of an autonomously replicating 
population of cells, so sufficient cell numbers cannot be obtained for a gene 
expression profiling control. This necessitates using cells that have been 
recently transduced with a MYC overexpressing retrovirus. This difference 
means that the proliferative rate and extent to which there are contaminating 
cells (eg T cells) may differ between sample and control cells. The recently 
transduced control could have been compared to MYC/Myb dual transduced 
cells Day 2 post transduction, but cell sorting would have been limited due to 
the difficulty identifying the Myb-transduced population. The analysis of cell 
cycle gene expression was performed in an effort to control for discrepancies in 
proliferative rate between recently transduced controls and outgrowths that 
have been proliferating in vitro for several weeks. Such differences may 
obscure the true results from pathway analyses, potentially increasing the false 
positive and false negative results. 
Microarray profiling of a larger set of independent samples, both transformed 
cells and MYC single transduced controls, would have enhanced this analysis. 
Clearly the more of each the better, but this needs to be weighed against the 
expense of multiple microarrays, the difficulty procuring the samples, and the 
benefit in terms of statistical power while controlling the false discovery rate. 
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Five outgrowth and 5 control replicates are likely to have given more reliable 
data while being mindful of resource utilisation. A more statistically robust 
method would be to limit the number of genes being assessed, focusing on 
specific pathways, and thus a required sample number could be calculated to 
optimise the chance of meaningful results. 
The advantage of the AN OVA analyses is that in addition to fold changes, p 
values are able to be obtained because there are duplicates within groups. 
Ideally the p value should be more stringent than p<0.01 as there is likely to be 
a high false discovery rate due to the number of genes being compared, but the 
small numbers of samples and controls makes this difficult to achieve in this 
study. The disadvantage of this analysis in this setting is that the two controls 
(one activated and MYC transduced B cells, and the other activated but not 
transduced B cells) need to be considered as 'biological replicates'. The initial 
method of microarray analysis specifically compared these two populations and 
showed that while there were many genes which were similarly expressed in 
the two populations, the expression of some genes differed by up to 65 fold. 
The analysis of NF-KB pathway target gene expression in the outgrowths 
revealed reduced expression compared to MYC singly transduced controls. As 
discussed in Section 6.4 this has been observed as one of the primary gene 
expression signatures differentiating Burkitt lymphoma from Germinal centre-
type Diffuse Large B cell Lymphoma [344]. The findings here are interesting 
because control cells in this analysis were MYC overexpressing cells, 
suggesting that the relative suppression of the NF-KB pathway is not solely due 
to the MYC overexpression and is potentially induced by Myb. Indeed several 
of the genes in this set have been confirmed to be suppressed by Myb in 
activated B cells by FACS of their encoded proteins , in follow-up studies by Y 
Jeelall . As noted in the results , among this set of downregulated genes is 
Nfkb1 , encoding one of the subunits of NF-kB, and Traf1 encoding one of the 
activators of NF-kB nuclear translocation. These two genes have been shown 
in independent studies to both bind and be repressed by Myb [475]. Hence it is 
reasonable to hypothesise that Myb 9irectly binds to and inhibits transcription of 
Nfkb 1 and Traf1 , diminishing expression of many B cell genes that would 
otherwise be induced by NF-kB. 
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How might inhibition of NF-kB by Myb relate to the gene expression signature of 
Burkitt lymphoma? Myb itself was not defined as increased in Burkitt lymphoma 
in the array analysis of Dave et al [344]. However, as a result of the 
observations described in this chapter, a collaboration with Dr Staudt's 
laboratory has revealed in RNA-seq datasets that Myb mRNA is indeed highly 
increased selectively in Burkitt lymphoma, and is indeed a Burkitt signature 
gene. Collectively, these results support the conclusion that high Myb 
expression contributes to a distinctive signature of low NF-kB induced gene 
expression both in Myb+MYC p53-mutant transformed non-germinal centre 
mouse B cells (here) and in MYC+p53-mutant transformed human Burkitt 
lymphomas. Why Myb would be highly expressed in Burkitt lymphoma is 
unknown. 
Given the important role of NF-KB in mature B cell activation, survival and 
proliferation [42] it is an interesting question whether the suppression of this 
response by Myb is a benefit or a cost to neoplastic growth . Based on the 
recent finding that constitutively active lkbkb abolishes survival of antigen-
activated B cells in vivo [101 ], limiting NF-KB activity may have a survival 
advantage for activated B cells through an unresolved pathway. On the other 
hand, repressing NF-KB would certainly have a cost since Myc itself is normally 
an immediate early NF-KB target gene in antigen-activated B cells [49]. 
Uncoupling MYC expression from NF-KB dependence, either through linking it 
to a retroviral L TR as done here or by translocation to the lgH genes as occurs 
in Burkitt lymphoma, would allow the transformed B cells to avoid loss of MYC 
when NF-kB was suppressed by MYB. It may be that some of the MYB-
induced genes substitute for other proliferative effects of NF-kB. Thus the co-
operation between dysregulated Myb and MYC and inactive Trp53 shown here 
may help explain many of the cardinal features of Burkitt lymphoma. 
While several of the dysregulated genes identified in the analysis of the NF-KB 
pathway were validated by FACS as above, the very preliminary results of the 
pathway analysis will require confirmation by an independent method (usually 
real time PCR) prior to further research. 
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7. Discussion 
MYC dysregulation by translocation to the immunoglobulin genes is a hallmark 
of Burkitt lymphoma, frequently accompanied by inactivation of Trp53 or its 
upstream activators. While published literature indicates the pairing of these 
two defects can be sufficient for neoplastic transformation in fibroblasts, work by 
a previous PhD student and findings in this thesis demonstrate that these are 
insufficient for mature activated B cells to proliferate independently from the 
normal mitogenic signals received through antigen receptors and CD40. This 
thesis sought to identify what additional "oncogenic hits" are required for 
neoplastic proliferation of mature B cells. 
I focussed on rare clones of activated mature B cells that had been transformed 
into neoplastic growth in vivo , emerging out of hundreds of thousands that 
already carried homozygous inactivation of Trp53 and had been transduced 
with a replication defective retrovirus encoding a dysregulated MYC gene but 
that did not proliferate. The hypothesis pursued was that retroviral integration 
served as an additional mutagen by dysregulating expression of adjacent genes 
that co-operated with dysregulated MYC and inactive Trp53 to complete an 
oncogenic constellation sufficient for mitogen-independent proliferation of 
mature B cells. 
Analysis of integration sites revealed a high fraction that were frequently 
targeted in other retrovirus-induced cancers and that had flanking genes 
possibly associated with cancer, providing suggestive evidence to support the 
hypothesis. Four flanking genes , Myb, Lmo2, lkbkb , and Laptm5, were tested 
for co-operation with dysregulated MYC and inactive Trp53 by dysregulating 
their expression as cDNAs in a second , co-transduced retrovirus introduced into 
activated B cells deprived of normal mitogens. Two of the cDNAs , Lmo2 and 
Laptm5, had no measurable activity on B cell proliferation in the absence of 
mitogens. lkbkb induced transient proliferation for several days , with or without 
MYC dysregulation , but then the cells ceased proliferating and died off. 
However, transduction with a vector carrying the Myb cDNA reproducibly 
transformed at least one activated B cell in several hundred into continuous 
proliferation in the absence of mitog~ns, but only in conjunction with retroviral 
MYC dysregulation and Trp53 inactivation. This result identifies Myb as a 
powerful "third oncogenic hit" cooperating with dysregulated MYC and inactive 
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Trp53 to uncouple mature B cell proliferation from its normal strict dependence 
on antigen and T cell help. The findings focus attention on Myb in human 
Burkitt lymphoma, where it has not previously been considered as a co-
operating oncogene, and provide additional impetus to pursue the longstanding 
question of the role of c-Myb (as opposed to v-Myb) as a proto-oncogene. 
7. 1 Myb dysregulation in B cell 
lymphoma 
The work in this thesis confirms that Myb is an oncogene in B cell lymphoma, 
but the way in which it is activated to unleash its full oncogenic capacity and co-
operating lesions remains to be defined. 
Truncated or mutated myb, exemplified by v-myb, has clear oncogenic activity 
when it is constitutively expressed, as discussed in Section 1.8. The locus 
around Myb is a frequently isolated retroviral integration site in the Retroviral 
Tagged Cancer Gene Database, also strongly suggesting that Myb is a proto-
oncogene. However, most of the retroviral insertion sites in murine lymphoma 
models in the vicinity of the Myb locus are not intragenic, raising the question of 
whether the integrations increase expression of full length Myb to promote 
lymphoma or other haemopoietic malignancies. It has proved difficult to 
demonstrate elevated Myb mRNA in malignant cells harbouring retroviral 
integrations in or near Myb [482]. Since Myb is alternatively spliced, an 
interesting possibility would be that the proviral integrations increase the 
production of mRNA encoding the alternative spliced Myb product lacking the 
C-terminal inhibitory domain [228,229,261]. In my studies, Myb mRNA was 
increased 20-30 fold in the double transduced B cells that were transformed into 
continuous proliferation in culture. However what remains to be determined in 
future studies is whether this elevated Myb mRNA is truly derived from the 
integrated provirus, and whether it encodes full length or truncated Myb protein. 
The question of what form of Myb is produced in the transformed B cells is 
highlighted by the consistent finding that double transduced cells expressing 
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both DsRed from the Myb/DsRed vector and GFP from the MYCIGFP vector 
were clearly detectable by flow cytometry during the first 6-10 days of culture 
but showed no evidence of spontaneous proliferation. Their frequency or 
numbers did not increase over time. In fact B cells measurably expressing both 
vectors were reproducibly smaller than their counterparts expressing only GFP 
on Day 7 of culture , implying a suppressive effect of the Myb/OsRed vector on B 
cell growth. 
By contrast, the transformed B cells that only became detectable on Day 11 
displayed a different phenotype with no measurable expression of DsRed. 
Since the transformed B cells expressed greatly increased Myb mRNA detected 
by RT-PCR and microarray, it is reasonable to infer that it is provirally-derived 
although that remains to be demonstrated. If so , there are three possibilities to 
explain the consistent lack of DsRed fluorescence in the transformed B cells. 
First, it may reflect a translational difference, for example if the transformation 
process extinguished activity of the IRES. Second, it may reflect selection for 
integration sites that express the Myb-lRES-OsRed mRNA at lower levels, still 
greatly elevating Myb relative to single MYC-transduced counterparts but 
insufficient to produce detectable DsRed protein. This possibility is reasonable, 
since the DsRed protein was at lower levels in all cells receiving the Myb-lRES-
OsRed vector compared to empty-lRES-OsRed vector. Third, the transformed 
B cells have been transduced with an altered form of the Myb-lRES-OsRed 
vector that has lost some or all of the IRES-OsRed segment but retains the Myb 
elements measured by RT-PCR and microarray. For example, occurrence of a 
cryptic internal RNA splicing event in a small fraction of the vector RNA in the 
packaging cell line could produce a subset of retroviral particles encoding a 
truncated Myb protein and no DsRed protein. Given the strong evidence that 
removal of the Myb C-terminal inhibitory domain is important for oncogenic 
activity in other cell types [225 ,229 ,231], this is an attractive possibility. 
To resolve amongst these possibilities , it will be important in future studies to 
ampl ify and sequence the Myb mRNA in the transformed outgrowths and 
compare its level of expression and sequence with that in control B cells singly 
transduced with the Myb/DsRed vector or the MYC/GFP vector. It would also 
be valuable to repeat the co-transduction experiments with .Myb/OsRed vector 
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encoding a C-terminally truncated Myb protein, to test if DsRed+ GFP+ double 
expressing cells are now induced to proliferate in the first 6 days of culture. 
The consequences of Myb overexpression in mature B cells is not well defined 
as most research has focussed on its role in immature cells. Further research 
into the feasibility of overexpressing Myb in other mature B cell models and the 
pathways subsequently deregulated may help clarify the oncogenic potential of 
unmutated Myb. The ultimate test would be the in vivo consequences of 
overexpressing Myb under the control of a mature B cell-specific promoter. 
7.2 Myb, Myc and Trp53 co-operation 
7.2.1 Myc and Myb 
Several avenues of research have confirmed that Myc and Myb co-operate in 
lymphomagenesis. Davies et al [483] demonstrated that transgenic mice 
constitutively overexpressing v-myb in their T cells and subsequently infected 
with Moloney Murine Leukaemia Virus have reduced latency to T cell lymphoma 
compared to non-infected controls. Analysis of the retroviral insertion sites 
demonstrated that in most lymphomas the retrovirus had inserted into the c-myc 
or N-myc locus, suggesting co-operation between the Myb and Myc genes. 
Similarly Barr et al [484] confirmed that the vicinity of the Myb locus was the 
common insertion site in T cell lymphoma induced by a feline leukaemia virus-
Myc recombinant retrovirus. Hanlon et al [485] showed that mice expressing 
both CD2-vMyb and CD2-MYC-ER transgenes developed T cell lymphoma 
more rapidly than those expressing a single transgene. Interrogation of the 
Retroviral Tagged Cancer Gene Database [94] demonstrates that tumour 
models that have Myb as a common insertion site frequently have Myc as 
another common insertion site. 
Several publications have demonstrated that Myb is able to increase the 
expression of Myc [486], although most of this work is not in B cells. Early work 
by Evans et al [487] demonstrated that in T-cells transfection of a Myb-
expressing retrovirus resulted in increased Myc expression and that the Myb 
277 
protein transactivates a portion of the Myc gene promoter. Schmidt et al [488] 
showed that Myc is a direct transcriptionally regulated target of Myb in a 
myeloblastic cell line and proposed that Myc mediates Myb's proliferative effect. 
Kumar et al [489] confirmed that overexpression of Myb resulted in 
overexpression of Myc, however showed that Myc overexpression alone was 
insufficient to explain the Myb-mediated myeloid differentiation block. These · 
observations are less relevant to the co-operation observed here , since MYC 
transcription in the transformed cells was controlled by the MSCV long terminal 
repeat. 
Indirect mechanisms of Myb-Myc co-operation are also highly likely with 
dysregulation of one gene modulating the downstream effects of the other. The 
Bc/2 family may potentially facilitate such co-operation. As discussed in Section 
5.3 , Myb induces Bc/2 expression in T cells [448 ,449] and other MYB family 
members have been shown to upregulate Bc/2 in B cells [450,451]. Myc 
induced lymphomagenesis is facilitated by dysregulation of Bc/2 family 
members [212 ,335 ,490] , which could thus potentially be facilitated by Myb. 
Recent publications [179 ,180] showing that rather than targeting specific genes, 
Myc exponentially amplifies the output of existing transcription ally active genes 
further supports a potential indirect mechanism of cooperation. 
A small number of studies have demonstrated that Myb and Myc expression 
can result in epigenetic modifications , another potential mechanism of co-
operation . Myb has been shown [491] to modulate the expression of the 
histone variant gene H2A.Z in T cells , Martinato et al [492] demonstrated that 
Myc has diverse actions on chromatin structure in a B cell line and Knoepfler et 
al [493] demonstrated that N-myc null neurones have different chromatin 
transcriptio nal activity to normal neurones. The consequences of epigenetic 
changes due to Myb or Myc dysregulation in B cells remain , however, to be well 
defined. 
MicroRNAs are critical components of genetic regulation. miR-150 expression 
is lower in germinal centre cells than ,in naive or memory B cells [494] and is 
markedly suppressed in Burkitt lymphoma cells compared to other B cell Non 
Hodgkin Lymphomas [342]. miR-150 is a negative regulator of Myb and its 
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experimental overexpression in a Myc-mediated lymphoma model results in 
marked tumour regression [495], potentially as a consequence of Myb 
suppression. Since miR-150 targets sequences in the 3' untranslated region of 
the Myb mRNA [267] that are absent from our proviral vector, this potential 
mechanism for modulating tumour growth would be bypassed in our lymphoma 
model, but miR-150 is an example of microRNAs modulating gene interactions. 
7.2.2 Myb and Trp53 
The interactions between Myb overexpression and Trp53 deficiency are also of 
importance. p53 induces cell cycle arrest at the G1 checkpoint and 
consolidates cell cycle arrest at the G2 checkpoint in response to DNA damage. 
B-myb has been shown [496] to reduce p53 dependent cell cycle arrest at the 
G1 checkpoint in cell lines. Mannefeld et al [497] have recently described that 
B-myb promotes recovery from the G2 checkpoint in p53 mutant cells. These 
actions of the 8-myb gene may allow ongoing proliferation of defective cells , 
consolidating the effect of loss of the Trp53 tumour suppressor gene, but the 
specific impact of c-Myb overexpression remains to be clarified. Dysregulated 
Myb may relieve cell cycle blocks through its established role 1n transcriptionally 
inducing a number of key G1-S phase and G2-M phase mediators including 
Ccnb1 [472], Ccne1 [498] and Cenat [499], although additional experiments 
would be needed to confirm this. 
Myb may also potentially enhance the apoptotic defect in p53 defective cells. 
As discussed in Chapter 1 the Bcl2 family of proteins are downstream effectors 
of Myc-mediated p53 dependent and independent apoptosis. Myb 
overexpression in B cells could potentially enhance Bc/2 expression, 
broadening the apoptotic defect seen with a p53 defect alone, and thus 
enhancing the cells' transformation potential. 
With regards to the potential impact of p53 on Myb, Takikawa et al [500] 
demonstrated that p53 negatively regulates Myb activity through increased 
degradation and inhibition of Myb-dependent transactivation in cell lines. This 
suggests that p53 defective cells may have enhanced Myb-mediated cell 
proliferation. 
279 
7.2.3 Triple MybJ Myc and Trp53 dysregulation 
As discussed in Section 1.12 Sander et al [14] demonstrated that activation of 
the phosphoinositide 3-kinase (Pl3K) pathway could cooperate with MYC 
overexpression in a murine Burkitt Lymphoma model. Pl3K is activated by 
antigen binding to the B cell receptor, is a critical mediator of mature B cell 
survival [22] and has also been shown to stabilise Myc [501 ]. Schmitz et al 
showed that mutations in TCF3 and its negative regulator /03 were found in 
70% of cases of sporadic Burkitt lymphoma analysed, and promoted Pl3K 
signalling. The role of Myb in Pl3K signalling remains to be well defined as 
detailed in the discussion of Chapter 4. It could be postulated that Myb is a 
downstream mediator of the prosurvival signals from the Pl3K pathway, or 
enhances the activity of this signaling pathway. Myb mRNA is induced by Pl3K-
AKT-mTOR signalling in T cells [430] and uncoupling Myb induction from its 
normal sensitivity to rapamycin relieves the inhibitory effect of this drug on 
HTL V1 replication in T cells [502]. Myb overexpression could thus circumvent 
the necessity for mutations in the Pl3K pathway. Other integration sites 
discussed in Chapter 4 may also contribute to lymphomagenesis through 
modulation of this pathway, although none clearly fall into the same 
complementation group as Myb. 
The high frequency of p53 pathway mutations and Pl3K pathway dysregulation 
in Burkitt lymphoma confirms that these are not infrequently found together and 
may cooperate with the MYC overexpression that defines this lymphoma. One 
potential mechanism through which MYC, Myb and Trp53 dysregulation all 
cooperate is through FoxO transcription factors which mediate components of 
cell survival and proliferation pathways, among other roles. They are 
inactivated by protein kinase B/Akt (components of the Pl3K pathway) -
mediated phosphorylation. Bouchard et al [364] showed that disruption of FoxO 
function dramatically accelerates Myc-driven lymphomagenesis by 
compromising Ati induction and thus p53 function. It could thus be 
hypothesised that increased Pl3K pathway activity (potentially mediated by Myb 
overexpression) enhances the oncogenic function of both Myc and Trp53, 
explaining the triple gene co-operative (rather than merely additive) effect. 
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Are these three genetic defects 
sufficient for lymphomagenesis? 
The data presented in this thesis indicate that triple MYC, Myb and Trp53 
dysregulation may complete an oncogenic triad sufficient for mature B cell to 
proliferate autonomously. However, as discussed in Chapter 5, it is possible 
that the observed transformation efficiency of less than 100 percent is due to 
the requirement for additional mutations to accumulate prior to cell 
transformation. The high efficiency of transformation - at least 1 in 210 
MYC/GFP+ cells and 1 in 50 double-transduced cells - rules out the need for 
the vector to target a specific additional oncogene by insertional mutagenesis 
because there is not such a great degree of bias to retroviral integration sites. 
Moreover, the consistency and efficiency of transformation from experiment to 
experiment makes it very unlikely that the subset of B cells transformed are 
selected based on carrying a pre-existing fourth mutation elsewhere in their 
genome. As discussed in Chapter 5 and above, the factor that limits 
transformation to 1 cell in 50 double transduced B cells may sjmply be the need 
for the MYC provirus to integrate in a highly permissive locus, since the 
outgrowths uniformly displayed much higher GFP than the majority of 
transduced cells. Alternatively, the remaining factor may be transduction with 
an internally spliced Myb vector that lacks the C-terminus of Myb, IRES and 
DsRed coding elements, as discussed above. 
Further in vitro studies are needed to confirm and expand upon our findings that 
MYC and Myb overexpression in conjunction with a p53 defect co-operate to 
facilitate B cell proliferation in vitro. Initially the in vitro experimental system 
described in this thesis could be used to determine the effects of 
overexpressing other genes of interest such as Gng7 and Ltb/Ltb. Selective 
overexpression of genes activating the Pl3K pathway or suppressing the NF-KB 
pathway would also be of interest as these pathways are dysregulated in Burkitt 
lymphoma. Different in vitro techniques could also be used to confirm that our 
findings are generalisable. These could include the use of a Cre-Lox system to 
excise Trp53 at a later time point in an effort to limit the number of random 
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genetic mutations acquired by cells. Inducible gene systems such as the 
tetracycline dependent system could also be used to overexpress Myb or MYC 
at specific time points. Linking Myb or MYC overexpression to promoters which 
are only active in mature B cells may help to confirm the B cell maturation stage 
which facilitates the genetic co-operation. A robust study of the pathways 
dysregulated by the triple gene defect would also be of significant interest due 
to the limitations of our small pilot microarray study as discussed in Chapter 6. 
In vivo studies are critical, particularly as this triple gene combination would 
have been predicted to facilitate cell proliferation in vitro. Initially, the malignant 
nature of the cellular outgrowth should be confirmed by injecting autonomously 
proliferating cells with the MYC/Myb/Trp53 triple gene defect in vitro into 
syngeneic murine recipients. Further experiments, guided by the success of 
supplementary in vitro studies, would include selective induction of MYC and 
Myb and deletion of Trp53 in mature B cells in vivo. If the triple gene defect 
were confirmed to be co-operative, subsequent normalisation of the 
dysregulated genes in vivo would be of considerable interest to determine if the 
lymphoma remains addicted to the dysregulated gene(s). 
7.4 Application 
Assuming that different in vitro and in vivo models are able to confirm that Myb, 
Myc and Trp53 dysregulation facilitates autonomous B cell proliferation, the 
potential broader application of this finding needs exploration. This research 
has looked at the dysregulated gene combination that initiates autonomous B 
cell proliferation, which may not be the same as the dysregulated genes 
required for maintenance of a mature B cell lymphoma. While the 
autonomously growing cells in vitro still had overexpression of MYC 
(extrapolated from GFP positivity), Myb (confirmed with real time PCR) and 
defective p53 function (mouse genotype) the scope of this research did not 
include normalising expression of these genes individually within the 
autonomously growing cells to determine if they were still necessary for their 
ongoing viability. 
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If this triple gene combination were demonstrated to only be critical for the initial 
transformation rather than maintenance of the lymphoma, targeted therapies 
based on these results may be of benefit in patients at high risk of developing 
MYC overexpressing B cell lymphoma (particularly Burkitt lymphoma), such as 
those with HIV or post transplantation. Alternatively, such a therapy may 
potentially be of use in patients with low grade lymphoma in an effort to prevent 
a high grade transformation which portends a poorer prognosis. 
If it were confirmed that dysregulation of this triple gene combination were 
critical for persistence of the autonomously proliferating cells in vivo, these 
results could be used as a basis for the development of targeted treatments. 
Targeted therapies usually complement rather than replace combination 
chemotherapy to optimise therapeutic response while minimising toxicity and 
resistance. Monoclonal antibodies have demonstrated significant therapeutic 
efficacy in B cell lymphoma. An example of such an approach is the 
development of rituximab, a monoclonal anti CD20 antibody, which is given in 
conjunction with chemotherapy and has significantly improved survival [503] in 
several subtypes of B cell lymphoma. Monoclonal antibodies may be unlabelled 
where their mechanism of action include antibody-dependent ·cell lysis and 
complement dependent cytolysis, or may be conjugated to a toxin or 
radioisotope in an attempt to optimise local toxicity. Monoclonal antibodies are 
not the only type of targeted therapy and have the disadvantage of requiring the 
surface expression of the antigen of interest. Targeted therapies currently in 
clinical and preclinical studies for B cell lymphoma include those inhibiting the 
proteasome [504], Bruton's tyrosine kinase [505] and Bcl2 [506]. 
Based on our research findings it could be proposed that induction of TP53 
expression or suppression of MYC or MYB expression may be a valid 
therapeutic goal. Many groups have attempted to increase p53 levels in p53 
defective tumours to induce cell cycle arrest and apoptosis. Martins et al [360] 
used as Eµ-myc model where the p53 status could be modulated. Reinstitution 
of p53 function precipitated apoptosis and increased survival, but also selected 
for tumours with mutations further down the p53 pathway. Mdm2 
haploinsufficiency has also been shown to suppress lymphomagenesis in the 
Eµ-myc model [507]. Nutlins [508] which occupy the p53-binding pocket in 
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Mdm2, preventing its binding to p53, have showed preclinical potential, however 
some research groups have demonstrated that increased p53 levels promote 
ageing [509,51 O] and Mdm2 helps protect mice from the lethal effects of 
ionizing radiation [511], tempering enthusiasm for research in this area. 
Suppression of MYC overexpression is also theoretically a worthwhile target in 
tumour cells, although its critical role in normal cellular homeostasis 
necessitates caution in view of the possible off-target ramifications. Soucek et 
al [512] engineered a mouse model with an inducible dominant-interfering Myc 
mutant which, when activated, resulted in the regression of early and 
established lung adenocarcinomas, although accompanied by reversible 
suppression of normal actively dividing cells. Further murine research by 
Delmore et al [513] showed that the BET bromodomain inhibitor JQ1 (which 
selectively down regulates Myc and Myc-dependent target genes) has shown 
efficacy in Myc-dependent myeloma in vitro and in vivo. 
Targeting Myb is not a new concept, and the potential therapeutic role of 
targeting Myb in leukaemia has been reviewed by Pattabiraman and Gonda 
[514]. Enthusiasm for this approach needs to be tempered with caution due to 
the key role that Myb plays in normal haemopoiesis. It may, however, be 
possible to identify a therapeutic window as preliminary experiments have 
shown [515] that myeloid or lymphoid leukaemia cells have a heightened 
sensitivity to Myb oligonucleotides compared to normal cells. There has been 
interest in Myb antisense oligonucleotides for over a decade (reviewed in [516]). 
More recently Brignole et al [517] refined a technique using anti-
disialoganglioside GD2 liposomal c-myb-selective antisense oligonucleotides, 
the Myb downregulation and reduced cell proliferation only being seen in GD2 
positive neuroblastoma cell lines as targeted. It could be postulated that anti-
CD20 liposomal Myb-selective antisense oligonucleotides may have therapeutic 
efficacy in lymphoma while avoiding the detrimental effects that Myb 
downregulation may have on early haemopoietic precursors. Short interfering 
RNAs would be another possible mechanism of Myb suppression. Zuber et al 
[518] demonstrated that this approac,h could knock down Myb expression and 
suppress Acute Myeloid Leukaemia in a MLL-AF9 murine model. Of critical 
importance, normal granulopoiesis and erythropoiesis were able to be 
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reconstituted when cells expressing this Myb shRNA were injected into lethally 
irradiated mice, although lymphopoiesis was adversely affected. 
Alternatively, once the critical co-activators specific for Myb's function in B cells 
are more clearly defined, small molecules or peptides could be designed to 
block such interactions. The targeting of co-activators in myeloid cells, which 
may also be applicable to B cells, was reviewed by Pattabiraman and Gonda 
[514]. As discussed in this article, targeting of upstream or downstream 
components of Myb pathways also has merit as these are being more clearly 
defined (reviewed by Ramsay and Gonda [216]). 
Any efficacy of such a targeted therapeutic approach would clearly be a 
gratifying confirmation of the in vitro research presented in this thesis. 
7.5 Synthesis 
This thesis demonstrates that Myb overexpression is able to co-operate with 
MYC overexpression and a Trp53 defect to induce uncontroll~d mature B cell 
proliferation in vitro. To our knowledge this is the first time that this has been 
demonstrated. This suggests that three genetic defects may be sufficient to 
immortalise a B cell, although requires confirmation in other experimental 
systems. This finding enhances understanding of the genetic basis of B cell 
transformation, and further research based on these findings may provide 
insights into the pathogenesis and cellular pathways implicated in the 
development of B cell lymphoma. In the current era of targeted therapies better 
defining such pathways is likely to optimise development of new anti-lymphoma 
therapeutics. 
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9. Appendix 
Below are the read outs obtained after the gel bands post splinkerette PCR 
were sequenced using the Big Dye Terminator v3.1 Cycle Sequencing Kit. Only 
those which were well correlated with the mouse genome using the USCS 
(University of California Santa Cruz) Genome Browser BLAT search function 
(July 2007 assembly) are included below (ie sequences amplifying only internal 
retroviral DNA are not shown). The primer used to obtain the sequence is also 
listed, as on some occasions one primer did not result in a productive readout, 
although often both primers gave very similar results, as indicated. The 
sequence corresponding to the murine genome is underlined. 
9.1.1 Lymphoma 1 
Specimen 1 b 
HMSp2 primer 
GGTAGCATTATTATATAAGTTTATCTTGGATCTTGCCAGAGTTCTGTTTCTG 
GTAGATGGGGTATTGTGTTTTGACTCTCTCACCTTTTTAGAATCAGAGACTT 
ACTTTGACACATTTGATATGAGAGACTGGGACTCAGACAGAGATAGAGAGA 
TAGCAAGTGAGTGTGCTTGAGAGAGACAGAGAGACAGAGAGACAGAGACA 
GACAGAAATACACACACTCTCACACACACACACACACACACACACACAGAG 
AGAGTATAAAGTGTGTTGTGTGCTCTCTCTTGTGTTTTTTGAAACCCCCCCT 
GTGTGTTTTTGAC 
Specimen 1d 
HM001 (same localisation with HMSp2 primer) 
ACTCCGTGGGTTTTTGTGACACGGGGTCTGTCATAGCCTCTCTCAACTGTT 
ATCAAAATGATAGGAACCCGGGATGATATGTACAATGTGGTTCAACAGTAG 
AACTCTTGTTGGCTTACTCTCCCCCCTGACACCCCTCTGTCCATGATGCCT 
CATTTGGACAAAAGTGGCTAGGACCACTTGGAAGCTGTTGCTATCTTCCCC 
AGAAATGAAGCTTCTGACTGGCTGTGTGTTCAATGATAACTTGTTGCCCTG 
GTGACAAGGTTGCTATGACAGATATTTCTGTCAATCAAAGGAGAATTCTTG 
ATGCTGTCTGGTAATTGGAGTTTCTGTTGAAAAGTGTTGGATTCTCCTGCT 
GTATGCACATGTAGAGAGTGGGTAACCACAGAACAGGAGGCCCATGTTAA 
CTTACTTAACTGGCTGGAAACATGTCAACTGTCTGCGTTTTGAACTGGCTG 
AATGCACACAGACAGTAATACATACAAAAGACAAAGGAAAGTTATGGAAAT 
ATTATCATAAAATCATTACCATCCCCCACCTTTGTGCTAGGAATGGAACTTA 
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GGGTCCTTATAGGCTAGGGAGTGTTCTATCTCTGAGATATACCCCTAGTCT 
CACCCGGCTCCTGTGTGCGGCGCATGTGGAATCTAGAGATTAACATTGTA 
CATCTTCCCTTAATCGCTTTTCACTTTCTTTTTTTCTTTTTTGAGAAAAGGAT 
TCTCTAAG 
9.1.2 Lymphoma 2 
Specimen 2b 
HMSp2 (same localisation with HM001 primer) 
ATGGTGCCTCTTCAGTACCCGAGGACACATCCCAAGACCCTGAGCAATAA 
TGAAAAAGAAAACAGAGCCAGACATTATAACCATCACTAAGAGACACAAAG 
TTTGCTACAATTGTAACAAAATTACCACATCACCACCAAGGAGCATTCAGC 
ACAGAAGGTCCTGCCTACCATTCCCTCACTCAGGAAGCTGAGGCAGTAGG 
ATGGCCACCAGCTTGAAACCAGCCTGGGCTGCAAAGTAAAGCTATCCTAC 
TGGAGAAAAGCGGGCAGGCAAAAGAGAAAAAGGGGGAGTCAAAGCCGTG 
TTGGCCGCGGGTGTTAAGGGGACCTACTGA 
Specimen 2c 
HM001 (same localisation as HMSp2 primer) 
AAGGTGATACAGAGCTGAGTAATCCCCTTGGGGCCCCTAGGCTCGGCCAC 
CAGCCAGAGCACGGGCCACGGCGGAGGTTGGGTGGGGTTGTCGGTGGC 
CAGGAGGACCCCTGGGAGGACTTGGCCAGCAAAATGAGTTGGCTCTGGC 
CCAGGCCTGCTGGATCTGGAAAGCACCAGCCAGATGGGGAGTTCCTCCC 
CTTCTCTGCATACCCAGGGCTCCCCGCGTGTCTGCTGTGTCCATCTGTTTG 
GCCCCACTTTTATTTATGCAACAGTGGATTGGCGGGAGTTTTAAGCACTGT 
CAAGTGCTCTTCCTGAAGGCACACAGCACAGCCAGGCTGATGTTAGCTTC 
TGTGGGTGGGTCAAGGGTGACCGTTTGTGTCACTATCTGCCTGTGCCGTC 
TTCAGGAAAGGCCACCTCCAGTCCAGCCGTCACGCTGTGTCTCCTGCAGA 
TTTGCTGGGAAGAAATCCACGATTAGGAACCCCGTGGCATTTGGTTGTGG 
GTTCCTGGGACAAGGCGTCAGA 
9.1.3 Lymphoma 3 
Specimen 3a 
HMSp2 (same localisation with HM001 primer) 
331 
CGATTCATGAAGCACTCGTACTCTTTGTAGGCTCTCTGAGAGGCTGCACCT 
CCCAGGCACCACACCTGTGCATTGCTTGCCCACAGCCCTTTGCAGACACG 
GTTCCCGCTACCCGAATGCCTGCCCCAGCCTTCTGGTTGAGTCCCACTCA 
CTCTCTGAGACACCAGGCAGGCCTCCTTGGTTCACCTTTCCAGGCTAGGC 
CAGCATCTCCGCAGCTTATTCCCTTACTTGGAAGTTGAGCAAAAGACTTGC 
CCAAGGTCACACATTCAGTGAGGTGGAATCAGGATTAGAACAAGAGCCTG 
CTGTTTCCTGGTGGGAGGGAAGTGCTCAAGGCCAGACTGCTGGAGAGGC 
TAGAGTGTGAAAGACCCCACCTGTAGGTTTGGCAAAAA 
Specimen 3b 
HM001 (same localisation with HMSp2 primer) 
AATCCTTAATCTCTGGAGATCTGCCTTGCTTGCCTCTTGAGTCCATGCTCC 
ACCACCCTGTCGTCCCAATTGAGTATCCAGGTTTTAAACTGGGTGACCTAA 
GGAAACTCCACTACAATATCAAGGGGATCAAGTTACCTCATATCAAAACCT 
CCGCCACAATGAGAAAGCCCCGGCTCTGGCTGTCCCCAGTTACCCAGTTA 
GAGAGGCTTAACTGCCACTCACCTGTCCATGAGCAGAACCAAAGGGGAAG 
CCGCCATGATTCTACTGTGACCACACAGTCCTCAGGGACCATCCACAGTT 
GCTCTGAATCTCCTGGTGCCTCATACCTGGCAAGCCACAGTGTCAAGGCC 
ACA 
9.1.4 Lymphoma 4 
Specimen 4a 
HMSp2 (same localisation with HM001 primer) 
ACTGGTTTGATTAAAGCAGCAGTGGAATATCTGATGGTACAAAGAGATAGC 
CCACTCCAAGGTACTCACCCAGGCCCAGGTATACTCACAGGACAGACACT 
GCCCTCTGTGGTGACCTGTGATGCTCACGGCCAGTGTGTGACTGCCTGTG 
CCTGGCTGACCCATGGGCCCCTTCCAGGTCAGGCTGCCTCCTTTCTTCCT 
TCCCAGGCAGGCTCAGGACCTTGCCAACCAGGCTGCCCTCCTTTCTCCCC 
TCAGCTGTGTTTCTCTGGGCTCAGTTTTGCCTTTCACCCTCTTAAGCTTGG 
GAGTTTGAGAGATTGATTACC 
Specimen 4b 
HMSp2 primer 
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GCCCAAAGCACCACTATCGAGGCTATAGAGGTTCTGGGTCATGTGATACT 
GCACATCAAAGGCTGATTTTGGAGGAGGGGGGTTGGATTGCGCCCGGTAA 
CTTCCCGACCCAACTGTTTTGTGTGCTGCCTGGTGCCACACCTTTCTGTGG 
CCTTAAACTGATGTCATCCAGATCTGCGCACCGTCCTACTTATTTACGTTG 
ATTTTGAAGAACCTCTTCCGAGACCTAGAAATCTGTTTCCCTCGGGTTCTG 
TCTGATGCACTGATCCCTATAAATGTTTGGGACTCAAATACCTAACTGTGG 
CCAGGGACATGGGGTGAGGGGTAAATCCCAAAAGAAGCAAACCGAGCCT 
CCAATTTTAGGCCATTCCCCATGGACACCCATAGCCCAGGTCACTAGTAAT 
GTACCTGGGGTCACACTGTGACAATGACTCCCACTGTGACATGCTGGCTG 
CCCCCCACCACCCCCGACCCATTCCCCAGCCACAAAGCTTAACCCATCCT 
TGAAGGGAGAAGGTGACAGCTTGACTGAGCTGCTGCTGAGAGGAAGCAG 
TCGCTGGTTCCCAGTGAGAAGTCCAAAGGTAAACCCCCTTCCTCATTTCTG 
AAAGCTTCCTCCCCCCCTACACCCCGGCCTGTGTGGAGCTAGGTCTCCTG 
CAACTATCACAACCTGCACTCCTCCCTTTTGCCAGCCTGCCTTTCTCTTTG 
CACAGCCACAAACCAAAAGGGCACTATTCTGTTCATCTCACAAGTAACTAC 
TAAGGCCAGGATAACTCCGGGCTTGTACCGGGCC 
9.1.5 Lymphoma 6 
Specimen 6b 
HMSp2. Same localisation with HM001 primer 
GGCCAGCAGCAAATGGCTGGAGGAGAACAGAGGGACAGATACCTTCTAA 
GAGTAAAGTTCAAAGTTGAAGGAAAGATGGACACTAGTCTATTTTCTAAATT 
GAAGTTGCCATCTGATAATTAAACGTTTACCCTTCCTTCTGCCTTCAGCCTC 
TTTTTACATATCTGGATTTGCACAAAGGAGCTCTGGCATTGCTGAGCCGTG 
CTCTGGGCAGTGAAGTGGGCAGAAGAGAGATGCTGCCAACCTGGGGAAA 
TTCAGACTACCCAATCAGAGATAAGGGGCAAAGAACCTTTGTCACTGTTGT 
CCCTTGCATTTCCCTTCTCACAAATTCATTCAGCAAGTCATGGTGACTCCAT 
CTATGTCTTCAGACGCTGGCTCAACACAAAAGCTAGAATAAAGATAACATG 
TCTTCATTTATGAAGTAATTCTGATATAATATCTCGAACCACTGTCTTTCATA 
TTAGGTTAATTGTTCCTAGCACAAAAGCCCTGAAATAATACCCAACTCTCTC 
ATGGAGCTGTTCTTTGTTTGATAACAGTGAACAAAAGCTCAGGCAACACTG 
AAAATGTTTTACTGACCTTCTAAGTCAAGGTCATGTAGCACGAGAGTAACC 
CTTGAAAGACCCCACCTGTAGGTTAGGCAA 
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9.1.6 Lymphoma 7 
Specimen 7a 
HM001 primer. Same localisation with HMSp2 primer 
ATCGCCAGCCCCTTGTGATGAGGCTGACATTTATTTGAATTACACACTTCT 
GCCAGTTGCATATGCCGAAAGTTGTCCTACACGCATAGCACAAGCATACC 
GGAAGCTCTACCCTGTCAGCCACGCAACGACCGCAGTGTGGCCTGTCATT 
CACTATCGCAGCAGCGGCCACCTCATGGAGCTGAAGGGAACTGCCCAGC 
ATGCCCAGCCTGTTGTGCACACAGACTGTCCAACTCCTACCCAAGGGCTC 
GATTTCCAGAACTTAATCCTCAGAAACAAGGTACTCGTTCAGATACTGTCTT 
CCATGCTAGATTATAAGGGCAAGGACTAGATCCCACTAGTGTCGACACCA 
GTCTCATTCAGCCACAA 
Specimen 7b 
HMSp2 primer. Same localisation with HM001 primer 
TTGGATTATATAATGAGAGTGTCTCATAGGTCAGGTGGGTAATTTTCTTAGA 
AACTGAAGTTTGCGTTGTACTTTCCTGTGCATTATTCATTTCTTCCTCACAG 
CTGCTCTGCATGGCGCCTGGCCTTACTTAACAAGAACAGACAGCACACCC 
AGAGAAATTACTGGCATGGCAGGGTCTCAGCCCTATCCCACTAGTTCCGG 
GGACAGTGGCCCTGCCTACCATTGGCCTCTTACACCTTCAATTATTCCATT 
GTAAACTAGGGATAAAAATACTCGGTAGGGCGCTGTCTTCACTCACAGGG 
AATGTGATCTGGACACCAGCCTCCCTGAGGCTGCTAACTTTCTGGTGAATG 
GAGAAAAGGGCTTCCTGAGAAAGTGACCCTGAAGCAGATTCTGGAAGAAG 
GTAAGGAATTGAAAGACCCCACCTGTAGGTTTGGCA 
9.1.7 Lymphoma 8 
Specimen Ba 
HM001 Primer. Same localisation with HMSp2 primer. 
CAATCCCCCCTTTTTTGTTTCCACACACACACACACATTAAATATATAAACT 
ACGAGTTTAAAATAGACCAGCCGATAGTGATCCCACCTGGTCAAATTCTCC 
CTGTTTCCCCCACGCTGTCAGCTGCCACACTTCACCATACAGGGCCTCCC 
CAAATCTCCAGGGGTCATGCACCTT,GATCCCACTAGTGTCGACACCAGTCT 
CATTCAGCCACAAA 
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9.1.8 Lymphoma 10 
Specimen 1 Oa 
HM001 primer. Same localisation with HMSp2 primer. 
GGCTCCCCCCCCCCCTGCTACTTAACTTGACTTACAAGGTCAGCAGAACAT 
TTGCAGAGTTGCCTGAGCTCCCTGATCACTGTTATCAAACAAAGAACAGCT 
CCATGAGAGAGTTGGGTATTATTTCAGGGCTTTTGTGCTAGGAACAATTAA 
CCTATTATGAAAGACAGTGGTTCGAGATATTATATCAGAATTACTTCATAAC 
TGAAAACATGTTATCTTTATTCTAGCTTTTGTGTTGAGCCAGCGTCTGAAGA 
CATAAATGGAGTCACCATGACTTG 
9.1.9 Lymphoma 11 
Specimen 11 b 
HMSp2 primer. Same localisation as HM001 primer. 
GATGACTTGTTATTTTTGAGTGCATCACTCAGCTGTCGAGCTGCTAATTAAT 
GAGATAGAAATGATTTTTTTTCTTCTTCTAAGAAGCGGGGGAATGAAACAC 
CCCCCCTGTAAGTTTGGCACTTGTTTGTACTTTATTTACTCGGAAAGATACA 
TTGAGGACCCATGATGTAGGTTTTTTTTCTTCATTTTTTTGTGGGT ATGTCC 
AATTTTCAAATGAGTGAATAATCATTTTACTTATTAGGAAAAATAAATCATTA 
CACCTATCGAATTTCTTGTGAGGGACCCTGAAACGGAGCTCAGACGTTGT 
CACTGAGGTAGAGTGACCATTTCAGTTTATTTTTATGGTTGGATATTGTTGG 
TGTTGTTATAAAAACGAATGTAGGCACATTACACACATTCTCCTCTATTGAC 
CGTTTGGTAATATTGGCTAACATATTTATTTGGTTGCCAAAGCTTGCTTGGG 
ACGAAGGAAAGCTGTTACTGATGTGATGAAATAGAGGCCCGAAATGCTGC 
CAAGACCCTGCCCTGCCGCCTTCCCCCCCTCCCGCCCCCCGCCCCGCCC 
CAAGGTGACAAACACTGATATGGCCTACAGCACCACTCAGTGCCAATTTTG 
AGAAACGGTGACCACTCTCAACATGTCTGTCAATAGTTTCTGTTCAGCCAT 
TTTCCTCTACC 
9.1.10 Lymphoma 12 
Specimen 12a 
HM001 primer. Same localisation as HMSp2 primer. 
335 
CCCCCCCCTTTTTTTCTGTAAACTAAATAAAAACTTTTATATTATCAGGGTAC 
TAGGCTAATTGCGGAGGGCCTCTAGTGTTCTGGGGTCTCACCACACCTCT 
CCTATAGTGCCTTTTCTTCTCATCCCAGCACAGTATTCCATTCGAGCTGCT 
CTTAAATGTCTGAGCACAATTACTTTTCTCAGCTAGGTTTGAGCTAAACAAG 
AAGGGCTAACCTCGAGTGCTTAAATCAGTGGCTGGCTCACAGAGAGGTCT 
CAAACACTTTTACCAACAAATTAGGATCCCACTAGTGTCGACACCAGTCTC 
ATTCAGCCACAA 
Specimen 12b 
HM001 primer. Same localisation as HMSp2 primer. 
TCCCCCTTTTGGGAGCTTAATCTGATGGTTTTTTAGCTCATGGCCAGCCTG 
GTCTACAGTTCCAGGACAGCCAGGGCTATACAGACAAAACTGAAAAGTAG 
AATTAAATAAATACAACGTGGAGCACACCCTCTAATCCAGCGCTCCCCAGG 
TCGAGGCCAGCCTGGACTAGTTAAACAGTGAGTCTATCTCAAAAAACAAAC 
AAACAAAAAAACCAGACAGACAGACAACCAAAGCCTGGTATGGTGGCACA 
TTCCAGCAGTTCGGAGGCTGAGGGAGTAAGGAAAAACTGAAGTTGAAGGC 
TGTACACAGCCCCATGTCCAGATGAAATCATCTTGGATTACATGTGTGAGA 
TCCCACTAGTGTCGACACCAGTCTCATTCAGCCACAA 
Specimen 12c 
HM001 primer. Same localisation with HMSp2 primer. 
AACGAACGGGTTGGAGACTTAATGTTACTGTCTTGAGCTTTGTACTACTTC 
GGGACGATGGCCCTTCGGCATCCTCGGGTTTTTAAACACATTGAACTAACT 
CGCAGTTCACTGGTGTGTGCATCTCTCTCTGTGTGTACTTATATGCTGTTTT 
TGTCCCAGACCTTCCTCTTCCTGACATTTCGGCTGGTAACAAGGTCACAGG 
CCTTCTAAAACTCTCCTCCATGTCACATGGTTTTGTGGACTCAAGTCTTTGC 
ATAGATGATTTCGGGAGTAACATGACTTTGCCTGCTGGGTCACACAAGCCA 
GCAGACAAGCCAAGACTAATTCAGGGATTTTATGTTTCTAGTACTTTGAAAA 
AGGAAAAGCTCTTTGGCAACTTCCTTAATTAGCACTCCAGACACCACAGGA 
GCCACAGAGTTAGGCTGTGAGTCTCTTCTTTCAAGACCAAAGGGTGACAA 
GAATGACCCAAAAGCACATGGCTCTGGGACTTGGCAGAGTTAAGAGATCC 
CACTAGTGTCGACACCAGTCTCATTCAGACACAA 
Specimen 12d 
336 
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HM001 primer. Same localisation with HMSp2 primer. 
TTTTACGGTTTGTCTGGAGCTAGACATATCTTTTATTTTATCTCAGACTTGC 
ACAGTTCGGAATGCCGAGAGTGAGCCCACTAAAGTCCAAACACTTCTCATT 
CAGCCTTTTACTCGGTGGCACCATTCTATCTGGCTATACAGTATGAACGTG 
TTCGCCCTCCCTTAAAGTCCCTCTGTTCGGATGCTCCCGAGAGAGCCGGA 
GATTGACCCCCGTGCGCATGTGAAGTGTGGGCACGCTCTACCCTTCCTCC 
ATCCTCTACAGCTCTGTTCAGGATGGTCCTGACTTCCACACATACTCTAGG 
GAAAAAACCAGGCCTTACTTCCTGGGGTCCTCTCTTCATGTTTCTGTATTC 
ATTTCCCTAACATATAACATTGTGCTACAACAAACCACAGTGTTTCCATTGC 
ACTTTCTGTTGCCTTCTGCATTTGCTGTGTGAAGGCTCACTTAAGAACCTCT 
TCCTTTTTCTGTCGTTAGGAAAAATCCTGTAACAATATGTTTGCCATCTGTA 
TTGATAAAACTTTCAGGCATTCCGAATGCATCTAAATGTTTTTCAGAAACAG 
GCAGAATTTGTTTAGTTCGTGTCCCTTCACAGGATGTGGCTAGGATGGAGC 
AGCTGTCTCGCACTCCTCTGGATAATCCCACATGTAGCTCTGTCCAGTGGT 
TTCCTCAGACCCTCCCACCTGTCGTCTGTGTCCATCCCATCCCTTCCCTAG 
ATCCCACTAGTGTCGACACCAGTCTCATTCAGCCACA 
9.1.11 Lymphoma 13 
Specimen 13a 
HMSp2 primer. 
CATGACGTGCTAGCATCTGGTGGTTTAGCTGCCCACCAATTTTTGTATCCA 
AGTCGGAGGTTAAGGCACCTGATCTCCTAGAACTCTGTGAGACCCCCTGC 
AACGCAAGGACATTCTGCATTGCCCAGCCCTTTGCAATGATTCGTATACAA 
TCTCTCTAGATGTCACCCCCCTACGAGGTTTTGAGTGTCTCGGAGCCAATA 
CATGCTACTTTAGTCCCCTGGAGTCGACGCTGCCTACAACTCTGCTTCCTG 
TTCACTAATTCTTCATTGCATTCAGCCTTGGACCCTTGAATTCCCATAATGG 
CCTATTGAAAAACCCCACCTGTAGGTTTGGCAA 
Specimen13b 
HM001 primer. Same localisation with HMSp2 primer. 
TCCCCCCCATTTCTGGGATCTATCTAACATCTTTTATTTTATCTATTACTTGT 
ACAGCTCGTCCATGCCGAGAGTGATCCCACGAGTGTCGGCTGGAGTCTCA 
TTCTGCCTCCCCGCATTTACCCAGTGGCTCCCAGATGGGCACCGTGCTTT 
337 
GCCCGAGGTCACAGGTTTCTGTAAGTACATCCAGAACTTCATCCTAGGCCT 
ACCTGTTCTGTGCCAGGCAAGCAGGTGACTCACTCTTGTAACTCCAGTACT 
GGGAGAGTAAGGCAGAGGAGAGCCACCACTCCAGGACTAGCCTGGGCTA 
TGTCGTGAGACATTTAATATTATTTACAAAGGAATGATATACAGATGGAGAA 
TGAAAAGCAAAGAAGAGGCCCAATGGGCTGGAGAGGCAGCTCCGTGGTT 
AGGAGAAATTGTTGTTGCAGAGGACCCAGGTTTGGTTTTCCAGCACCCAC 
GTGGAGGTTCCATACTTCCTCAGGCACCAGGCACAGATGTGAGCCTTGCC 
TCTCGGTGCTTTGACTTGTACCTTGTTTGATCCCACTAGTGTCGACACCAG 
TCTCATTCAGCCACAG 
9.1.12 Lymphoma 14 
Specimen 14a 
HM001 primer. Same localisation with HMSp2 primer. 
CCCCCTTCTGACTGTATTTTGCTACTGTTATGAGCTATAAGGTAAATATGTG 
ATATGCAGGAGATCTGATATGTGACACCTCCGCCCCCAAAGGGGTCATGA 
CCCACACAGTCAAGAACCACTGCTCTAAGGAAAAATCAAACCACCACCAAC 
AAACAACCATTGTATATCCATTTTGAACACCAACTACCTCAAAGAATCAGAG 
TTCCTGGGGCAGAGAGCAAAGTCCAGAGAGCACTACACATGCTGAAACAG 
ATGAAATACTTCGTTTCATCATACTAAGTAAATTTGTTGCACACATGGGAAA 
TAGGAATCAATTACTTCTAAAGTTGAGAGTGTATTGGAGAAATGATTTTTTT 
TACAGGAACAGGAAGAAGAAGATACACTTAAATGGTAACTAAGTGTGTAGT 
TACTTTATACTAAATAAAAAGATCCCACTAGTGTCGACACCAGTCTCATTCA 
GCCACAA 
Specimen 14b 
HM001 primer. Same localisation with HMSp2 primer. 
AACTCCCCGGCAGCAGTGTACACCACCCTCACCCCAGACTTGTTTATCTAG 
ATAGACTGTTGTGACGGACTCATAGGCGCCTGGGTGCTGGGAAGACATAA 
ACCAACCCTCCATTCTGCAAAGCTCCCAAGCAGCCCAGCCCCCACCGTCC 
CGGGGGCTGGGGATTTGAGGGGGGGGAGGCGAACCCTACTCACATCGTC 
CCACTTGATGAAGCGCTCCCCTTGGCTCAGATATGCCTTCACGTTAGGGG 
GCAATAGAACAGGGTTGAGCAAAGACATGATGTCAAGTGTCCCTCTTTGGA 
GAGGTTGGGCAAACCTCTCCAGGGGACAGGAGAAGAGAAGGAAGAAGGG 
TGAACAGGAGAGGAAGCTTAGGCTAGGCTCACATGGCACCCGCCCAGTAC 
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TGGTCCGGAAGTCGGGTGCTCTTATAGCCTGCGGGGTGGCAGTAGCTGG 
ATGCAGGACTCAGAGCTTCAGGCCAGGGCCCAGTTGATCCCACTAGTGTC 
GACACCAGTCTCATTCAGCCACAAA 
9.1.13 Lymphoma 15 
Specimen 15a 
HM001 primer. Same location with HMSp2 primer. 
GCCCCGGGTCCCCTGGAGATATATAAAATCTTTTATTTTATCTCTGTACTTG 
TACAGCTCGTCTTGCCTAGAGTGATCCCACGAGGGTCAACACCGGCCCGG 
ATACTGACTTCCTGTCTTTAACAAATTGGACTTCTCGCCTCTACTCCGGAC 
GCATGGGGGCGGGTATCACCGGCCCCACAGGTGGGGTTGCTGGGGCCTA 
TATCGCCGACATCACCGATGGGGAGGATCCCACTAGCGTCTACACCAGTC 
TCATTCAGCCACAAGAACGGGAAGTTAAGTTTTATCTCCTGAGCAAGCTAG 
ATCCCAGTAGGGGCGACGCCAGTCTCATTCAGCCACAA 
Specimen 15b 
HMSp2 primer. Same localisation with HM001 primer. 
TGCATCACGCGACTTCTAGGTGGGGCGAGCGGGAGACCAAGGCCATAAA 
TAAAAAACTTGGTTTGATCGCCTGAGGTACCCTGGAGCCAAGTAAGTTGG 
GACAAACTACGGCAGCCACCCTCTGAGCTTCGGGGCTGCTCTTGTCCACC 
TTTTACATAAGAGGAAGTTACGACTCGGAAGCTTAGAAGCTTGTCCCAGCC 
TACAGAGCTCACAAGCAGCAGCCCTGGCTGTGTGGCCTTGCAGGGCCAA 
GAAAGAGTCAAGGAGAAAGGTCAGGCCAGCACTTGGGAGGGGGAGGAAG 
GAAAGTCAAGAGTTCAAGGTTCATCCTCACAGTGTGGGCTACCTGTCTTAA 
AACTGAAAGACCCCACCTGTAGGTTTGGCAA 
Specimen 15d 
HM001 primer. 
ATCGCTTTTTCTGGAGATTATAGATCTTTTATTTTATCTCTTTACTTGTACAG 
CTCGTCTTGCCGAGAGTGATCCCACTAGTCGTCAACACCCCCCTCATTCC 
GCCACTTCACGTCTTTAACAAATTGGACTATTCACCTCTACGCCGGACGCA 
TCGTGCTCGGCATCTCCGGCGCCACAGGTGCGGTTGCTGGGGCCTATAT 
CGCCGACCTCACCGATGGGGAAGATCCCCCTAGTGTCTACCCCAGTCTCA 
TTCAGCCACCTACAGAGTCTGCTGGAAAAACGATTACCTGGAACCTGGCG 
339 
AGCCACACAGGCTGCATTATCTCAAAGTCAGCTGTTCACTTTTCTACACGT 
GTGTTATTTTGCCTGTATTGTGGTAGGGACAGAGCCTAGGGCCTCTCACTT 
ACAGGCAAGTGTTCTAACCACTGAGCAACCCCTCCATCCCTTAGTGTTATT 
CCTTCTTGCTTGCTTGGCT 
9.1.14 Lymphoma 16 
Specimen 16a 
HMSp2 primer. Same localisation with HM001 primer. 
GTTCTGCGATTTGATAGCGACGTCCGGCTGACTTATACCCATTATTCTTGT 
CACATGCTCCTGATATTAGGCCAGGTTCCTTAACTGTTCCTGTCCCTGTCA 
ACTACCAGGGGTAATGAGGCTGTTTTGGCAATTGCCTGTAGCCCAAACTCA 
CCAGCTTCCAGGCTGGATTGTTTAACCCACCTCTTCCCTAGCCCTCTCAGG 
CAGCCTCATGGGCTAGTTGGAACCTGCATCTCCAGTGACCCTCTGTAGGT 
GACTGGGGTGAGTCAGAACTTCAAGGCTCCCTCCAGTACAGAGCACAAGC 
CACTGGCTGTTAGTCTCTTTTCTGTTACTGAAACTGCAAGCCACAAATGGA 
CCAATGTATAACAAAACGGCTTATTCAGTTTATATTCTAAATGAAAGACCCC 
ACCTGTAGGTTTGGCAA 
Specimen 16b 
HMSp2 primer. 
TAGTTGATTTTGATCCAGACTCGCGTCAGGGCGACATGATGCTGTGATAAA 
AATGTAGATTGACACTGGTGGCGCCCCCCTTGCACCCCATGCTTGGACTT 
AGCCACGTGTGCGGGTTTGTTGTTCACACAGCTGCCGTCTTTGAGTGCGA 
GGGTGTGTGAGGGTGTGTGTGAAAACCCTGCCTCCCCCCGTGGGTGGTC 
TGAAACTTACCTTGGGGGCTGACTTAGAGAGACACCGAGCCACAGGGTCT 
GTTTGCCTCCTTCCTCCCCTAGAGCTACAAATCCAAAGTGGTGCCTACAGG 
CCGGTCTTCTTTCCTGTGGCGTGTGGGCTCATCTCGGGCTTTCCTGCTTG 
CAAGGCAAATACTTCATCATAGATGGTCTTTGCTATTTTGTGGGTTCCTTTT 
TTTCTATCATTTATCCCCGCCCCCATTTTTACCCCCTATCAGTAAGATAAAA 
GAGAGGGGAATGTATGACTCTAATTTCTTCCTTCTTTTTTTCTTCTTTGTTTG 
TAACTGGTTTTTGCTACTTTGCATTTTATTTTTCCCACCCTTCCCCTCCCCC 
ACTAAAAGACCACCCCTTAATGTTGGACAT 
340 
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9.1.15 Lymphoma 17 
Specimen 17a 
HM001 primer. 
CCCCCGGCGGGAAGGGGCTTATTTAATTCTTTATTTTATCTCTTAGTTGTAC 
TGGTCGTCCAAGCCGATAGTGATCCCACCTGTGTCACTTCCTGACCAATTT 
TGTCCCAGTGGTATTCTAAGTTCTGTGTCCTGTTCGCTGGTGAGATGTGGG 
GATACGATGCCTACTAGCCTGGCTTGCCTCTGTATGATCTTCTGAAATCAG 
CCATCATCCTGATCCCGGTAACGTTGACCCCAGTCTCGTACAGCCACA 
Specimen 17b 
HM001 primer. Same localisation with HMSp2 primer. 
CGAATCACTTTTTTAAGGGGAATAAATAAGATCTTTTATTTTATCTCGTTCTT 
GTCCTGCTCGCCCGAGCCGATTAGCTCCATAGAGACATAGATCAATAGATA 
GATAGATACATAGGCCTAAGTCCCGTCCCTTCGCTTATTGTTGTGTGACCC 
CTCAAGCTGGAGCTGAAACTCTAACTTTTGAAGCATGCCCTTCCCACCCCC 
TGTCCATTAACATTTAAGGTTAAAGTGGCAGCAAGGATGGCTGTGAATTCT 
ACCTAAGAGTAGGGGAGGGGGAGCAAAATAAAGGGCTGCTCTCTCCTTCC 
AGAGCACAGCCTCCCTCTCCTCAAACCTGGGGAAGGAGGACTTCTCATTC 
TTCCCAAAGACCCGGGAGCTGAGAAAGTAGAAGGCCGTGTGTCTGTCTAG 
GGATCCCACTAGTGTCGACACCAGTCTCATTCAGCCACA 
Specimen 17c 
HM001 primer. 
GCCATGGGAGGGGGGGGGAAAGGAAGAGCGAATTCTGATATGTCATATTT 
CGGACAGGTCGCCCATGCCAAGAGTGTTTCGAATCATTTTCATACACCCCC 
CCCACACACAAAGCCAACCACACACACACACGCTGTTAGGGGTAATCGAA 
GAGTTTTACAAAACCTTACATTATTTACACCCTTTTTGGCTAAGATTTTTTGA 
AAATTAACCTCCACTAATGCAGCTACACCAGGAAAAGCCTGGGCCTTAGAA 
TTGTCCTCAGTAAAGAATAGAGAACAGGGTGGCCTTGAGGGACAGGGTTT 
TTTGGAAGATGAAATGGGTTATTTGAAAAAGAAGCTAATCTTTTGCTTGCCT 
CT 
341 
9.1.16 Lymphoma 18 
Specimen 18c 
HM001 primer. Same localisation with HMSp2 primer. 
AGTCCCCGTTGTTCAGGAAAGCTATAATATCTTTGTTTTATCTCATTCTTTA 
CAGAACTCGTCCCTGCCGCTAGAGATCGTTCTACCCCAGTCACCAGACGG 
CTTCAACAACACCTGTGTTCCTCGGCTTGAGCCTCCCTCCCGCCTCCCAC 
AGCAAGCCCCCCCCCACCCCCCACGTCATGAATTGCGGAAATAGGACCTC 
AGTTGCTGGGCGGGATGATTGCACTGGGGGCTGGCCACCTCGCCGGGGG 
AGGCTGCCATGTGGCTGCTGCTCTGGTCCCCCCGAAGGTGCTGGGGACT 
AAAGAAGCCTAGCTGCCAGGGGCACTGATGCAGATGTGGCGCTCCCGCT 
CCTGGGACGTGCCACACATCCCACTACTGTCGACACCACTCTCATTCAGC 
CACACCACAG 
9.1.17 Lymphoma 19 
Specimen 19a 
HM001 primer. Same localisation with HMSp2 primer. 
AGTCAAATTTGTATCCTTTGCACATGCATTCCAGTACCACACTTGCTAAACT 
GGAACTAAAATACCTCACAGTTTACCTTTTCTGTTAGAACATTCTTGGTATT 
CCCGGTATAACTTGAGCTGAGCACAAGTGGTTCCCACTATGCGGACTCCC 
CTTTGCATGCAGGACCCTGAAGCATCTAAAATTTCCTGATCCCACTACTGT 
CGACACCAGTCTCATTCAGCCACAA 
Specimen 19b 
HmSp2 primer. 
GGTGGATGTCATCATGCAGTGGACTCCGGCTGGGAGCTGTCAGTCTCGAG 
AAGGTAAAGATTTTGTTTCGTCTCCGATGTAGGGGGGATGACGAGCGCAA 
CTGAGGGGTTGGCAGAGATAGATGAATATGAGCCAGCAGGCACAAGAGG 
CCGAGTGCTCCTCCTCCTCCCCCTCTTCTTCCTCTTCTTCCTCCTTTCCCT 
CTTCCTCTTCCTTTTCCTTTTCTTCATATTTCTCTTTGAATTAATCATTATATC 
TTCACATTGCCTATACTGCATATGGTGAAAGACCCCACCTGTAGGTTTGGC 
AA 
Specimen 19c 
342 
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HM001 primer. 
CCAGGGGGAGAGGTATGAAGACAGGAAGGACTGAATGTTTAACTCATTAA 
TTGGAAACTCGTCCTGCCCAGAGGGATCCCCTGAGTGGCCTGGGTCAGCT 
GGACATCCGTCACCCTCCATGCCACACATCTGGAGGAAGCTCCAGACTGT 
GAACTGGAAGGAGAAGGCCAGCTCCCTTAGTTGTCCTGTGGTTTCCATATA 
TGTGCACACCCACACAAACCCGAACACACACATGCACACACACGGGGATG 
GGGTGGAGGCAAGTTTTTTTTTTTTAAACAAATTGATTTTTCTTTTTTAAGTC 
TTCTCGTGGCCAAATTTTTTTGTAGGGACAGGGGGGGCACACTCCCAATTA 
A 
Specimen 19d 
HmSp2 primer. Same localisation with HM001 primer. 
AAGCATGTTCATCATGAGCGTGAAGGAGCGTGCACGACCTGCAAAGGACC 
TGCATCCTGCGTGTTAGCCCGGATCTGAGTTCCTGCTCTAACTTCCAAAGA 
GGCCACTGTTTGTTTCTCCCTGGGTCTAGCTTATATTTCCGTGTTTCCCTCT 
ATAAACCTATCGTTCCATGAACATCCATGAATCGAATCTGTATGCATGGATT 
TCACTATGGCCCTCTCTTTCCTGATCTGTATTTCTGATGGTTGACTGATGTT 
TGAGTGGTTTTGTGGGGGAGGGTGGGGAAAAAGATTCCATCACGGGTTTT 
GTT ATCAGACATGGAGCTGCAGAA TTTGGGGGTTTCTClGATGGGTTTGGT 
TTGATTTTCCCTTACTATGCTTCATTTCTCCCTTTTTGAACAGGACGATTTTC 
TCTATGCCACTGAAAAACCCCTTCTGTAGGTTCGGTTTCTAGGGTCGTGTT 
TTCTCCT 
Specimen 19e 
HM001 primer. Same localisation with HMSp2 primer. 
GATCCAGGGTTGGTAAGCCATTGCTCATTAGACACGAATGTTACTGGCCG 
GTGCTCAGTGAGACGTGGGACCTTTTATCTCTAAAAGGTTCTGACTTAGTG 
GGCTTGCCTTACATGAACAGGACCCTGCGAGAGGCAACTTTCGGTTGGGT 
TTGCTCTTCCTCTCCCCCTCCTGTTTTGCCTCGCTCAAGACTTTGAGCTCC 
AATTCCCTCGGTCTGTCCGTCCATCTGTTCCTCTCCTTACTGAGCCCGAGG 
AGTGTGATTGCCTCGTGTTCTGTGTGGTTGCTTTCACCCCCCCACCTCTCC 
CAACCCCCTGGATTCCTGCCCTCGGTGCACACCAATCTCTGGACTGGCAG 
GTTCTGTTCTGACTTCCCTGTTTGGACCTCGCTTATTCGAGATTGCCTGTTA 
TACCCGCCACACAAACAAGACATCCGGGCTATTATTTTTAAAAGCGGGAGT 
GCATGGTTTTGTGTTTGGAGAGACTTCATGACACATTTGGGAATCCAGTAT 
343 
CAAACTCTTTGCTTTCTACAAGCCCTGATTGGAAGGTAGGCTGGACAGCAA 
TATCCCTCTACCGTAGACACCAGTCTCATTCACACACAA 
9.1.18 Lymphoma 20 
Specimen 20a 
HmSp2 primer. Same localisation with HM001 primer. 
GGTAATACTTGACTGGCGGGCAGAGCGGAGTGGGGGAGGGGGTCACCTG 
ACCCGGCTGGGGTGCGGATGGGAATCGCTGCTGAGTCACTGGGGACTCC 
GGGTTTTTCCCGGCTCAGGCTCCACCTCCGGGCATCCGAGAACCTGAAAG 
ACCCCACCTGTAGGTTTGG 
Specimen 20b 
HMSp2 primer. Same localisation with HM001 primer. 
ATGCATAGTTATTTATGCAGTTGATCGTGTTCTGCCTCCTGAGTTCTGGGG 
TCAAGGCATGTACCATCACACTCAGCCCTCAACATTTATTTTCTTCATAAAC 
AAAAACTGAAGGTATCATCCCAAATAAATAAAGTTCTGAGGGGACAGAATC 
TTGGCCCCAAGTGGTTTCATATACTTAGCAAATATCTCAATCAAATAATGTT 
TTGAATTTTCCTTGAAACTATAGAAAGGCAACACAAAAAGAGGAAGCAATC 
ACTTTGAAAGACCCCACCTGTAGGTTTGGCAA 
Specimen 20c 
HM001 primer. Same localisation with HMSp2 primer. 
ATTTTCCGTCGGGCCCATCACCGTCCTTAGTGTCTTTTCCATCGTATGTTG 
TTTAACGCACGGACGTATTTGGTGTCATTTCTTGAAGATAAGTTTTAAATTC 
CCTCCCTGGAATCTGTCTCCCTCTCGCCTTCCCTCTGTGCGGTGTTTCACA 
GTACAAGGCCCCTTGACTAACAGGAACTGGTAAGATTTTCCCCATCATCAA 
GACTCGTGGGTAGAGATGATGCCTGTCTTGTCTCCACCATCCTTTGTACCC 
ACCGCCCCTCACTCAGCTCACCGCCCACTCACTCCTCAGTGTGAAAAGCA 
ACTCTCCCTTCTAATAAAACGAAATTGTCTCTCTTAAAATTCGTAATCGTCT 
AGTTTGTGAACCTACGAGGTCCTTTCAATTCTCGCCCAGCAGATCCCACTA 
GTGTCGACACCAGTCTCATTCAGCCACAA 
Specimen 20d 
HMSp2 primer. Same localisation with HM001 primer. 
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CCGGTTCTTAGTTATTATGCAATTAGATCTTGAGAGACTCACACAGAGTACT 
TTTTTTATGCACCATCTCCTTCATTCCCCGGGTCAATCAACTCCACCTTTAC 
CAGTTTGGGGCTTTGGATTCTACCATGTATGTGATTTACAAAATCGGTCTTA 
CTCATAATGTAAGGAGGCTTAAAAAAGTTGAACCAAGAGGAGATACTCGTT 
CAATATAGACATAATTTGGGACTCAATACTACCCCAGGCCCCAATTTCTTCA 
TTCTTGCCATTCCCTACTGAGAGAGATTCAGAAATGGCTCCACAAATCCCT 
GTACCTACTACACAACCGTTGGAACACACGGCTCCGTGTCAACCTACGTAA 
AAAAAGAATCTTCATGGTATGGTTCAATAACACTACCTCTCTTTTGCAAAA 
9.1.19 Lymphoma 22 
Specimen 22c 
HM001 primer. Same localisation with HM001 primer. 
GATCCTGATGTTCTGAAGATAATGAAATCTTTTATTTTATCTCATTACTTGTA 
CATTTCCCCCGTGCCGAGAGGGATCCCACAAGTGTGTTTTTTTTTCCATTA 
ATCCGTTGTAGTTTTAATTTTGTGTGTGGTATTACTTATGTATGTGTGTGGA 
GGCCTGAAGTTAGTTAATTACTTTCAACCATTAAAATTTTGGGGGTGGGAG 
GATGGGGCTGGATGGCTGGCTCAGTGATTAAGAGAACTTGTTGCTCCTGC 
AAAGGATCCC 
9.1.20 Lymphoma 23 
Specimen 23a 
HM001 primer. 
CAGTTTCCAATTCTCTGGAGATAATAGAATCTTTTATTTTATCTCATTACTTG 
TACAGCTCGTCCATGCCGAGAGTGATCCCTGAGTGTCCACACCAGCCTCA 
TTCAGCCGCACTGAGGGGTGCGGGACAGTGTGGTCTCTCTTATTTGTGGC 
TTATGGGGGGGGGGACGAAGTGATTCACTGTCGTTTGAAAAAGACTATGC 
AAATCAAAAAAGCTGGTGCCCCAGGCTTCTCCAAATTTAGAACCCAATAAT 
GGCGACACCAGGCTCATTCAGCCAC 
Specimen 23c 
HM001 primer. Same localisation with HMSp2 primer. 
CAAAGGGGTCTCTGGGAGAAA T AAAA TCTTTT ATTTT ATCTCA TT ACTTGTA 
CAGCTCGTCCATGCCGAGAGTGATCCCACTATTGTCTACTTATTCTGTTCC 
345 
TCACATGTCTTGTTCCTGGATCCTGTACCTCTGACCGAGGGGGGGGATTG 
GGGCACCGTTTCAAATTCTGGTTTGAAAATATCCAGTGGCCGGAGTTTCAC 
TGTCCCAGCGCTTTAAACGGGTTTCTTGAGTGCATAAACACAGAAGCAGAG 
AACTGAGTTACTATGTTTACTCTG 
9.1.21 Lymphoma 24 
Specimen 24a 
HM001 primer. Same localisation with HMSp2 primer. 
ATTCCTGGCTGCTAGACATAGATTGATCTTTCATCTTATCTTACTTCTTGGA 
CAGTTCGTTCATGTATGTGTTGATCGCTTGTGTGTGTGTTGTGTGCATCAT 
CAGCACCGTCCCTGACTCACACAACTTAAGTGGAATGAACAGGAAGATCC 
CACTAGTGTCGACACCAGTCTCATTCAGCCACAA 
Specimen 24b 
HM001 primer. Same localisation with HMSp2 primer. 
AGGATGGTTGCTTGATAGGGTACAATCTTTTATTTTATCTCATTACTTGTCC 
GGCTGTGTCCATGGACTGCAGTGATCCCAGGAGTGTTATCGTCAGTTATC 
GACTCTGAAGGCACTTCCTACTTAGTCATCTCATCACAGCAGTCAAGCTTT 
CTGCTGTCCTCCAACTAGTAGTTCCAGCCACTAAATGGAGACACGTCTTAA 
ATTTATGTATGTGCCCACATGGGCCAGGGTATGTTGGGAGTCCCTGGAGC 
GAAAGCTACACAGCCTCTTGTCTATGAACCCCACCTGATACTCCAGAAACC 
CTTACCTCATGGTGGGATGATACTGCTCCTATTCCACGTTGTCAACGTCCC 
GTCTGAAAGGTTAGAAGAGTAAGAGTCATGAGGGGCAATTAGAACACTTGT 
GTTCAGCTTTGGGTCGCCGAGGCTTAAACGACTGCAGTCAGCTAACTAGG 
GATGTCGTCAGTTGTCGCATCG 
Specimen 24c 
HM001 primer. 
AATTCCCGGTTTTGCTGGATATAGATAAATCTTTTATCTTCTCTTATTTCTTG 
TCCAGATCCTCCCTGAAACTCTCATTTACCCCCAACGTCTTGCTTGGTCAT 
CTGTAAAAAGCAGTGCCCTCCTTTCTTTTTGTCCCCACCCCACCGAACTGT 
CCTATAGGTGAAGGAGGAAGGCCGGTCATAAAACAGGATGGACAGTTGCT 
TTCGGGTGAAACCCACCCAGGGTCCTCAGGCTTGTCGCTGACTGCATTTA 
GATTTAACAATCAAGGCCTGTGACCTGGAGGCTCTTTCCAGCTGCTCTCTG 
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CCATGTTGACATGAGAGAATTTGCTAATTCTGGCCCGGGATTTTCCCTGTG 
TGGCTGTTTTTCTTCTTTATCTTCATCAAATGAAGAGCGCTC 
347 
